Abstract

Vertical Tabs

General Information

SUBMIT YOUR ABSTRACT: CLICK HERE

Submission deadline: 09 October 2024 (23h59 CET)

The poster exhibition and the oral poster communication session are the mainstay of the annual European Association of Hospital Pharmacists (EAHP) Congress and only the best are selected!

The EAHP Scientific Committee (SC) encourages all hospital pharmacists, other health care professionals and scientists to submit their work for consideration leading to possible acceptance and display at the annual EAHP Congress. The SC strives to receive submissions of hospital pharmacy related initiatives from applicants in Europe and all over the world. All potential contributors are requested to carefully read and comply with the guidelines presented in this webpage. Abstracts/posters which have already been published at the international level may only be submitted if new data is included, the work is presented from the hospital pharmacy perspective or in a new context giving new inspirations for colleagues. Data, which have been published in international, peer-reviewed journals, should not be submitted.

IMPORTANT: When submitting your abstract, please be sure that your hospital server will accept emails from abstract[at]eahp[dot]eu. Otherwise, you will not receive the emails from our system. Alternatively, you may use a personal email address such as gmail, hotmail, etc... You can submit multiple abstracts. We also recommend that when submitting your Abstract, you use the same name and email address used for registering your participation to the Congress.

If you have made an error in your submitted Abstract, DO NOT RESUBMIT. Contact abstract[at]eahp[dot]eu and request permission to bring the needed modifications. Inform of the number and title. Once received, consideration will be given to the request, within the submission deadline only.

You are allowed to submit up to 6 abstracts.

DEADLINES	ACTION
Wednesday, 09 October 2024	Deadline for abstract submissions. Abstracts submitted after the deadline will not be accepted (Deadline, 23h59 CET)
Tuesday, 12 November 2024	Presenting Authors will be advised of their abstract status after the first review. Please check your spam if you did not receive the email.
Tuesday, 19 November 2024	Deadline for modifications due from abstract authors who were requested to make changes (Deadline, 23h59 CET)
Tuesday, 26 November 2024	Presenting Authors will be advised of their abstract status after review of modifications
Friday, 06 December 2024	Deadline for Accepted Abstract to notify EAHP they do NOT want be included in the published EJHP (European Journal of Hospital Pharmacy) (Deadline, 23h59 CET)
Friday, 13 January 2025	Accepted Abstracts will receive an email with: Abstract Title and Text edit, new Abstract/Poster Number and QR Code
Friday, 07 February 2025	Accepted Abstract/Poster Authors to be registered and have confirmed attendance to the EAHP Congress 2025, to be guaranteed a Poster Panel at the Congress (Deadline, 23h59 CET)
Friday, 07 February 2025	Accepted Abstract Authors to be registered and have confirmed attendance to the EAHP Congress 2025, in order to be included in the Abstract Book (Deadline, 23h59 CET)
Friday, 07 February 2025	Accepted Abstract Posters to be sent to EAHP in PDF format for inclusion in order to be included on the Online Abstract Poster Wall (Deadline, 23h59 CET)
Wednesday, 12 March 2025	Accepted Abstract/Posters to be delivered and hung in the EAHP Congress 2025 Poster Area (from 10.15 to 17.00)
Friday, 14 March 2025	Accepted Abstract/Posters to be removed from the EAHP Congress 2025 Poster Area (from 13.00 to 14.00)
Thursday, 13 May 2025	Abstract/Posters present at the EAHP Congress 2025 to request a duplicate of the Poster Certificate (originaly sent on Friday 14 March 2025)

The SC accepts two types of abstracts:

Scientific abstracts and
"Good Practice Initiatives" (GPIs). GPIs comprise hospital pharmacy practice or education initiatives, which may inspire colleagues internationally, but do not necessarily comply with the traditional abstract demands. For further information regarding definition of a GPI, please go here. For authors interested in submitting a GPI, please go here.

If you have any questions concerning the abstract submission process, please send an email to abstract[at]eahp[dot]eu.

Abstract Submissions and guidelines

SUBMIT YOUR ABSTRACT: CLICK HERE
Submission deadline: 09 October 2024 (23h59 CET)

The SC accepts two types of abstracts: scientific abstracts and "Good Practice Initiatives" (GPIs). GPIs comprise hospital pharmacy practice or education initiatives, which may inspire colleagues internationally, but do not necessarily comply with the traditional abstract demands. For further information regarding definition of a GPI, please go here.

To check if your abstract meets the eligibility criteria for being a GPI or an abstract, answer all the following questions:

Table 1: The eligibility criteria for being a GPI or an abstract.

QUESTION	DEFINITION
1. Is your abstract relevant for hospital pharmacists?	Yes: Your abstract may be a scientific abstract or a GPI
1. Is your abstract relevant for hospital pharmacists?	No: Please do not submit your work to EAHP
2. Does your abstract describe a protocol or plan for a project not yet conducted?	Yes: Please do not submit your work to EAHP
	No: Your abstract may be a scientific abstract or a GPI
3. Is your abstract about the development and implementation of a pharmacy practice or a program in pharmacy education?	Yes: Your abstract may be a GPI
	No: Your abstract may be a scientific abstract
4. Can other colleagues use your experience as the basis to introduce the same type of improvement in their settings by e.g. observing what you did in your setting?	Yes: Your abstract may be a GPI
	No: Your abstract may be a scientific abstract
5. Does your abstract describe a project conducted as a scientific study using e.g. robust methodology?	Yes: Your abstract may be a scientific abstract
	No: Your abstract may be a GPI

For authors interested in submitting a GPI, please go here.

If you want to submit a scientific abstract, please check the instructions below.

ABSTRACT SUBMISSIONS AND GUIDELINES

IMPORTANT: When submitting your abstract, please be sure that your hospital server will accept emails from abstract[at]eahp[dot]eu. Otherwise, you will not receive the emails from our system. Alternatively, you may use a personal email address such as gmail, hotmail, etc... You can submit multiple abstracts. We also recommend that when submitting your Abstract, you use the same name and email address used for registering your participation to the Congress. You are allowed to submit up to 6 abstracts.

The EAHP Scientific Committee (SC) is looking for contributions with:

A high grade of relevance and/or innovation to the European community of Hospital Pharmacists,
A high impact on the future of hospital pharmacy practice, or
A high relevance regarding practice changes due to the investigated intervention.

SCOPE OF ABSTRACTS AND TOPIC GROUPS

We encourage the submission of abstracts from all disciplines of hospital pharmacy or related areas. The major categories and examples of topics are illustrated in the table below. The topics are not meant to represent a complete and exclusive list, but examples only that guide authors to select the most appropriate topic groups during the submission process.

Table 2: Categories for abstract submission with examples.

CATEGORY	EXAMPLES OF TOPICS
Section 1: Introductory Statements and Governance	Management theories, human resources, training requirements, financing, resource optimization, staffing, organisation, working environment, medicines management policies, drug & therapeutics committees, communication technology (telepharmacy, eHealth), national standards of hospital pharmacy services, pharmacoeconomics, health technology assessment
Section 2: Selection, Procurement and Distribution	Procurement processes, logistics, storage conditions, ordering systems, drug distribution technology (e.g., bar code scanning, electronic cabinets, dose dispensing), home delivery, supply chain management, medicines shortages, policy for medicines brought into the hospital by patients, preparation conditions, dispensing conditions, distribution conditions, disposal of medicines, medicines formulary systems, drug use evaluations
Section 3: Production and Compounding	Production technology, use of suitable commercially available pharmaceutical equivalents, risk assessment prior to production, formulation, quality control, best practice quality requirements, procedures for reconstitution or mixing of medicines, stability studies
Section 4: Clinical Pharmacy Services	Multidisciplinary therapeutic decision-making, quality improvement interventions, adherence, seamless care between and within healthcare settings, monitoring medication changes, service evaluation, service implementation, outcome evaluation, medicines reconciliation, medication history, prescription review, medication management review, medication appropriateness, drug-related problems, patient education, career education, health care professional education, patient knowledge, therapeutic drug monitoring, interactions, clinical pharmacokinetics, drug information and pharmacotherapy, nutrition support
Section 5: Patient Safety and Quality Assurance	Medication errors, adverse drug events, pharmacovigilance, medication error reporting, root cause analysis, high-risk medicines, patient safety programmes, risk minimization procedures, computerised decision support, safe transcription steps, accurate recording of allergy etc., quality and safety procedures, safe medicines use (preparation and administration), labelling, quality assurance, traceability, drug efficacy/safety evaluations
Section 6: Education and Research	Development of curricula, participation in European-wide competency frameworks (e.g., for initial post graduate education and training in hospital pharmacy), research methods, publication skills, pharmacy practice research, pharmacoepidemiology, protocols

IMPORTANT ITEMS TO CONSIDER BEFORE WRITING YOUR ABSTRACT

We kindly invite all applicants to carefully consider the following before submitting your abstract:

The prerequisite for a good abstract is a well-conducted study with clear study aims and methodology.
The purpose of the study should be understandable and should allow the reader to follow what has been done at a glance.
The interventions and relevant outcomes should be clearly defined.
The authors are strongly requested, prior to submission, to see what is published in their relevant field and reflect on the added value of their work (e.g. if they present data of national or even local peculiarities).
Before writing the abstract, clarify for yourself what is the new evidence you want to present and consider why colleagues should be interested in your study.
The person listed as Presenting Author will receive all email notifications and information

ABSTRACT STRUCTURE

Abstracts must be structured and written in five paragraphs: (1) Background and importance, (2) Aim and objectives, (3) Materials and methods, (4) Results, (5) Conclusion and relevance.

This structure of an EAHP congress abstract has to be strictly adhered to. The online abstract submission will guide you through this process. Abstracts are limited to no more than 350 words (or less if you use graphs or tables) and must be typed in English. The online submission system does not allow you to enter abstracts above this limit.

A blinded approach is used during the abstract review process, so it is recommended that the institution name and/or country name are NOT indicated in the abstract title and text. Contact data will not be displayed during the review process. This process is meant to ensure that the reviews are conducted in the most ethical and professional way possible.

Title: The title of the abstract must be strictly coherent with the data included in the abstract. Do not use abbreviations. If you are submitting a case report, the area of focus and "case report" should appear in the title.
Contact data: The name of every author, preceded by initials, and the name of the presenting author underlined and entered as instructed via the online submission process. Omit degrees, titles or institutional appointments. Then, insert the institution, city, country where the study took place or the case occurred, as well as the email address of the presenting author.
(1) Background and importance: The background sets the frame of your study. To set the scene you must answer the following questions: What is already known about this topic? what are the unmet needs which brought you to conduct this study? To answer those questions, you have to do a literature search to identify whether other observations in this field are already published. You should present the problem you want to focus on and highlight why the answer to the problem is important. For case reports briefly summarize why this case is unique with medical literature references.
(2) Aim and objectives: State the aim of the study. This very clear and concise text should state: What did you investigate and among whom? If you present a case report give patient information regarding the main concerns and symptoms of the patient in this section. Add medical, family, and psychosocial history including genetic information if applicable and needed. Relevant past interventions and their outcomes should also be reported here.
(3) Materials and methods: Describe the method, facilities (e.g. equipment/statistics, models), design, setting and participants and interventions being used. Please describe the intervention and which outcome measures were used, when applicable. If you do a literature review or a meta-analysis you have to give information regarding the data sources and the study selection criteria. For case reports relevant physical examination (PE) and other clinical findings should be reported in this section. Also the timeline of the case with relevant data from this episode of care organized as a timeline could be important. In some cases diagnostics and prognostic characteristics should be given when applicable. Please present therapeutic Interventions in this section.
(4) Results: Present the necessary data in a way that it is easy to understand. There is no discussion of the results in this part. For case reports clinician- and patient-assessed outcomes when appropriate should be given here. Please refer also to important follow-up diagnostic and other test results. Intervention adherence and tolerability (how was this assessed?) besides adverse and unanticipated events should be reported.
(5) Conclusion and relevance: Discuss your results and compare to literature data if available. Are other observations in this field already published and relevant to be mentioned? Based on your results, what are the answers to the problem you focused on? What are the new findings? What are the implications for practice and research? For case reports, please present strengths and limitations in your approach to this case. Please discuss the relevant medical literature and the rationale for your conclusions. You must present the primary "take-away" lessons from this case report.
References and/or acknowledgements: These may be given at the end of the abstract.

Please click here to download the abstract structure template which can give you an idea of an abstract structure before the online submission. Please note that only submitted online abstracts will be reviewed.

We advise authors to use scientifically common principles in abstract writing.

Abbreviations may be used only if they are defined (spelled out in full text at first mention, followed by abbreviation in parentheses). Only general standard abbreviations for e.g. millilitres, seconds, and moles may be used without explanation.
Don't use excessive decimals e.g. a person might weigh 70,237 kg at a given moment, but only 70 kg should be mentioned.
References should be limited to a minimum, unless they are important for understanding methods, background or conclusions drawn. References should be added in a special field during the abstract submission, which is optional for use and not mandatory. Comprehensive bibliography can be displayed on the poster.
The authors are encouraged to submit well-edited abstracts and avoid submission of negligent work.

THE SUBMISSION PROCESS

Please consider the selection of the appropriate topic group before submission and compare with the examples prior to submission (Table 2). The topics are directly related to the EAHP statements.
For every abstract there must be 3-5 keywords selected by the authors. These are used for indexing purposes and have to be strictly in line with the content of the abstract.
You can only add 1 presenting author and up to 10 co-authors.
If you include an image, it must be a JPEG, Max. size of 500pxl. You can upload it in the section required when submitting your text.
You can submit multiple abstracts (Maximum 6).

THE REVIEW PROCESS

Each abstract is read, assessed and scored independently by two members of the SC and considered from two perspectives: the scientific content and the practical value of the submission.
In case of divergence between the two reviewers, the full SC discusses the submission in plenum and comes to a view whether to accept the abstract or not.
You will be notified in a timely manner as to the outcomes of the review process. You may be asked to revise your abstract and re-submit it.
All accepted abstracts will be allocated a spot for display at the congress.
The SC selects outstanding abstracts for poster walks and poster prize competition. Only those abstracts that are considered to have a high grade of relevance, innovation and added value in a well-written form are eligible for winning the poster prize.
The person listed as Presenting Author will receive all email notifications and information

SPECIFICS REGARDING STUDY TYPES AND METHODOLOGY

Particular attention is given to those abstracts that report scientifically valid results with appropriate study methodology giving the type of study design, interventions and outcomes. Outcomes could comprise either direct patient benefit, economical or clinical outcomes, or a combination of these.
Quantitative studies should include at least 30 patients.
Case Reports of a single or of a few patients will be accepted only if they include original and new data, that is not as yet published in literature. Please find below more information.
Case reports of ADRs will only be accepted if they present some kind of causality or probability assessment (e.g. Naranjo algorithm)
Everyday clinical practice studies are of interest if effectiveness is reported in an adequately chosen size of study population, which is in line with the prevalence of the disease studied.
New drug interactions not already described in the literature are encouraged to be reported but should come with a possible mechanism or explanation.If interventions of improvements processes are reported, please always report baseline values or data regarding the situation prior to the intervention as well. Otherwise comparison is not scientifically valid and therefore of limited value and validity.
Abstracts reporting purely lab sciences or associated sciences to pharmacy (e.g. microbiology, biology, chemistry etc.) are only accepted if the implications of these basic study findings to hospital pharmacy practice are made clear by the authors.
Drug Usage Evaluation (DUE) will only be considered if data of at least 30 patients are reported.
Authors planning to perform and report the results of a DUE are referred to relevant guidelines (e.g. those from American Society of Health-system Pharmacists).

EAHP welcomes well-described reports of cases that include the following:

Unreported or unusual side effects or adverse interactions involving medications.
Unexpected or unusual presentations of a disease.
New associations or variations in disease processes.
Presentations, diagnoses and/or management of new and emerging diseases.
An unexpected association between diseases or symptoms.
An unexpected event in the course of observing or treating a patient.
Findings that shed new light on the possible pathogenesis of a disease or an adverse effect.

Abstracts of case reports submited to the SC of EAHP with the aim to present a poster at the EAHP Congress should make a contribution to medical knowledge and must have educational value or highlight the need for a change in clinical practice or diagnostic/prognostic approaches. EAHP will not consider case reports describing preventive or therapeutic interventions, as these generally require stronger evidence.

Case reports should be writen in the same way like the other abstracts, meaning you have to use the same template.

REASONS FOR REJECTION

Abstracts/posters which have already been published at the international level may only be submitted if new data is included, the work is presented from the hospital pharmacy perspective or in a new context giving new inspirations for colleagues. Data, which have been published in international, peer-reviewed journals, should not be submitted.

This practice is well established in many countries.
This abstract is not relevant to Hospital Pharmacy.
The committee did not understand the abstract either due to English use or other reasons.
Quantitative studies should usually include at least 30 participants.
The abstract does not follow the given structure.
The conclusion does not cover the aim of the study.
Insufficient data was included to support your conclusions.
An inappropriate or weak study methodology was used.
The abstract is not presenting a study with a defined aim, a described method to obtain results, presentation of the obtained results and/or a conclusion based on these findings.
The abstract may be better suited as a GPI. Please resubmit using the appropriate format.
This topic has already been studied and published several times.
If a same author or a same group of authors has submitted the same abstract several times by mistake, they should send an email to the EAHP office to inform them and delete the duplicated abstracts. Otherwise, the judges will reject all abstracts.
If a same abstract has been submitted by its author(s) both as a Good Practice Initiative and as an abstract, the judges will reject both abstracts.
Other

RECOMMENDATIONS

Prior to conducting your study, reflect on the appropriate methodology and the number of patients (e.g. power analysis) that is necessary for this study design. Your study must include at least 30 patients to be accepted.
Ask other colleagues who are not involved in the study if the abstract is understandable and your proposed message is conveyed.
Consider the coherence of the abstract. If not coherent, please strongly consider rewriting your abstract.
The conclusion should be limited to statements that directly arise from the results presented. General statements without reflection of results or not in line with the aim of the study have to be avoided, as this is a common reason for abstract rejection.
The word count has to be adhered to. Be aware, that this is an abstract. The purpose of an abstract is to report clear, concise and relevant scientific results. Additional data, which are not ultimately needed for understanding, can be shown in the final poster.
Please avoid formatting of abstracts, don't use bold type, and ensure that at the final checking stage that any special characters or symbols used are displayed correctly.
Abstracts reporting vague or unclear interventions and/or irrelevant outcomes will be rejected.

DISCLAIMER

While every effort is made by publishers and editorial board to see that no inaccurate or misleading data, opinions, or statements appear in this Journal, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned.

Accordingly, the publishers and the European Association of Hospital Pharmacists (EAHP), the editorial committee and their respective employees, officers and agents, accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement. While every effort is made to ensure that drug doses and other quantities are presented accurately, readers are advised that new methods and techniques involving drug usage, described within this Journal, should only be followed in conjunction with the drug manufacturer's own published literature.

The author is responsible for obtaining the permission and licenses used to complete his/her study. Please note that EAHP cannot be held responsible in case an author disrespects his/her obligation to obtain the permission and licenses.

Please click here to read the author licence from BMJ.

IMPORTANT: The abstracts that were rejected last year CANNOT BE RESUBMITTED again unless major modifications have been made. Should the authors not follow this rule, they will be banned from the submission process for the following EAHP congresses.

Good luck to all!

The EAHP Scientific Committee

Poster guidelines

ABSTRACT POSTER GUIDELINES

The Registration of the Abstract/Poster Submitting Author to the EAHP Congress 2025 must be finalized by 07 February 2025. Passed this deadline, no poster panel will be provided at the Congress.
The PDF Version of the Poster must be sent to abstract[at]eahp[dot]eu by 07 February 2025.

SIZE:

841mm wide x 1189 mm high (A0) - portrait format (posters may not be smaller or larger than this size).

ASSISTANCE PROVIDED AT CONGRESS CENTRE

A poster panel on which to hang posters
A number for each poster board: this number indicates your assigned display station and also corresponds to the abstract number
Mounting materials, including double sided adhesive tape. Note that the use of drawing pins will NOT be allowed
Staff to advise during poster mounting

THE FOLLOWING COMPONENTS SHOULD BE INCLUDED AND USED AS HEADING WHERE APPROPRIATE

Title
Contact data
Background and Importance
Aim and Objectives
Materials and Methods
Results
Conclusion and Relevance
References and/or Acknowledgements

IT IS OFTEN USEFUL TO HAVE A SUMMARISED VERSION OF THE POSTER TO HAND TO INTERESTED READERS

You should also provide a notepad so that interested readers can leave their contact addresses, and a drop-box in which they can leave business cards or envelopes.

DESIGNING THE POSTER

Remember that viewers should be able to grasp the meaning of the poster without listening to an explanation or reading a report. To assist in this:

Communicate the message simply
Do not clutter the poster with too much detail
Only use materials that can be mounted on the poster board (plus handouts)
Use title lettering at least 2.5 cm high with text lettering at least 8 mm high and 0.7 mm thick. Test readability from 1 m or more away.
Use pie charts, histograms, graphs, tables, clip art, drawings, symbols and photos to illustrate key points. Use colour effectively in these and make them simple, rather than complex.
Design the poster to be read from left to right and top to bottom
Where possible, use one-line statements or bullet phrases to highlight key points, rather than full sentences (this list is set off by bullet points)
Use bold face type for headings and sub-headings
Proof-read the poster carefully. Ask a person independent of the project to review the text for clarity, organisation and brevity
Bring white correction tape or fluid and black felt tip pen to the meeting to correct errors or scratches

POSTER CERTIFICATES

Poster certificates for the presented posters will be sent to the authors by email within 15 days after the Congress. The duplicates can be provided by the author's request within 60 days after the last Congress. Please note that in case of loss of your poster certificates, the certificate duplicates of the last EAHP congress as well as any other previous EAHP congresses certificates will not be provided after the deadline of 60 days (13 May 2025).

POSTER PDFs FOR WEB SITE

Authors should send a pdf of their poster to abstract[at]eahp[dot]eu for inclusion on the EAHP web site following the congress. Deadline for receipt of your poster pdf is 07 February 2025.

DURING THE CONGRESS

The deadline to deliver and hang your poster at the Congress is Wednesday, 20 March 2024 from 10.15 to 17.00. Please note that there will be no access to the poster area to hang your posters before the indicated time. Please go to the poster area and check-in with the hostesses on duty to find out where and how to hang your poster. Note that all posters will be hung according to the Sections of the European Statements of Hospital Pharmacy and ATC code.

Presenters are expected to be present at their poster during 2 coffee breaks:

Thursday 13 March 2025, from 10.30 to 11.00
Friday 14 March 2025, from 10.30 to 11.30

DISCIPLINARY ACTION

If an author is unable to present his poster during the congress, he absolutely needs to notify the EAHP by sending an email to abstract[at]eahp[dot]eu. If same situation happens 3 years in a row, the EAHP reserves the right to reject any other abstracts submitted by the same author for future congresses. In addition, should the author not insure that their poster is hung during the congress either by the author or a colleague, the abstract will be removed from the online version of the abstract book.

Poster prize winners

ENCOURAGEMENT PRIZE FOR INVESTIGATORS

The best abstracts/posters (up to 12 award nominees) – with regards to aspects like originality, scientific quality and practical applicability – will be awarded with 3 prizes amounting EURO 750, EURO 500 and EURO 250.

Please be aware that the judges reserve the right not to award prizes if there are no clear winners.

Award nominees will be requested to give an oral presentation, taking place in different dates and times throughout the congress.

2025 award nominee oral presentations

TBC

Oral presentations are to consist of 5 minutes for presentation and 2 minutes for questions and answers. Poster prize nominees should disclose whether their work or comparable/similar work was submitted at an earlier International conference or somewhere else. More details will be sent to the authors by email. The winners will be announced at the closing ceremony on 14 March 2025.

Check the posters of past Congress winners below.

The Scientific Committee also choose up to 18 abstracts for the Poster walk. These abstracts will be highlighted in the online poster area in the congress platform and will include a recorded video of their presentation so you can watch their presentation at any time!

2024 Poster prize Winners (click on the title to download the poster)

1st Prize

COST-EFFECTIVENESS OF PHARMACEUTICAL PREOPERATIVE CONSULTATIONS: A FIVE-YEAR ANALYSIS

Gomez Daniel
(represented by Almudena Ribed Sanchez)

2nd Prize

A REVIEW OF THE EXPOSURE TO POTENTIALLY HARMFUL EXCIPIENTS THROUGH ORAL LIQUID FORMS IN PEDIATRIC INPATIENTS IN FRANCE

Marianne Bobillot

3rd Prize

SEVENTEEN DRUGS, ONE SAMPLE: ANALYSING MULTIPLE ANTI-TUBERCULOSIS DRUGS SIMULTANEOUSLY USING ONE METHOD

Mathieu Bolhuis
(represented by Aris Prins)

2023 Poster prize Winners (click on the title to download the poster)

27AC - Abstract 1st Prize - Shannon Nally

1st Prize

EVALUATING THE POTENTIAL CLINICAL AND ECONOMIC IMPACT OF CHEMOTHERAPY PRESCRIBING BY PHARMACISTS AT A UNIVERSITY TEACHING HOSPITAL

Shannon Nally

2nd Prize

BEDSIDE CHECK OF MEDICATION APPROPRIATENESS (BED-CMA) AS A RISK-BASED TOOL FOR BEDSIDE CLINICAL PHARMACY SERVICES: A PROOF-OF-CONCEPT STUDY AT THE TRAUMA SURGERY WARD

Greet van de Sijpe

3rd Prize

SING A TEXT-MINING APPROACH TO IDENTIFY THE CONTEXT VARIABLES LANGUAGE BARRIER, LIVING ALONE, COGNITIVE FRAILTY AND NON-ADHERENCE FROM ELECTRONIC HEALTH RECORDS (EHRs)

Simone ten Hoope

2022 Poster prize Winners (click on the title to download the poster)

1st Prize

IMPLEMENTATION OF AN INTERPROFESSIONAL PREOPERATIVE MEDICATION MANAGEMENT PROGRAMME IN CARDIAC SURGERY: A PRE–POST QUALITY IMPROVEMENT STUDY

Benedict Morath

2nd Prize

SELECTION OF CLINICAL RULES FOR THE SCREENING OF HIGH-RISK SITUATIONS IN PAEDIATRIC MEDICINE

Christian Skalafouris

3rd Prize

POSITIVE IMPACT OF AN IMPLEMENTED WARD PHARMACIST IN A MULTIPROFESSIONAL CANCER CARE TEAM IN GERMANY

Svenja Dierkes

2021 WINNERS (click on the title of the abstract to download the poster)

1^st Prize - Tessa Jaspers: EFFECT OF A MULTIFACETED CLINICAL DECISION SUPPORT INTERVENTION ON ADHERENCE TO THROMBOPROPHYLAXIS GUIDELINES IN NON-SURGICAL PATIENTS

2^nd Prize - Trine Andersen: A SCREENING MODEL TO IDENTIFY ELDERLY POLYPHARMACY PATIENTS THAT MAY BENEFIT FROM PHARMACIST LED MEDICATION REVIEW DURING HOSPITAL ADMISSION

3^rd Prize - Stefanie Sauer : USING DIFFERENT TECHNIQUES TO PREPARE ORODISPERSIBLE FILMS IN A HOSPITAL PHARMACY

2020 WINNERS (click on the title of the abstract to download the poster)

1^st Prize - Ulrika Gillespie: FACILITATORS AND BARRIERS TO PERFORMING COMPREHENSIVE MEDICATION REVIEWS AND FOLLOW-UP IN OLDER HOSPITALISED PATIENTS BY MULTIPROFESSIONAL WARD TEAMS INCLUDING A CLINICAL PHARMACIST

2^nd Prize - Ana Idoate: COST EFFECTIVENESS ANALYSIS OF MEROPENEM DOSE OPTIMISATION IN CRITICAL PATIENTS

3^rd Prize - Charlotte Quintens: UNDERDOSING WITH HIGH DOSE PIPERACILLIN/TAZOBACTAM ADMINISTERED VIA CONTINUOUS INFUSION IN OUTPATIENT PARENTERAL ANTIMICROBIAL THERAPY: A STABILITY OR VISCOSITY PROBLEM?

2019 WINNERS (click on the title of the abstract to download the poster)

1^st Prize - Meshal Alshakrah: DETERMINING THE NECESSARY COMPONENTS OF A PHARMACEUTICAL CARE COMPLEXITY SCREENING TOOL: AN E-DELPHI STUDY

2^nd Prize - Antonella Tonna: ENCOURAGING THE RESPONSIBLE USE OF ANTIBIOTICS: AWARENESS AND UNDERSTANDING AMONG A UNIVERSITY STUDENT POPULATION OF A COMMUNITY PHARMACY PUBLIC HEALTH CAMPAIGN IN SCOTLAND

3^rd Prize - Rana Al Adawi (the abstract was presented by Antonella Tonna): A SYSTEMATIC REVIEW OF PHARMACIST INPUT IN THE SCREENING, MANAGEMENT AND PREVENTION OF METABOLIC SYNDROME

Online abstract poster walks

Please find below the online abstract Poster Walks of the last EAHP Congresses.

Please select the desired annual Congress to view the posters presented in the different topic categories.

28th Congress of the EAHP

National Poster Prize Winners
PDF document	Poster number	Poster Title
	NP-001	EXTEMPORANEOUS FLUCYTOSINE 15,5% INTRAVAGINAL GEL TO TREAT REFRACTORY CANDIDA GLABRATA VULVOVAGINTIS – CASE REPORT
	NP-002	MEDICATION SAFETY: STRATEGIES & OPPORTUNITIES IN CLINICAL PHARMACY PRACTICE
	NP-003	PATIENT MEDICINE GUIDES SUPPORT SAFE MEDICATION TREATMENT AND DISCHARGE FROM THE HOSPITAL IN PAEDIATRIC SPECIALISED MEDICAL CARE
	NP-004	PALL-OLU.DE: A NEW DATABASE ON THE OFF-LABEL USE OF DRUGS IN PALLIATIVE MEDICINE
	NP-005	UNAUTHORISED MEDICATION USE IN ESTONIAN HOSPITALS
	NP-006	DRUGHOST, THE FIRST DATABASE OF UNAVAILABLE DRUGS IN EUROPE—AN ITALIAN MODEL: DATA ONE YEAR AFTER THE START OF THE PLATFORM
	NP-007	VALIDATION OF ANTIMICROBIAL DEFINED DAILY DOSE (DDD) FOR THE PAEDIATRIC POPULATION: FINAL RESULTS OF KIDDDS PROJECT
	NP-008	CASE REPORT : SINGLE-USE CRANIAL DRILLS, HIGH-RISK DEVICES!
	NP-009	BARRIERS AND FACILITATORS TO PHARMACY PROFESSIONALS’ SPECIALIST PUBLIC HEALTH SKILLS: A MIXED METHODS UK-WIDE PHARMACEUTICAL PUBLIC HEALTH EVIDENCE REVIEW
	NP-010	COMPATIBILITY OF LOCAL ANESTHETIC AND CORTICOSTEROID MIXTURES IN TRANSFORAMINAL EPIDURAL STEROID INJECTIONS
	NP-011	LINEZOLID THERAPEUTIC DRUG MONITORING AMONG CRITICALLY ILL ADULT PATIENTS AFTER CARDIOVASCULAR SURGERY
	NP-012	IMPROVING THE CLINICAL PHARMACIST HANDOVER PROCESS USING AN ADAPTED ISBAR COMMUNICATION TOOL WHEN TRANSFERRING PATIENTS FROM CORK UNIVERSITY MATERNITY HOSPITAL (CUMH) TO AN INTENSIVE CARE UNIT (ICU) WITHIN CORK UNIVERSITY HOSPITAL (CUH).

Section 1: Introductory Statements and Governance
PDF document	Poster number	Poster Title
	1ISG-001	ANALYSIS OF THE USE OF ORAL ONCOLOGY TARGETED THERAPIES IN A REGION OF SPAIN
	1ISG-002	PHARMACIST RISK STRATIFICATION: A CHARACTERISATION OF PATIENTS WITH LOW SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR WHO DIED WITHIN 90 DAYS OF HOSPITAL DISCHARGE
	1ISG-003	DIGITAL TRANSFORMATION OF THE HOSPITAL/TERRITORIAL PHARMACY - TELEPHARMACY NEW DIMENSION OF PATIENT CARE MODELS
	1ISG-004	MULTIDISCIPLINARY MANAGEMENT OF CENTRAL VENOUS CATHETERS (CVCS) IN HEMODIALYSIS PATIENTS.
	1ISG-005	ASSESSMENT OF A MANAGEMENT TOOL REGARDING MEDICAL DEVICE VIGILANCE
	1ISG-006	ECONOMIC SAVING OF THE PREPARATION OF SUBCUTANEOUS FORMULATIONS COMPARED TO INTRAVENOUS: FOCUS ON DARATUMUMAB IN THREE HEALTHCARE COMPANIES
	1ISG-007	HTA ANALYSIS FOR THE INCLUSION OF ANDEXANET ALFA (AA) WITHIN THE HOSPITAL THERAPEUTIC HANDBOOK (HTH) - THE EXPERIENCE OF AN ITALIAN CENTER SPECIALIZING IN CARDIOVASCULAR DISEASES
	1ISG-008	USABILITY EVALUATION OF AN INSULIN MANAGEMENT SOLUTION WITHIN AN ELECTRONIC PATIENT RECORD
	1ISG-009	PHARMACOECONOMIC ANALYSIS OF AN ALTERNATIVE DOSAGE REGIMEN FOR PALIVIZUMAB
	1ISG-010	ECONOMIC IMPACT OF THE CLINICAL PHARMACIST ON THE REDUCTION OF DRUG-RELATED PROBLEMS BEFORE THE INITIATION OF AN ANTI-TUMOR TREATMENT - A PROSPECTIVE MULTICENTER TRIAL
	1ISG-011	OPPORTUNITY FOR DAILY HOME-BASED MANAGEMENT OF CHRONIC PATIENTS FROM THE SAME AREA USING AN INTERPROFESSIONAL NETWORK MODEL DEVISED, SET UP AND IMPLEMENDET FOR THE COVID-19
	1ISG-012	BALANCING CLINICAL BENEFITS AND COST SAVINGS: COMPASSIONATE DRUG USE AT AN ITALIAN UNIVERSITY HOSPITAL – EVIDENCE AND INSIGHTS
	1ISG-013	REAL-LIFE DATA OF CDK4/6 INHIBITORS PALBOCICLIB, RIBOCICLIB AND ABEMACICLIB IN LOCALLY ADVANCED OR METASTATIC BREAST CANCER: EFFECTIVENESS EVALUATION
	1ISG-014	SUSTAINABLE HEALTHCARE: AN EXAMPLE OF PHARMACEUTICAL INTERVENTION
	1ISG-015	ASSESSMENT OF PREPARATORY STAFF'S KNOWLEDGE OF CARCINOGENIC, MUTAGENIC AND REPROTOXIC (CMR) RISKS
	1ISG-016	OCRELIZUMAB FOR THE TREATMENT OF RECAPTING AND PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS IN NATIONAL HEALTH SYSTEM: A COST EFFECTIVENESS ANALYSIS
	1ISG-017	THE THREE HORIZONS METHOD AS A TOOL FOR DEFINING THE HOSPITAL PHARMACY RESIDENT OF THE FUTURE(HPRF)
	1ISG-018	TEN-YEAR DRUG SURVIVAL ANALYSIS IN MODERATE TO SEVERE PLAQUE PSORIASIS FIRST-LINE TREATMENT
	1ISG-019	DO ALL SURGICAL SPECIALTIES HAVE AN IDENTICAL CARBON FOOTPRINT WHITIN AN AMBULATORY UNIT ?
	1ISG-020	DRUG DAY THERAPY APPLIED TO LUSPATERCEPT: RESULTS OBTAINED IN AN ITALIAN ANTIBLASTIC DRUG UNIT
	1ISG-021	1 YEAR-REVIEW OF THE EKOSONIC® ENDOVASCULAR SYSTEM (BOSTON SCIENTIFIC) IN THE MANAGEMENT OF PULMONARY EMBOLISM IN AN INTERVENTIONAL CARDIOLOGY DEPARTMENT
	1ISG-022	HOSPITAL PHARMACISTS' PERCEPTIONS OF THEIR PROFESSION IN TWO EUROPEAN COUNTRIES
	1ISG-023	ECONOMIC IMPACT DERIVED FROM PARTICIPATION ON ANTIRETROVIRAL THERAPY CLINICAL TRIALS IN A THIRD-LEVEL HOSPITAL
	1ISG-024	SINGLE-USE MEDICAL DEVICES IN THE TREATMENT OF CHRONIC DISEASES: WHAT IS THE ENVIRONMENTAL IMPACT?
	1ISG-025	ANALYSIS OF THE COMPLEXITY OF THE CLINICAL TRIALS CARRIED OUT IN A THIRD-LEVEL HOSPITAL

Section 2: Selection, Procurement and Distribution
PDF document	Poster number	Poster Title
	2SPD-001	CLINICAL IMPACT AND COST SAVINGS OF AN OUTPATIENT ANTIMICROBIAL THERAPY PROGRAMME: A FOCUS ON SELF-ADMINISTRATION
	2SPD-002	EVALUATION OF THE EFFECTIVENESS AND RELATED COST OF ONCOLOGY DRUGS USED IN SPECIAL SITUATIONS, IN A THIRD-LEVEL UNIVERSITY HOSPITAL
	2SPD-003	PROPER MANAGEMENT AND ECONOMIC BURDEN OF UNUSED MEDICATIONS DISPOSAL IN A SUSTAINABLE LATIN AMERICAN HOSPITAL: A RETROSPECTIVE STUDY
	2SPD-004	BUDGETARY IMPACT OF THE INTRODUCTION OF CABOTEGRAVIR PLUS RILPIVIRINE LONG-ACTING IN A THIRD LEVEL HOSPITAL
	2SPD-005	ALTERNATIVE TO THE TREATMENT OF POOR GRAFT FUNCTION AFTER HAEMATOPOIETIC STEM CELL TRANSPLANTATION: ELTROMBOPAG
	2SPD-006	IMPACT AND CONSEQUENCES OF THE USE OF HUMAN POLYVALENT IMMUNOGLOBULIN DURING THE COVID-19 PANDEMIC (2019-2022)
	2SPD-007	USE AND COST EVOLUTION OF ADALIMUMAB OVER EIGHT YEARS IN A LOCAL HOSPITAL
	2SPD-008	SWITCHING TO A BIOSIMILAR ADALIMUMAB IN DUTCH UNIVERSITY MEDICAL CENTERS: IT IS NOT THAT HARD!
	2SPD-009	A FIVE-YEAR RETROSPECTIVE REPORT ON COMPREHENSIVE MEDICINE PROCUREMENT WITHIN A PUBLIC GROUP PROCUREMENT ORGANISATION
	2SPD-010	IDENTIFYING AND QUANTIFYING DRUG-RELATED WASTE IN A HEALTHCARE ESTABLISHMENT
	2SPD-011	AVAILABILITY OF LIQUID ANTIMICROBIALS – A NATIONAL ANALYSIS OF THE CURRENT SUPPLY SITUATION
	2SPD-012	APPLICATION OF FAILURE MODE AND EFFECTS ANALYSIS TO IMPROVE AUTOMATED DISPENSING CABINETS' DRUG STOCK MANAGEMENT PROCESSES
	2SPD-013	A COMPARATIVE LIFE CYCLE ASSESSMENT OF DIFFERENT PACKAGING OPTIONS FOR ALBUMIN DISTRIBUTION
	2SPD-014	ECO-CONSCIOUS HEALTHCARE PRODUCTS SUPPLY: INVESTIGATING THE EFFECTS OF FEWER ORDERS
	2SPD-015	INTEGRATED HEALTHCARE LOGISTICS: KANBAN SOLUTION FOR MANAGEMENT OF DIALYSIS WAREHOUSES PILOT CASE
	2SPD-016	DATA-DRIVEN SELECTION OF A MEDICATION MANAGEMENT MODEL IN HOSPITALISATION WARDS
	2SPD-017	RISK IDENTIFICATION IN ANTIDOTE AND EMERGENCY PREPAREDNESS
	2SPD-018	IMPACT OF INHALERS ON CO2 EMISSION IN A HEALTH AREA
	2SPD-019	TOWARDS A SUSTAINABLE OPERATING ROOM : FEEDBACK ON ACTIONS CARRIED OUT AROUND MEDICAL DEVICES
	2SPD-020	DESIGN AND EVALUATION OF AN INNOVATIVE AIRBORNE TRANSPORT SYSTEM FOR BLOOD-DERIVED DRUGS UNDER EMERGENCY CONDITIONS

Section 3: Production and Compounding
PDF document	Poster number	Poster Title
	3PC-001	TOPICAL COMPOUNDED CLINDAMYCIN SOLUTION MADE FROM ORAL DOSAGE FORMS, CONTROL AND STABILITY STUDY
	3PC-002	STABILITY OF TENECTEPLASE SYRINGES AFTER FRACTIONATION
	3PC-003	SUITABILITY OF ELASTOMERIC PUMPS FOR DRUG STORAGE
	3PC-004	DRUG WASTE OF READY-TO-ADMINISTER SYRINGES IN THE INTENSIVE CARE UNIT: ASEPTICALLY PREPARED SYRINGES VERSUS PREFILLED STERILISED SRYINGES
	3PC-005	PREPARATION OF EPICUTANEOUS TESTS WITH MINOXIDIL AT 2% AND 5%.
	3PC-006	STABILITY STUDY OF CLOBAZAM LIQUID ORAL FORMS FOR PEDIATRIC PATIENTS
	3PC-007	CONTAINMENT PERFORMANCE ASSESSMENT OF CHEMFORT® (ONGUARD®2) CLOSED SYSTEM TRANSFER DEVICE ACCORDING TO 2016 DRAFT NIOSH PROTOCOL AT FIRST AND TENTH ACTIVATIONS END OF SHELF LIFE.
	3PC-008	STABILITY OF PARENTERAL NUTRITION ADMIXTURES: FOCUS ON PRECIPITATION.
	3PC-009	THE EFFECT OF ACCELERATED LIGHT (STRESS) AND NATURAL SUNLIGHT EXPOSURES ON CETUXIMAB (ERBITUX®): EVALUATION OF AGGREGATE FORMATION AND FUNCTIONALITY
	3PC-010	DEVELOPMENT OF A STABLE PARENTERAL SOLUTION OF TOPIRAMATE FOR EMERGENCY TREATMENT OF STATUS EPILEPTICUS
	3PC-011	MUCOSECTOMY : FEASIBILITY STUDY OF THE AUTOMATED PREPARATION OF A STERILE SOLUTION OF 5/10% FRUCTOSE GLYCEROL.
	3PC-012	CONTENT UNIFORMITY OF SODIUM BENZOATE CAPSULES: VALIDATION OF A METHOD USING QCPREP®
	3PC-013	RADIOPHARMACEUTICAL SINGLE-VIAL COLD KIT FORMULATION OF FAPI-04, AN EXPERIMENTAL VECTOR FOR GALLIUM-68 PET IMAGING IN ONCOLOGY
	3PC-014	PHYSICOCHEMICAL STABILITY OF BEVACIZUMAB 25 MG/ML CONCENTRATE (VEGZELMA®) IN ORIGINAL GLASS VIALS AFTER FIRST OPENING
	3PC-015	MICROBIOLOGICAL PERFORMANCE QUALIFICATION OF THE ROBOTIC SYSTEMS APOTECASYRINGE AND APOTECAUNIT
	3PC-016	PHYSICOCHEMICAL STABILITY OF MOXIFLOXACIN 1 MG/0,2 ML SYRINGES FOR INTRACAMERAL ADMINISTRATION
	3PC-017	ELABORATION OF DEFEROXAMINE EMULSION 0.5% FOR HYPERPIGMENTATION DUE TO INTRAVENOUS IRON EXTRAVASATION
	3PC-018	GLASS AMPOULE HANDLING PRACTICES IN DUTCH HEALTHCARE: A COMPREHENSIVE ASSESSMENT
	3PC-019	DEVELOPMENT A TOPICAL EMULSION FOR THE TREATMENT OF THIRD-DEGREE BURN PATIENTS CANDIDATES FOR SKIN GRAFT
	3PC-020	PREVENTION OF INFECTIOUS RISK IN PATIENTS TREATED WITH TUMOR NECROSIS FACTOR ALPHA INHIBITORS (ANTI-TNFΑ)
	3PC-021	FORMULATION OF VORICONAZOLE OVULES AND EFFICACY IN VULVOVAGINAL CANDIDIASIS BY CANDIDA GLABRATA: A CASE REPORT.
	3PC-022	DESIGN AND STABILITY STUDY OF AN ISONIAZID AND PYRIDOXINE ORAL LIQUID FORMULATION
	3PC-023	NEW ACTIVITIES WITHIN A CLINICAL TRIAL MANAGEMENT UNIT: WHAT NEW RISKS FOR THE STAFF?
	3PC-024	IMPLEMENTATION OF A STRATEGY TO OVERCOME THE POTENTIAL TOXIC EFFECTS OF PROPYLENE GLYCOL IN NEONATES
	3PC-025	STABILITY STUDY OF STANDARDISED FLUID THERAPY PREPARED BY THE PHARMACY DEPARTMENT TO TREAT PEDIATRIC DIABETIC KETOACIDOSIS
	3PC-026	COST SAVINGS ASSOCIATED WITH ROMIPLOSTIM REPACKAGING IN PATTIENT WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA
	3PC-027	USE OF AUTOMATED COMPOUNDING DEVICES IN PEDIATRIC PARENTERAL NUTRITION: A GOOD WAY TO ENSURE SAFETY
	3PC-028	FOR A MORE ECONOMICAL AND ECOLOGICAL CENTRAL STERILE SERVICES DEPARTMENT (CSSD) : BACK TO THE CONTAINER
	3PC-029	PH MEASUREMENT: NOT AS SIMPLE AS WE THINK? A CASE OF SODIUM PERCHLORATE INJECTIONS
	3PC-030	STABILITY STUDY OF AN EPIDURAL ANALGESIC CONCENTRATE FOR INFUSION USED DURING CHILDBIRTH
	3PC-031	USABILITY OF SEMI-SOLID EXTRUSION 3D PRINTING IN HOSPITAL PHARMACY SETTINGS TO PRODUCE PERSONALISED ORAL MEDICATIONS FOR PEDIATRIC PATIENTS
	3PC-032	OPTIMIZATION OF AN INSULIN 1 IU/ML EYE DROP FORMULATION FOR THE TREATMENT OF CORNEAL ULCERS
	3PC-033	KIRO ISOLATOR®: A NEW, RELIABLE, ROBOTIC DEVICE FOR THE COMPOUNDING OF INJECTABLE ANTICANCER DRUGS
	3PC-034	FORMULATION OF KETAMINE 1% AND AMITRIPTYLINE 1% GEL IN PRURITIC EPIDERMOLYSIS BULLOSA: A CASE REPORT
	3PC-035	PATCH TESTS WITH HAZARDOUS DRUGS: IS IT POSSIBLE TO ENSURE SAFETY DURING PRODUCTION?
	3PC-036	RISK ANALYSIS OF THE PHARMACEUTICAL CIRCUIT FOR INJECTABLE CHEMOTHERAPIES AFTER IMPLEMENTATION OF DRUGLOG ®.
	3PC-037	ALUMINIUM IN PEDIATRIC PARENTERAL NUTRITION: ARE MULTICHAMBER-BAGS THE SAFER CHOICE?
	3PC-038	AUTOLOGOUS SERUM EYE DROPS PREPARATION: APPROACH TO THE FILTRATION STEP IMPACT ON THE CONCENTRATION OF ACTIVE MOLECULES
	3PC-039	EARLY DE-RISKING OF THE STABILITY OF A PERSONALISED, STERILE BACTERIOPHAGE SUSPENSION ON THE BASIS OF ADVANCED KINETIC MODELING
	3PC-040	RADIOCHEMICAL PURITY DETERMINATION OF 177LU-PSMA-617: DEVELOPMENT AND VALIDATION OF A HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY ANALYTICAL METHOD
	3PC-041	PUBLIC PRODUCTION OF THERAPEUTIC BACTERIOPHAGES
	3PC-042	STERILE AND NON-STERILE COMPOUNDING: RISK ANALYSIS AND IMPROVEMENT MEASURES
	3PC-043	INTRAVITREAL PREPARATION OF LIPOSOMAL B AMPHOTERICIN: FROM FORMULATION STUDY TO PREPARATION
	3PC-044	A PHYSICO-CHEMICAL STABILITY STUDY OF VANCOMYCIN EYE DROP AFTER DIFFERENT THAWING TIMES
	3PC-045	RETROSPECTIVE STUDY OVER 6 YEARS OF THE TREND IN FUNGAL CONTAMINATION OF CONTROLLED ATMOSPHERE AREAS WITHIN A CELL THERAPY UNIT.
	3PC-046	RISK OF PERSONNEL EXPOSURE TO HAZARDOUS DRUGS IN ROBOTIC COMPOUNDING
	3PC-047	PEDIATRIC IV ANTIFUNGAL ADMIXTURES: CENTRALISATION'S ECONOMIC CONSEQUENCES

Section 4: Clinical Pharmacy Services
PDF document	Poster number	Poster Title
	4CPS-001	COMPARATIVE ANALYSIS OF TWO PHARMACOKINETIC PROGRAMMES FOR LITHIUM ADJUSTMENT
	4CPS-002	PHARMACEUTICAL CARE IN POSTOPERATIVE PAIN MANAGEMENT AT ADMISSION AND DISCHARGE
	4CPS-003	EVALUATION OF CLINICAL VARIABLES IMPACT ON ENOXAPARIN DOSING AND ANTIXA CONCENTRATION
	4CPS-004	IMPACT OF INADEQUATE EMPIRICAL THERAPY ON THE MORTALITY RATE IN PSEUDOMONAS AERUGINOSA INFECTIONS
	4CPS-005	DRUG PERSISTENCE OF JAK INHIBITORS COMPARED TO BIOLOGIC DRUGS IN REAL-WORLD PRACTICE IN PATIENTS WITH RHEUMATOID ARTHRITIS
	4CPS-006	ADHERENCE TO NEBULIZED ANTIBIOTICS IN CYSTIC FIBROSIS PATIENTS AFTER STARTING ELEXACAFTOR/TEZACAFTOR/IVACAFTOR
	4CPS-007	ADALIMUMAB IN THE TREATMENT OF RECALCITRANT SWEET SYNDROME: A CASE REPORT
	4CPS-008	ANALYSIS OF PHARMACEUTICAL INTERVENTIONS RELATED TO ANTITHROMBOTIC DRUGS IN EMERGENCY DEPARTMENT
	4CPS-009	NEONATAL DIAGNOSIS AND TREATMENT OF STIFF BABY SYNDROME: A CASE REPORT
	4CPS-010	CAN ERENUMAB IMPROVE QUALITY OF LIFE PERCEIVED BY PATIENTS?
	4CPS-011	REAL-WORLD EFFECTIVENESS AND SURVIVAL OF GUSELKUMAB IN PATIENTS WITH PSORIASIS AND PSORIASIC ARTRHITIS: MULTICENTER ANALYSIS IN DAILY CLINICAL PRACTICE BY THE VALENCIAN COMMUNITY PSORIASIS GROUP.
	4CPS-012	IMPROVING PARENTAL MEDICATION LITERACY BY PHARMACIST-LED DISCHARGE COUNSELLING IN PAEDIATRIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION
	4CPS-013	INTRAVENOUS LEVETIRACETAM SUPPLETION DURING HAEMODIALYSIS PRESERVED STABLE THERAPEUTIC SERUM CONCENTRATIONS: A CASE REPORT
	4CPS-014	REAL WORLD DATA ON THE USE OF PCSK9 INHIBITOR TREATMENTS IN HYPERCHOLESTEROLEMIA
	4CPS-015	ASSESSMENT OF IN-HOSPITAL ANTIBIOTICS CONSUMPTION PATTERN ACCORDING TO THE WHO AWARE CLASSIFICATION IN A LOCAL HEALTH AUTHORITY
	4CPS-016	EXPERIENCES, VIEWS AND ATTITUDES OF HOSPITAL NURSING STAFF TOWARDS THE IMPLEMENTATION OF THE UNIT DOSE DISPENSING SYSTEM FOR INPATIENTS: A QUALITATIVE INTERVIEW STUDY
	4CPS-017	COMPARATIVE STUDY BETWEEN TIXAGEVIMAB/CILGAVIMAB AND SOTROVIMAB IN PATIENTS WITH COVID-19: A MONOCENTRIC EXPERIENCE AT UNIVERSITY HOSPITAL
	4CPS-018	SWITCHING BETWEEN CALCITONIN GENE RELATED PEPTIDE MONOCLONAL ANTIBODIES IN THE PROPHYLAXIS OF MIGRAINE
	4CPS-019	DIFFERENCES IN MEROPENEM DOSE ADJUSTMENT WITH CALCULATION OF GLOMERULAR FILTRATION RATE THROUGH DIFFERENT FORMULAS.
	4CPS-020	EVALUATION OF THE EFFECTIVENESS OF MONOCLONAL ANTIBODIES AGAINST MIGRAINE HEADACHE
	4CPS-021	PERFORMANCE OF MULTIPLE TRIGGER TOOLS IN IDENTIFYING MEDICATION-RELATED HOSPITAL READMISSIONS
	4CPS-022	THE EFFECT OF DIGITAL CLINICAL DECISION SUPPORT ON PHARMACOTHERAPY IN HOSPITALISED (MORBIDLY) OBESE PATIENTS: A PROSPECTIVE INTERVENTION STUDY
	4CPS-023	OPTIMISING BIOLOGIC THERAPY IN SEVERE UNCONTROLLED ASTHMA PATIENTS ON OMALIZUMAB TREATMENT
	4CPS-024	ANALYSIS OF POLYMEDICATION AND ADEQUACY TREATMENT RECOMMENDATIONS IN PATIENTS WITH MULTIPLE SCLEROSIS IN A TERTIARY LEVEL HOSPITAL.
	4CPS-025	MANAGEMENT OF COVID-19 WITH NIRMATRELVIR/RITONAVIR AND TACROLIMUS MONITORING IN RENAL TRANSPLANTATION: A CASE REPORT
	4CPS-026	ACCEPTABILITY AND WILLINGNESS TO SWITCH ANTIRETROVIRAL TREATMENT IN PATIENTS WITH LONG-ACTING INJECTABLE THERAPY CRITERIA.
	4CPS-027	ANALYSIS OF CARDIOVASCULAR RISK ASSOCIATED WITH IRREVERSIBLE INHIBITOR OF BRUTON'S TYROSINE KINASE TREATMENT IN PATIENTS WITH CHRONIC LYMPHOID LEUKEMIA
	4CPS-028	ANALYSIS OF INTERACTIONS DETECTED IN THE CONCOMITANT USE OF ANTINEOPLASTIC AGENTS AND PHYTOTHERAPY IN ONCOHEMATOLOGY PRACTICE AND INTERVENTIONS CARRIED OUT.
	4CPS-029	USE OF TOPICAL 1% CIDOFOVIR ON SKIN LESIONS IN A PATIENT WITH MONKEYPOX
	4CPS-030	ANALYSIS OF ADHERENCE TO GROWTH HORMONE TREATMENT IN PAEDIATRIC PATIENTS.
	4CPS-031	A POPULATION PHARMACOKINETIC MODEL OF VEDOLIZUMAB IN ADULT PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PRELIMINARY ANALYSIS
	4CPS-032	PHARMACEUTICAL INTERVENTIONS FOR MEDICATION RECONCILIATION IN COMPLEX CHRONICALLY ILL PATIENTS
	4CPS-033	REAL-WORLD TREATMENT PATTERNS AND OUTCOMES OF SELECTIVE CYCLIN-DEPENDENT KINASE (CDK) 4/6 INHIBITORS UTILISATION IN METASTATIC BREAST CANCER – REVEAL STUDY
	4CPS-034	REAL-WORLD SAFETY AND TOLERABILITY IN PATIENTS TREATED WITH ABEMACICLIB AND ENDOCRINE THERAPY: A RETROSPECTIVE OBSERVATIONAL STUDY
	4CPS-035	IMPACT OF ANTIBIOTIC STEWARDSHIP PROGRAMME (ASP) ON ANTIBIOTIC USE AND CLINICAL OUTCOMES IN PATIENTS HOSPITALISED WITH COMMUNITYACQUIRED PNEUMONIA (CAP): RETROSPECTIVE OBSERVATIONAL BEFORE-AFTER STUDY
	4CPS-036	EVALUATION OF THE DIAGNOSIS AND ANTIBIOTIC PRESCRIPTION PATTERN IN PATIENTS HOSPITALISED WITH URINARY TRACT INFECTIONS (UTIS)
	4CPS-037	INTEGRATION OF THE PHARMACIST IN THE MULTIDISCIPLINARY COMMITTEE OF URO ONCOLOGICAL PATHOLOGY
	4CPS-038	CASE REPORT ON AUTONOMIC NEUROPATHY INDUCED BY BORTEZOMIB
	4CPS-039	DRUG-RELATED PROBLEMS AT HOSPITAL ADMISSION IN ELDERLY PATIENTS WITH CARDIOVASCULAR DISEASES
	4CPS-040	ADHERENCE TO GUIDELINES AND PRESCRIBING TRENDS OF STATINS IN PATIENTS WITH ACUTE CORONARY SYNDROME
	4CPS-041	SILENCE SPEAKS LOUDER THAN WORDS: OMISSION OF PRESCRIPTION IN THE EMERGENCY ROOM
	4CPS-042	OVERDOSE OF DARBEPOETIN IN PATIENTS WITH CHRONIC KIDNEY FAILURE. ROOM FOR IMPROVEMENT WITH PHARMACIST INTERVENTIONS
	4CPS-043	EFFICACY AND SAFETY OF ANTI-CALCITONIN GENE-RELATED PEPTIDE MONOCLONAL ANTIBODIES FOR MIGRAINE PROPHYLAXIS: ONE-YEAR REAL-LIFE EXPERIENCE
	4CPS-044	PRE-EXPOSURE PROPHYLAXIS DROP-OUT: FOLLOW-UP AND RELINKING THROUGH TELEPHONE CONTACT
	4CPS-045	OPTIMISATION OF OMALIZUMAB FOR SEVERE ALLERGIC ASTHMA IN PEDIATRIC POPULATION
	4CPS-046	EVALUATION OF HEALTH IMPACT IN INFLIXIMAB-TREATED PATIENTS WITH INFLAMMATORY BOWEL DISEASE: INCORPORATION OF PATIENT REPORTED OUTCOME MEASURES (PROMS)
	4CPS-047	EVALUATION OF ANTIRESORPTIVE AGENT-RELATED OSTEONECROSIS THERAPY BY MEASURING CONCENTRATIONS OF PENICILLIN G IN JAWBONE
	4CPS-048	A COMPLEX, ADHERENCE-IMPROVING PHARMACIST INTERVENTION TO REDUCE HYPERPHOSPHATEMIA IN HEMODIALYSIS PATIENTS
	4CPS-049	TREATMENT OF ROSAI DORFMAN'S HISTIOCYTOSIS: CASE REPORT
	4CPS-050	PRE-EXPOSURE PROPHYLAXIS FOR HIV INFECTION: PREVALENCE OF SEXUALLY TRANSMITTED INFECTIONS (STIS) AND ADHERENCE DURING THE PROGRAMME
	4CPS-051	COST SAVING IMPACT OF BIOSIMILAR TRASTUZUMAB FOR THE TREATMENT OF HER-2 POSITIVE BREAST CANCER IN A HOSPITAL
	4CPS-052	EVALUATION OF USTEKINUMAB USE IN INFLAMMATORY BOWEL DISEASES
	4CPS-053	OUTCOMES OF INFRADOSED ANTIMICROBIALS PATIENTS WITH BACTEREMIA IN THE EMERGENCY DEPARTMENT
	4CPS-054	NETWORK META-ANALYSIS OF THERAPEUTIC ALTERNATIVES FOR MODERATE TO SEVERE ULCERATIVE COLITIS
	4CPS-055	PHARMACOGENETICS AND ITS APPLICATIONS IN PERSONALISED MEDICINE: A SYSTEMATIC REVIEW
	4CPS-056	EFFECTIVENESS AND SAFETY OF ERIBULIN THERAPY IN PATIENTS WITH METASTATIC BREAST CANCER.
	4CPS-057	EFFECTIVENESS, SAFETY, AND PATIENT-REPORTED OUTCOME OF JANUS KINASE INHIBITORS IN RHEUMATOID ARTHRITIS IN CLINICAL PRACTICE
	4CPS-058	ANALYSIS OF ANTIFUNGAL CONSUMPTION IN AN INTENSIVE CARE UNIT OVER 5 YEARS
	4CPS-059	SEVENTEEN DRUGS, ONE SAMPLE: ANALYSING MULTIPLE ANTI-TUBERCULOSIS DRUGS SIMULTANEOUSLY USING ONE METHOD
	4CPS-060	IMPACT OF OBESITY ON VANCOMYCIN PHARMACOKINETIC PARAMETERS IN ADULT PATIENTS
	4CPS-061	SAFETY AND EFFECTIVENESS OF THE OFF-LABEL USE OF CANGRELOR IN PERIOPERATIVE BRIDGING: A CASE SERIES
	4CPS-062	POSITIVE IMPACT OF EXTENDING NATALIZUMAB DOSAGE INTERVAL FROM EVERY 4 WEEKS TO EVERY 6 WEEKS IN MULTIPLE SCLEROSIS PATIENTS
	4CPS-063	CLINICAL PHARMACIST IN THE MULTIDISCIPLINARY TEAM IN THE INTENSIVE CARE UNIT IMPROVE THE QUALITY OF MEDICINE THROUGHOUT THE PATIENT'S HOSPITAL STAY
	4CPS-064	REVIEW OF USE OF IMMUNOGLOBULINS IN TERTIARY HOSPITAL
	4CPS-065	EXPERIENCE OF IMMUNOCHEMOTHERAPY VERSUS STANDARD TREATMENT IN SMALL-CELL LUNG CANCER
	4CPS-066	THERAPEUTIC DRUG MONITORING OF ANTI-TNF THERAPY IN INFLAMMATORY BOWEL DISEASE.
	4CPS-067	EFFECTIVENESS AND SAFETY OF 1 IU/ML TOPICAL INSULIN TO TREAT PERSISTENT CORNEAL ULCERS
	4CPS-068	TARGET THERAPY IN NON-SMALL CELL LUNG CANCER (NSCLC): A RETROSPECTIVE ANALYSIS TO GUARANTEE THE APPROPRIATENESS OF THE PRESCRIPTIONS IN OUR HOSPITAL
	4CPS-069	OUTPATIENT SATISFACTION IN THE TELEPHARMACY PROGRAMME OF A TERTIARY HOSPITAL PHARMACY SERVICE
	4CPS-070	EVALUATION OF AVOIDED COST IN CLINICAL TRIALS WITH IMMUNOTHERAPY IN LUNG CANCER
	4CPS-071	ANTIBIOTIC CONSUMPTION MONITORING BY AWARE CLASSIFICATION: A SIX MONTHS ANALYSIS
	4CPS-072	SETMELANOTIDE IN MONOGENIC OBESITY: A CASE REPORT
	4CPS-073	ANALYSIS OF THE REASONS FOR CHANGING TREATMENT IN PATJENTS WITH MULTIPLE SCLEROSIS
	4CPS-074	DRUG CLASSES COMMONLY RELATED TO MEDICATION ERRORS AT TRANSITION OF CARE
	4CPS-075	A SYSTEMATIC REVIEW OF THE TARGET PHARMACOKINETIC/PHARMACODYNAMIC PARAMETERS OF ANTIBIOTICS TREATING GRAM-NEGATIVE INFECTIONS
	4CPS-076	EFFECTIVENESS AND SAFETY OF DUPILUMAB AND TRALOKINUMAB IN ATOPIC DERMATITIS IN CLINICAL PRACTICE
	4CPS-077	PHARMACEUTICAL INTERVENTIONS AFTER DETECTION OF NON-HANDLING MEDICATIONS IN PATIENTS WITH DYSPHAGIA
	4CPS-078	QUALITY OF LIFE AND PATIENT-REPORTED OUTCOMES WITH MULTIPLE MYELOMA TREATEDS WITH DARATUMUMAB
	4CPS-079	INDIRECT COMPARISON OF IL-13 INHIBITORS PLUS TOPICAL CORTICOSTEROIDS IN MODERATE TO SEVERE ATOPIC DERMATITIS
	4CPS-080	METASTATIC HER2-POSITIVE BREAST CARCINOMA CASE REPORT: ANTI-HER2 TREATMENT MAINTENANCE DESPITE OLIGOPROGRESSION
	4CPS-081	CONSENSUS ON INDICATORS FOR MEDICATION-RELATED READMISSIONS: A DELPHI STUDY
	4CPS-082	DESCRIPTIVE STUDY OF POST-SURGERY ANALGESIC PRESCRIPTIONS
	4CPS-083	MEDICATION RECONCILIATION INTERVENTIONS IN AN EMERGENCY DEPARTMENT AT ADMISSION
	4CPS-084	GENOTYPING ANALYSIS OF POLYMORPHISMS IN THE DIAHYDROPYRHYDROMIDINE DEHYDROGENASE (DPYD) GENE PRIOR TO ADMINISTRATION OF FLUOROPIRMIDINES
	4CPS-085	LONG-TERM PERSISTENCE IN PSORIASIS PATIENTS WITH HIGH RESPONSE TO GUSELKUMAB: A REAL-WORLD RETROSPECTIVE STUDY.
	4CPS-086	ASSESSMENT OF THE CLINICAL RELEVANCE OF LEVETIRACETAM MONITORING
	4CPS-087	ADALIMUMAB PERSISTENCE IN CLINICAL PRACTICE AT A REGIONAL HOSPITAL
	4CPS-088	FOLIC ACID, FOLINIC ACID AND HEMATOTOXIC TREATMENTS: A REVIEW AT A UNIVERSITY HOSPITAL CENTRE
	4CPS-089	CLINICAL PHARMACIST EFFECTIVENESS IN HOSPITALISED PATIENTS: ANALYSIS OF THE INTERVENTION RECORD IN A SECONDARY ACUTE HOSPITAL
	4CPS-090	REAL-WORLD PERSISTENCE WITH FREMANEZUMAB VERSUS ERENUMAB AMONG MIGRAINE PATIENTS
	4CPS-091	REAL-LIFE PERSISTENCE, EFFECTIVENESS AND SAFETY OF FREMANEZUMAB IN PATIENTS WITH CHRONIC MIGRAINE
	4CPS-092	ANALYSIS OF ANTIBIOTICS CONSUMPTION AT AN ITALIAN CARDIOLOGY CENTRE: PHARMACOUSE PROFILE ACCORDING TO THE AWARE CLASSIFICATION
	4CPS-093	ANTIBIOTIC RESISTANCE IN THE HOSPITAL CONTEXT: RETROSPECTIVE ANALYSIS OF ANTIBIOGRAMS, RESISTANCE AND SENSITIVITY PROFILES AT AN ITALIAN HEART CENTER
	4CPS-094	RISK FACTORS FOR EMERGENCY DEPARTMENT RE-VISIT IN ELDERLY PATIENTS WITH GASTROINTESTINAL BLEEDING SECONDARY TO DIRECT ORAL ANTICOAGULANTS
	4CPS-095	EXPLORATORY ANALYSIS OF CARDIOVASCULAR EVENTS IN AN ASTHMATIC COHORT
	4CPS-096	USE OF COVID-19 ANTIVIRALS IN PATIENTS PREVIOUSLY TREATED WITH TIXAGEVIMAB/CILGAVIMAB PROPHYLAXIS: EXPERIENCE OF AN ITALIAN HOSPITAL
	4CPS-097	REAL-WORLD STUDY OF APALUTAMIDE TREATMENT IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER IN NINE HOSPITALS OF VALENCIAN COMMUNITY.
	4CPS-098	EFECTIVENESS AND SAFETY OF LONG-ACTING CABOTEGRAVIR/RILPIVIRINE IN REAL-LIFE POPULATION
	4CPS-099	CHIMERIC ANTIGEN RECEPTOR-T CELLS (CAR-T CELLS) AND ANTIBIOTICS : A NOT-SO-INNOCENT ASSOCIATION
	4CPS-100	THE UTILITY OF EARLY PHARMACEUTICAL VALIDATION OF SELECTED HIGH-RISK DRUGS IN A HOSPITAL EMERGENCY DEPARTMENT
	4CPS-101	MONITORING METABOLIC SYNDROME IN OLANZAPINE TREATED PATIENTS
	4CPS-102	AMIODARONE AND LITHIUM-INDUCED THYROID DYSFUNCTION: WHO INITIATES THE PRESCRIBING CASCADE?
	4CPS-103	ANALYSIS OF PNEUMONIA ASSOCIATED WITH MECHANICAL VENTILATION IN CRITICALLY ILL PATIENTS UNDERGOING SELECTIVE DIGESTIVE DECONTAMINATION.
	4CPS-104	COMORBIDITY PATTERNS IN THE OLDER HIV PATIENT
	4CPS-105	MEDICINES OPTIMISATION FOR PATIENTS IN A NURSING HOME
	4CPS-106	AUC-SURVIVAL REANALYSIS OF TROPICS-02 TRIAL WITH SACITUZUMAB GOVITECAN FOR METASTATIC LUMINAL BREAST CANCER.
	4CPS-107	ADHERENCE TO DAILY ORAL TREATMENT IN MULTIPLE SCLEROSIS
	4CPS-108	CLINICAL IMPACT OF PHARMACOKINETIC MONITORING OF INFLIXIMAB AND ADALIMUMAB IN INFLAMMATORY BOWEL DISEASE
	4CPS-109	SEX-RELATED DIFFERENCES IN THE EFFECTIVENESS OF JANUS KINASE INHIBITORS IN RHEUMATOID ARTHRITIS TREATMENT
	4CPS-110	SYSTEMATIC REVIEW AND E-QUESTIONNAIRE ON THE SERVICE CHARACTERISTICS, OPERATIONS AND ACTIVITIES OF CENTRES FOR MEDICINES INFORMATION (CMI)
	4CPS-111	PHARMACEUTICAL INTERVENTIONS IN PATIENTS UNDER CHRONIC OPIOID TREATMENT ADMITTED TO TRAUMATOLOGY UNITS
	4CPS-112	ANTIMICROBIAL STEWARDSHIP PROGRAMME INTERVENTIONS IN INTENSIVE CARE UNIT
	4CPS-113	THE EFFECTIVENESS OF JANUS KINASE INHIBITORS IN MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS
	4CPS-114	SUBLINGUAL ADMINISTRATION OF TACROLIMUS IN LIVER TRANSPLANT PATIENT WITH INTESTINAL MALABSORPTION: A CASE REPORT
	4CPS-115	CHRONIC MIGRAINE REVERSION AND SYMPTOMATIC MEDICATION REDUCTION WITH FREMANEZUMAB
	4CPS-116	REAL-WORLD EFFECTIVENESS AND COSTS OF USTEKINUMAB IN PATIENTS DIAGNOSED WITH INFLAMMATORY BOWEL DISEASE
	4CPS-117	UPDATE OF STOPP/START CRITERIA IN 2023: WHAT ARE THE IMPACTS ON OUR PHARMACEUTICAL INTERVENTIONS?
	4CPS-118	MEDICATION ADHERENCE TO PSORIASIS TREATMENTS: A POPULATION-BASED STUDY
	4CPS-119	A REAL-LIFE STUDY OF PHARMACOKINETIC MONITORING: NEPHROTOXIC IMPACT OF AMINOGLYCOSIDES AND VANCOMYCIN
	4CPS-120	EFFICACY OF PEMBROLIZUMAB FOR NON-SMALL CELL LUNG CANCER (NSCLC): PRELIMINARY REAL-WORLD ANALYSIS AND COMPARISON WITH THE PIVOTAL STUDY (PS)
	4CPS-121	OPTIMISING ANTIDIABETIC TREATMENT FOR ELDERLY PATIENTS ACCORDING TO THEIR FUNCTIONAL STATUS
	4CPS-122	ANALYSIS OF THE USE AND EFFECTIVENESS OF FIDAXOMICIN IN CLOSTRIDIOIDES DIFFICILE INFECTION
	4CPS-123	SARGRAMOSTIM AND LIPOSOMAL AMPHOTERICIN B FOR THE TREATMENT OF CHRONIC VISCERAL LEISHMANIASIS IN HIV CO-INFECTED PATIENT: A CASE REPORT
	4CPS-124	MONITORING OF HIGH-COST ANTIBIOTIC’S PRESCRIPTIONS IN ORDER TO ENSURE PRESCRIPTIVE APPROPRIATENESS, PATIENT SAFETY AND CONTAINING EXPENDITURE
	4CPS-125	PHARMACEUTICAL CONSULTATIONS DEDICATED TO DIRECT ORAL ANTICOAGULANTS FOR CANCER PATIENTS: A SINGLE-CENTER PROSPECTIVE STUDY
	4CPS-126	ADHERENCE, PERSISTENCE, AND SWITCHING MEDICATION IN PATIENTS WITH MULTIPLE SCLEROSIS INITIATING ORAL DISEASE MODIFYING THERAPIES: A RETROSPECTIVE REAL-WORLD STUDY
	4CPS-127	PERSISTENCE OF BIOLOGICAL DISEASE-MODIFYING DRUGS AND PHOSPHODIESTERASE-4- INHIBITORS IN PATIENTS WITH PSORIATIC ARTHRITHIS
	4CPS-128	POTENTIAL DRUG-DRUG INTERACTIONS IN HYPERTENSIVE PATIENTS
	4CPS-129	EVALUATION OF THE BENEFIT OF CAROB FLOUR ON NINTEDANIB DIARRHEA IN THE TREATMENT OF DIFFUSE INTERSTITIAL LUNG DISEASE
	4CPS-130	RISK OF HYPOKALAEMIA IN HOSPITALIZED PATIENTS ASSOCIATED WITH THE COMBINATION OF DIURETICS
	4CPS-131	UTILIZATION AND SAFETY PROFILE OF UPADACITINIB IN A TERTIARY HOSPITAL
	4CPS-132	RIBOCICLIB IN METASTASIC BREAST CANCER TREATMENT: FRECUENCY AND ANALYSIS OF DIFFERENTS ADVERSE EFFECTS WHICH REQUIRED INTERVENTION
	4CPS-133	EFFECTIVENESS AND SAFETY OF ANTI IL-5 DRUGS BENRALIZUMAB AND MEPOLIZUMAB IN SEVERE UNCONTROLLED EOSINOPHILIC ASTHMA PATIENTS
	4CPS-134	REAL WORLD EVIDENCE OF CEFIDEROCOL IN CLINICAL PRACTICE
	4CPS-135	EVALUATION AND MANAGEMENT OF CONSTIPATION IN THE CRITICALLY ILL PATIENT
	4CPS-136	ANALYSIS OF THE SITUATION OF PHARMACEUTICAL CARE FOR PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES BEFORE AND AFTER THE COVID-19 PANDEMIC
	4CPS-137	CEFIDEROCOL: UTILIZATION PROFILE IN THE TREATMENT OF MULTIDRUG-RESISTANT BACTERIA, A RETROSPECTIVE OVERVIEW.
	4CPS-138	CEFIDEROCOL: EFFECTIVENESS AND MORTALITY OF MULTIDRUG-RESISTANT BACTERIA INFECTIONS, A RETROSPECTIVE OVERVIEW.
	4CPS-139	VORICONAZOLE SERUM CONCENTRATIONS MONITORING
	4CPS-140	EXPERIENCE OF USING PALBOCICLIB, RIBOCICLIB AND ABEMACICLIB IN A TERTIARY HOSPITAL
	4CPS-141	REAL-LIFE IMPACT OF INCLUDING MONTELUKAST AS PREMEDICATION ON THE INCIDENCE OF INFUSION-RELATED REACTIONS TO ISATUXIMAB AND DESCRIPTION OF RISK FACTORS
	4CPS-142	COMMUNITY PHARMACY-BASED HBA1C SCREENING FOR EARLY DETECTION OF DIABETES AND PRE-DIABETES
	4CPS-143	A DESCRIPTION OF PHARMACISTS’ INTERVENTIONS TO OPTIMISE THE TREATMENT OF ADULTS WITH ORALLY AVAILABLE COVID-DRUG PAXLOVID®
	4CPS-144	BIOLOGICAL TREATMENTS IN THE PREVENTION OF MIGRAINE: RESTART AND DURATION OF THERAPEUTIC REST
	4CPS-145	COLLABORATIVE IMPLEMENTATION OF 'WALANT' (LOCAL ANESTHETIC) TECHNIQUE IN A HAND SURGERY WARD
	4CPS-146	ECONOMIC IMPACT ON MULTIPLE MYELOMA CLINICAL TRIALS IN THE PHARMACY SERVICE
	4CPS-147	OSIMERTINIB: A PROMISING TREATMENT FOR EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER
	4CPS-148	EAVLUATION OF DAILY DOSE MANUAL DRUG DISPENSING ACCURACY
	4CPS-149	CENTRAL VENOUS CATHETER-RELATED BLOODSTREAM INFECTIONS IN PATIENTS ON TOTAL PARENTERAL NUTRITION
	4CPS-150	PHARMACEUTICAL INTERVENTIONS IN OBESE PATIENTS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
	4CPS-151	ANALYSIS OF ANTIBIOTIC TREATMENT IN PATIENTS WITH VENTILATOR-ASSOCIATED PNEUMONIA
	4CPS-152	THE INCLUSION OF TRAMADOL FOR PARENTERAL USE IN THE NARCOTIC TABLE OF PHARMACOPOEIA: ANALYSIS OF EFFECTS AND CONSUMPTION IN A GENERAL HOSPITAL SETTING
	4CPS-153	ECONOMIC BENEFIT ANALYSIS ON LUNG CANCER CLINICAL TRIALS: MEDICATION AND MEDICAL TESTS
	4CPS-154	THERAPEUTIC DRUG MONITORING OF AMIKACIN IN NEONATES: ABOUT A NEW PROTOCOL
	4CPS-155	PERCEPTION OF HOSPITAL PHARMACIES ABOUT TELEPHARMACY IN THE PROVISION OF HEALTHCARE FOR PEOPLE LIVING WITH HIV
	4CPS-156	ANALYSIS OF THE PRESCRIPTION PATTERN AND DAYS OF HOSPITALIZATION AVOIDED BY OUTPATIENT INTRAVENOUS ANTIBIOTIC THERAPY AND THE SAFETY OF THIS PRACTICE
	4CPS-157	PERSPECTIVES OF PATIENTS AND MEDICAL PROVIDERS ON MULTIDISCIPLINARY MEDICATION RECONCILIATIONS SERVICE IN ADULT PATIENTS UNDERGOING THORACIC AND CARDIOVASCULAR SURGERY (MERITS STUDY)
	4CPS-158	RELAPSED/REFRACTORY MULTIPLE MYELOMA AND NEW THERAPEUTIC OPTIONS: EXPERIENCE IN A PHASE I CLINICAL TRIALS UNIT
	4CPS-159	ANALYSIS OF THE INTERVENTIONS CARRIED OUT IN THE GERIATRIC SERVICE IN COLLABORATION WITH THE INTERNAL MEDICINE AND MICROBIOLOGY SERVICES
	4CPS-160	LONG-TERM EFFECTIVENESS AND SAFETY RESULTS OF GALCANEZUMAB IN REAL-WORLD DATA IN MIGRAINE PROPHYLAXIS
	4CPS-161	VANCOMYCIN PHARMACOKINETIC MONITORING IN CRITICALLY ILL NEONATAL PATIENTS
	4CPS-162	"TO ERR IS HUMAN“: PRESENTING CASES OF MEDICATION ERRORS FROM REAL CLINICAL PRACTICE
	4CPS-163	EFFECTIVENESS OF SODIUM ZIRCONIUM CYCLOSILICATE IN HOSPITALISED PATIENTS WITH HYPERKALAEMIA
	4CPS-164	ANALYSIS OF USTEKINUMAB INTENSIFICATION IN INFLAMMATORY BOWEL DISEASE ACCORDING TO LINE OF TREATMENT
	4CPS-165	DETERMINATION OF PREDICTIVE FACTORS FOR IMMUNE-RELATED TOXICITY IN LUNG CANCER PATIENTS TREATED WITH IMMUNOTHERAPY
	4CPS-166	COMPREHENSIVE ASSESSMENT OF PHARMACOTHERAPY IN THE COMPLEX CHRONIC PATIENT: COLLABORATION BETWEEN DIFFERENT LEVELS OF CARE
	4CPS-167	USE OF STANDARD- AND HIGH-DOSE LIPOSOMAL AMPHOTERICIN B AND ITS RELATIONSHIP WITH HYPOMAGNESEMIA
	4CPS-168	EFFECTIVENESS, SAFETY AND ADHERENCE TO EVOLOCUMAB IN REAL CLINICAL PRACTICE
	4CPS-169	EVALUATION OF ANTICHOLINERGIC DRUG PRESCRIPTION USING A CLINICAL DECISION SUPPORT SYSTEM: A PROSPECTIVE STUDY IN A GERIATRIC REHABILITATION CENTER
	4CPS-170	CLINICAL PHARMACY PRIORITISATION ALGORITHM FOR PATIENTS IN PSYCHIATRIC LONG-TERM CARE: A PILOT STUDY
	4CPS-171	FIXED-DOSE VERSUS WEIGHT-BASED DOSING REGIMEN OF PEMBROLIZUMAB
	4CPS-172	IMPROVING POST-OPERATIVE ANALGESIA AND ASSOCIATED PRESCRIBING IN THE ORTHOPAEDIC SETTING
	4CPS-173	PRESCRIPTION OF PSYCHOTROPIC DRUGS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION ON INTEGRASE INHIBITOR-BASED ANTIRETROVIRAL THERAPY
	4CPS-174	NASAL ESKETAMINE USE FOR MAYOR DEPRESSIVE DISORDER, FROM A THIRD LEVEL HOSPITAL TO PERIPHERAL MENTAL CENTERS
	4CPS-175	EFFECTIVENESS OF IMMUNOTHERAPY AS A FUNCTION OF AGE: METHA-ANALYSIS OF THE APPROVED COMBINATIONS IN FIRST LINE METASTASIC NON-SMALL-CELL LUNG CANCER IN PATIENTS WITHOUT MUTATIONS.
	4CPS-176	USE AND PERSISTENCE OF GUSELKUMAB IN TREATMENT FOR RHEUMATIC AND DERMATOLOGICAL DISEASE
	4CPS-177	LONG-ACTING INTRAMUSCULAR ANTIRETROVIRALS: WHAT REAL-WORLD DATA DO WE HAVE?
	4CPS-178	EFFECT OF PCSK9 INHIBITORS ON HYPERCHOLESTEROLEMIA
	4CPS-179	REAL-LIFE ANALYSIS OF THE DEVELOPMENT OF ANTI-DRUG ANTIBODIES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND THERAPEUTIC APPROACH.
	4CPS-180	SACITUZUMAB-GOVITECAN IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER: COMPARISON OF OUR DATA TO THE ASCENT TRIAL AFTER TWO YEARS OF EXPERIENCE
	4CPS-181	ELECTRONIC PRESCRIBING IN THE NEONATAL INTENSIVE CARE UNIT: ANALYSIS OF PRESCRIBING ERRORS AND RISK FACTORS
	4CPS-182	DESCRIPTION OF A CLINICAL PHARMACIST INTERVENTION FOCUSED ON MANAGEMENT OF A CHRONIC DISEASE AT HOSPITAL: THE EXAMPLE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD).
	4CPS-183	PHARMACIST-LED OPT-OUT CESSATION TREATMENT PROTOCOL FOR COMBUSTIBLE TOBACCO SMOKING
	4CPS-184	THERAPIES IN ENDOMETRIAL CANCER WITH DNA MISMATCH REPAIR DEFICIENT OR MICROSATELLITE INSTABILITY: A SYSTEMATIC REVIEW
	4CPS-185	ANALYSIS OF THE USE OF MEDICATION NOT INCLUDED IN THE PHARMACOTHERAPEUTIC GUIDE OF A TERTIARY HOSPITAL
	4CPS-186	IMPLEMENTATION OF A PATIENT STRATIFICATION MODEL IN OUTPATIENT PHARMACY FOR IMMUNE-MEDIATED DERMATOLOGICAL DISEASES
	4CPS-187	DEVELOPMENT OF A POPULATION PHARMACOKINETIC MODEL OF CYCLOSPORINE
	4CPS-188	IMPLEMENTATION OF THIOPURINE PHARMACOGENETICS TO IMPROVE PEDIATRIC SAFETY AT A TERTIARY HOSPITAL
	4CPS-189	LOCAL EXPERIENCE ON THE USE OF CANNABIDIOL FOR THE TREATMENT OF REFRACTORY EPILEPSY. SAFETY AND EFFICACY ON A 10 PATIENT’S COHORT
	4CPS-190	DEVELOPMENT OF TRANSMURAL PHARMACEUTICAL CARE IN A GENERAL HOSPITAL
	4CPS-191	PRE-RADIOIODINE THERAPY SURGICAL MODALITIES: COMPARION OF POST-OPERATIVE THYROGLOBULIN LEVELS IN PATIENTS UNDERGOING 1- OR 2-STEP THYROIDECTOMY FOR DIFFERENTIATED THYROID CANCER
	4CPS-192	ASTHMA AND RISK OF CARDIOVASCULAR EVENTS: A RETROSPECTIVE STUDY
	4CPS-193	EFFECTIVENESS AND SAFETY OF INTRAVENOUS USTEKINUMAB INTENSIFICATION IN CROHN'S DISEASE WITH LOSS OF RESPONSE OR PARTIAL RESPONSE TO SUBCUTANEOUS THERAPY
	4CPS-194	EVOLUTION OF HOSPITAL CLINICAL PHARMACY SERVICES IN FINLAND DURING YEARS 2017-2022: A FOLLOW-UP SURVEY
	4CPS-195	CHARACTERIZATION OF INJECTABLE FORMULATIONS AND OPTIMIZATION OF THEIR DELIVERY BY ENTERAL TUBE: A PHYSICOCHEMICAL AND PHYSIOLOGICAL APPROACH
	4CPS-196	ASSESSMENT OF ORAL DRUG THERAPY REGARDING ABSORPTION DISORDERS IN PATIENTS WITH INTESTINAL OSTOMIES - AN OBSERVATIONAL STUDY
	4CPS-197	THE KTIA-SCORAC STUDY : SECURING THE MEDICATION MANAGEMENT OF ELDERLY PATIENTS BY THE SYSTEMATIC EVALUATION OF ANTICHOLINERGIC LOAD SCORES VIA A CLINICAL DECISION SUPPORT SYSTEM
	4CPS-198	EVALUATION OF PROA TEAM INTERVENTION ACCEPTANCE RATES THROUGH AN AUTOMATED MEASUREMENT SYSTEM
	4CPS-199	COMPARATIVE EVALUATION OF ENZYME-LINKED IMMUNOSORBENT ASSAY VERSUS A POINT-OF-CARE TECHNIQUE IN THE DETERMINATION OF ADALIMUMAB LEVELS
	4CPS-200	TRIPLE THERAPY FOR METASTATIC HORMONE-SENSITIVE PROSTATE CANCER PATIENTS BASED ON A PHARMACOLOGICAL TREATMENT ALGORITHM
	4CPS-201	CLINICAL EXPERIENCE OF TYROSINE-KINASE INHIBITORS DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA
	4CPS-202	EVALUATION OF THE EXCHANGE OF ANTICGRP MONOCLONAL ANTIBODIES FOR THE TREATMENT OF CHRONIC REFRACTORY MIGRAINE
	4CPS-203	DEVELOPMENT AND VALIDATION OF A DATA COLLECTION TOOL TO EVALUATE PHARMACEUTICAL INTERVENTIONS IN AN INTENSIVE CARE UNIT
	4CPS-204	MONITORING OF LINEZOLID IN HEMODIALYSIS: A CLINICAL CASE
	4CPS-205	RESULTS OF ANTIBIOTIC PROPHYLAXIS IN ACUTE BRONCHOASPIRATION PNEUMONITIS
	4CPS-206	PRE-EXPOSURE PROPHYLAXIS, ARE WE DOING IT RIGHT?
	4CPS-207	EVALUATION OF PROSTATIC SPECIFIC ANTIGEN DEPLETION WITH ABIRATERONE AS A PRONOSTATIVE FACTOR FOR SURVIVAL IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
	4CPS-208	ANALYSIS OF THE IMPLEMENTATION OF A MULTIDISCIPLINARY PHARMACEUTICAL CARE PROJECT FOR GERIATRIC HEMATO-ONCOLOGY PATIENTS
	4CPS-209	COMPARISON OF TWO PHARMACOKINETIC/PHARMACODYNAMIC INDICES IN CRITICALLY ILL PATIENTS TREATED WITH AMIKACIN
	4CPS-210	HOME INFUSION CHEMOTHERAPY TREATMENT FOR PATIENTS WITH MALIGNANT HAEMATOLOGICAL DISORDERS
	4CPS-211	TITLE: ANALYSIS OF THE PRESCRIPTION OF VITAMIN D SUPPLEMENTS IN A SOCIAL HEALTH CENTER.
	4CPS-212	MANAGEMENT OF POST CAR-T NEUROTOXICITY USING ANAKINRA. A CASE REPORT
	4CPS-213	RESULTS OF ANTIBIOTIC TREATMENT OF AORTIC ENDOPROSTHESIS INFECTIONS IN PATIENTS NOT CANDIDATES FOR SURGERY
	4CPS-214	MONITORING OF TACROLIMUS IN A KIDNEY TRANSPLANTED COHORT
	4CPS-215	ADJUSTMENT OF ANTIBIOTICS THROUGH THE HEMOFILTER: A CASE REPORT
	4CPS-216	EFFICACY AND SAFETY ANALYSIS OF OBETICHOLIC ACID IN PRIMARY BILIARY CHOLANGITIS: REAL-LIFE DATA.
	4CPS-217	A COMPARATIVE EVALUATION OF THE LONG-TERM EFFECTIVENESS OF GUSELKUMAB AND RISANKIZUMAB IN THE CLINICAL MANAGEMENT OF PLAQUE PSORIASIS.
	4CPS-218	OPIOID PRESCRIBING FOR ACUTE NON-CANCER PAIN, POST-OPERATIVE PAIN AND POST-PROCEDURE PAIN BY SURGICAL TEAMS AT A TERTIARY HOSPITAL: 1-DAY AUDIT
	4CPS-219	BEYOND THE EXPECTED: THE ENHANCED DETECTION OF DRUG RELATED PROBLEMS, THE MOST OF A PHARMACEUTICAL DECISION SUPPORT SYSTEM
	4CPS-220	EVALUATION OF THE IMPLEMENTATION OF A PRE-EXPOSURE PROPHYLAXIS PROGRAM. 2 YEARS EXPERIENCE IN OUR REGION
	4CPS-221	EVALUATION OF THE RELEVANCE OF STATINS PRESCRIPTION IN THE ELDERLY : TOWARDS A DEPRESCRIPTION ?
	4CPS-222	THE REAL LIFE OF BENZODIAZEPINES IN GERIATRIC DEPARTMENT : CAN THE PHARMACIST HAVE AN IMPACT ?
	4CPS-223	A STUDY ON THE PERCEPTION OF ELDERLY PATIENTS ON THE EXPIRATION DATE AND STORAGE OF PRESCRIBED MEDICATION: A QUESTIONNAIRE STUDY
	4CPS-224	MEDICATION RECONCILIATION IN A SURGERY DEPARTMENT: 6-MONTHS EXPERIENCE
	4CPS-225	DEFINING INTERNATIONAL CRITICAL CARE PHARMACIST ASPIRATIONS TO THE MANAGEMENT OF SEPSIS
	4CPS-226	PHARMACEUTICAL INTERVENTION ON THE ADEQUACY OF THE INDICATION OF SEMAGLUTIDE IN DIABETES MELLITUS 2
	4CPS-227	PHARMACEUTICAL REVIEW AND PHARMACEUTICAL INTERVENTION IN A NURSING HOME TO ENHANCE THE MEDICATION MANAGEMENT OF RESIDENTS.
	4CPS-228	IMPACT AND ACCEPTANCE OF PHARMACEUTICAL INTERVENTIONS FOR EARLY MEDICATION RECONCILIATION IN THE EMERGENCY DEPARTMENT
	4CPS-229	SUSTAINABILITY: A PERSON-CENTRED, WHOLE SYSTEMS APPROACH TO MEDICINES OPTIMISATION
	4CPS-230	CLINICAL PHARMACOGENOMICS FOR A SAFER USE OF FLUOROPYRIMIDINES

Section 5: Patient Safety and Quality Assurance
PDF document	Poster number	Poster Title
	5PSQ-001	INCIDENCE OF HEPATITIS B VIRUS REACTIVATION IN PSORIASIS PATIENTS TREATED WITH CYTOKINE INHIBITORS: A SYSTEMATIC REVIEW AND META-ANALYSIS
	5PSQ-002	PRESCRIBING TREND OFFLUOROQUINOLONES FOLLOWING LATEST EMA RECOMMENDATIONS
	5PSQ-003	IMPROVING MEDICINES MANAGEMENT OF INPATIENT PARKINSON’S DISEASE PATIENTS BY MAKING PHARMACY INTERVENTIONS
	5PSQ-004	COMPARISON BETWEEN BEERS 2019 CRITERIA AND THE EURO-FORTA 2018 LIST IN THE IDENTIFICATION OF POTENTIALLY INAPPROPRIATE MEDICATION IN ELDERLY PATIENTS IN THE PRIMARY HEALTHCARE CONTEXT
	5PSQ-005	UTILITY OF THE THERAPEUTIC COMPLEXITY INDEX ADAPTED TO CRITICALLY ILL PATIENTS AS A METHOD OF STRATIFICATION FOR PHARMACEUTICAL CARE
	5PSQ-006	FREQUENCY OF CREATININE TESTING AND ACUTE KIDNEY INJURY IDENTIFICATION AND STAGING.
	5PSQ-007	A REVIEW ON MEDICATION RECONCILIATION IN THE PERIOPERATIVE PERIOD: VARIABLES THAT LEAD TO MEDICATION ERRORS.
	5PSQ-008	IMMUNE-MEDIATED HEPATITIS SECONDARY TO TREATMENT WITH PEMBROLIZUMAB. A CASE REPORT.
	5PSQ-009	OFF-LABEL USE OF INTRAVENOUS CYCLOPHOSPHAMIDE IN SYSTEMIC LUPUS ERYTHEMATOSUS PRESENTING AS ACUTE LUPUS PNEUMONITIS: A CASE REPORT
	5PSQ-010	NATIONAL STANDARDISATION OF PRETERM PARENTERAL NUTRITION IN NEONATAL UNITS
	5PSQ-011	TOXICITY OF IMMUNOTHERAPY TREATMENT IN CLINICAL PRACTICE
	5PSQ-012	TOOLS OFFERED BY REGENERATIVE MEDICINE FOR THE TREATMENT OF OSTEOARTHRITIS – PLATELET RICH PLASMA (PRP).
	5PSQ-013	NEW METHOD FOR ASSESSMENT OF ENVIRONMENTAL VIRAL CONTAMINATION OF LIQUIDS PREPARED IN CLOSED-SYSTEM DRUG TRANSFER DEVICES
	5PSQ-014	ELECTRONIC COMMUNICATION OF THE DISCONTINUATION OF HOME TREATMENT PRESCRIBED TO PATIENTS IN A TERTIARY LEVEL HOSPITAL.
	5PSQ-015	ANALYSIS OF THE OCCURRENCE OF ATRIAL FIBRILLATION WITH THE ADMINISTRATION OF IBRUTINIB: SHOULD WE BE CAREFUL WITH THIS DRUG?
	5PSQ-016	ASSESSMENT OF THE ACCREDITATION AND CONTINUOUS EDUCATION TESTS FOR PHARMACY TECHNICIANS WITHIN A CYTOTOXIC RECONSTITUTION UNIT
	5PSQ-017	PHARMACEUTICAL INTERVENTIONS IN ORAL AND SUBCUTANEOUS MTX PRESCRIBING ERRORS
	5PSQ-018	ANALYSIS OF ERRORS IN THE MANUAL PREPARATION OF STERILE DRUGS FROM STOCK.
	5PSQ-019	VALIDATION PRIOR TO THE DISPENSING OF MEDICINES AS A TOOL TO IMPROVE THE QUALITY OF THE PRESCRIPTION
	5PSQ-020	EVALUATION OF THE EFFICACY AND SAFETY OF EPCORITAMAB-BYSP IN PATIENTS WITH FOLLICULAR B LYMPHOMA: A CASE REPORT.
	5PSQ-021	EVALUATION OF THE PREVALENCE OF MULTI-RESISTANT BACTERIA IN THE INTENSIVE CARE UNIT AFTER SELECTIVE DECONTAMINATION OF THE GASTROINTESTINAL TRACT.
	5PSQ-022	DRUG-INDUCED APLASTIC ANAEMIA: AN ANALYSIS OF THE FDA ADVERSE EVENT REPORTING SYSTEM (FAERS)
	5PSQ-023	SAFETY AND TOLERABILITY OF VORICONAZOLE TREATMENT: A RETROSPECTIVE OBSERVATIONAL STUDY
	5PSQ-024	ENHANCING SAFETY AND EFFICIENCY IN CHEMOTHERAPY PREPARATION AND ADMINISTRATION IN A SMALL ONCOLOGY HOSPITAL
	5PSQ-025	AUDIT ON THE CORRECT USE OF MEDICAL DEVICES FOR URINARY CATHETERISATION
	5PSQ-026	THE POTENTIAL OF PHARMACOVIGILANCE DATABASES TO ASSESS TOXICOLOGICAL RISK OF DIETARY SUPPLEMENTS AND OTHER UNSUPERVISED HEALTH PRODUCTS USED BY PATIENTS
	5PSQ-027	VARIABILITY IN VANCOMYCIN PLASMA CONCENTRATION IN NEUTROPENIC PATIENTS
	5PSQ-028	CASE REPORT: ANTITUMOR ACTIVITY AND TOXICITIES OF ENTRECTINIB IN A PATIENT WITH A PRIMARY CENTRAL NEUROCYTOMA
	5PSQ-029	THE OVERRIDING OF DRUG SAFETY ALERTS FIRED BY THE CLINICAL DECISION SUPPORT TOOL: EVALUATION OF APPROPRIATE RESPONSES AND ALERT FATIGUE SOLUTIONS
	5PSQ-030	CONCORDANCE OF MEDICATION PRESCRIPTION RECORDS IN THE HOSPITALISED SURGICAL PATIENT
	5PSQ-031	"ASSESSING HEALTHCARE PROFESSIONALS "VIEWS ON DEPRESCRIPTION
	5PSQ-032	USE OF THE "PRECAUTIONARY ANNULMENTS" TOOL BY A HOSPITAL PHARMACY SERVICE
	5PSQ-033	TEMPORAL TRENDS OF ATYPICAL DRUG ACCESS AT AN ACADEMIC ONCOLOGY UNIT: THE VERONA UNIVERSITY HOSPITAL EXPERIENCE
	5PSQ-034	COMPARISON OF TOXICITY IN CLINICAL PRACTICE OF ANTI-PD-1/PD-L1 ANTIBODIES IN MONOTHERAPY IN NON-SMALL CELL LUNG CANCER
	5PSQ-035	SACITUZUMAB-GOVITECAN IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER: A MULTICENTER EFFECTIVENESS AND SAFETY STUDY
	5PSQ-036	ANALYSIS OF PHARMACEUTICAL INTERVENTIONS ON ANTIMICROBIAL PRESCRIPTIONS IN THE POSTOPERATIVE RESUSCITATION UNIT
	5PSQ-037	PERIPHERAL BLOOD BIOMARKERS DYNAMICS PREDICT CLINICAL RESPONSE TO PEMBROLIZUMAB PLUS CHEMOTHERAPY IN PATIENTS WITH NON-SQUAMOUS METASTATIC NON-SMALL CELL LUNG CANCER
	5PSQ-038	REAL-WORLD SAFETY OF IBRUTINIB IN CLINICAL PRACTICE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA
	5PSQ-039	IMPACT OF TAILORED SCREENING INTERVALS ON THE BURDEN OF DRUG-DRUG INTERACTION ALERTS: AN INTERRUPTED TIME SERIES ANALYSIS
	5PSQ-040	VOLUNTARY MEDICATION ERRORS REPORTING SYSTEM IN AN ORTHOPEDIC SURGERY AND TRAUMATOLOGY UNIT
	5PSQ-041	IMPACT OF INTRODUCING PREFILLED ATROPINE SYRINGES IN OCULAR SURGERY: PROACTIVE ASSESSMENT OF DRUG COSTS AND MEDICATION SAFETY
	5PSQ-042	FOCUS ON MEDICATION ERRORS ON HIGH-RISK MEDICATIONS IN A HOSPITAL'S ELECTRONIC INCIDENT REPORTING SYSTEM
	5PSQ-043	DESCRIPTIVE STUDY OF MARKETED MEDICINES CONTAINING ASPARTAME
	5PSQ-044	SAFETY OF PEMBROLIZUMAB +/- CHEMOTHERAPY IN FIRST-LINE METASTATIC NON-SMALL-CELL LUNG CARCINOMA IN REAL-WORLD PRACTICE
	5PSQ-045	ANALYSIS OF A PHARMACEUTICAL INTERVENTION IN POLYMEDICATED PATIENTS WITH DEMENTIA AND IN TREATMENT WITH HIGH ANTICHOLINERGIC ACTIVITY DRUGS
	5PSQ-046	SYNDROME OF INAPPROPRIATE SECRETION OF ANTIDIURETIC HORMONE INDUCED BY ALPRAZOLAM: A CASE REPORT
	5PSQ-047	THE PERCEIVED IMPACT ON PATIENT SAFETY AND QUALITY OF CARE OF PHARMACEUTICAL TECHNICAL ASSISTANTS ON NURSING WARDS: A QUALITATIVE STUDY
	5PSQ-048	COST-SAVING IMPACT OF USING NUSINERSEN BY CLINICAL TRIALS FOR SPINAL MUSCULAR ATROPHY
	5PSQ-049	MEDICATION PRESCRIBING ERRORS PROSPECTIVE OBSERVATIONAL STUDY IN AN INTENSIVE CARE UNIT
	5PSQ-050	IT IS POSSIBLE TO IMPROVE THE HIPOPOTASEMIC MANAGMENT IN THE HOSPITAL?
	5PSQ-051	EFFECTIVENESS AND SAFETY OF NIRMATRELVIR/RITONAVIR IN OLDER PATIENTS AT NURSING HOME WITH COVID-19.
	5PSQ-052	ANALYSIS OF POTENTIAL PROGNOSTIC FACTORS OF EFFICACY IN TISAGENLECLEUCEL TREATMENT IN A COHORT OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
	5PSQ-053	EFFECTIVENESS AND SAFETY OF GALCANEZUMAB. REAL-LIFE RESULTS.
	5PSQ-054	EVALUATION OF AN APPLICATION TO HELP FOR THE ADEQUACY OF THE DOSAGE OF ANTIBIOTICS IN RENAL FAILURE
	5PSQ-055	EFFICACY AND SAFETY OF DALBAVANCIN IN GRAM-POSITIVE INFECTIONS TREATMENT
	5PSQ-056	VACCINATION COVERAGE AGAINST PENUMOCOCCUS FOR PEOPLE LIVING WITH HIV BEFORE AND AFTER THE COVI-19 PANDEMIC
	5PSQ-057	ANTICHOLINERGIC BURDEN ASSESSMENT IN INSTITUTIONALIZED PATIENTS
	5PSQ-058	EFFICACY EVALUATION OF ANTI-PCSK9 DRUGS FOR THE TREATMENT OF PRIMARY HYPERCHOLESTEROLAEMIA OR MIXED DYSLIPIDAEMIA.
	5PSQ-059	STUDY OF THE USE OF CEFTAZIDIME/AVIBACTAM IN A FIRST LEVEL HOSPITAL
	5PSQ-060	REAL-LIFE DATA ON THE EFFECTIVENESS AND SAFETY OF CABOTEGRAVIR/RILPIVIRINE IN A THIRD-LEVEL HOSPITAL
	5PSQ-061	CURRENT PRACTICE OF PEDIATRIC OFF-LABEL PRESCRIPTIONS IN A PEDIATRIC HOSPITAL
	5PSQ-062	SAFETY EVALUATION OF PEMBROLIZUMAB IN MONOTHERAPY
	5PSQ-063	ADJUVANTE ANALGESICS INTERACTIONS: HOW TO MANAGE PAIN IN PATIENTS RECEIVING ORAL THERAPY FOR BREAST CANCER TREATMENT
	5PSQ-064	ANALYSIS OF PHARMACEUTICAL INTERVENTIONS ON DIRECT ACTING ORAL ANTICOAGULANTS IN A TERTIARY CARE HOSPITAL.
	5PSQ-065	INTESTINAL PERFORATION AFTER CRS AND ICANS IN A CAR-T TREATED PATIENT: A CLINICAL CASE REPORT.
	5PSQ-066	SURVIVAL ANALYSIS OF REGORAFENIB IN PATIENTS WITH COLORECTAL CANCER. FIRST RESULTS OF REGORAFENIB USE IN REAL CLINICAL PRACTICE
	5PSQ-067	DRUG UTILIZATION PROFILES OF ADVANCED THERAPY MEDICINAL PRODUCTS: A REAL WORLD EVIDENCE STUDY
	5PSQ-068	THE HOSPITAL PHARMACIST'S INTERVENTIONS IN THE POST-MARKETING PHARMACOVIGILANCE OF ANTI-ASTHMATIC BIOLOGICS: A REAL LIFE ANALYSIS
	5PSQ-069	COMPARISON OF RENAL GLOMERULAR FILTRATION ESTIMATION FORMULAS IN VANCOMYCIN PHARMACOKINETIC MONITORING
	5PSQ-070	DUPILUMAB IS A MONOCLONAL ANTIBODY USED FOR THE TREATMENT OF ATOPIC DERMATITIS. THIS STUDY EVALUATES THE EFFECTIVENESS AND PERSISTENCE. DUPILUMAB PRESENTS GOOD EFFECTIVENESS AND PERSISTENCE.
	5PSQ-071	MULTIDISCIPLINARY MANAGEMENT OF DRESS SYNDROME: A CASE REPORT
	5PSQ-072	TREATMENT WITH GALCANEZUMAB IN REAL WORLD DATA: SAFETY.
	5PSQ-073	RISK SCORE FOR DRUG DISCREPANCY AND ADHERENCE IN CLINICAL TRIAL PATIENTS
	5PSQ-074	PHARMACEUTICAL INTERVENTIONS IN PAIN MANAGEMENT
	5PSQ-075	ADHERENCE TO LOCAL ANTIBIOTIC PRESCRIBING GUIDELINES WITHIN 48 HOURS OF INPATIENT ADMISSION
	5PSQ-076	EFFICACY AND SAFETY OF NIVOLUMAB MONOTHERAPY VS NIVOLUMAB PLUS IPILIMUMAB IN RENAL CELL CARCINOMA IN CLINICAL PRACTICE
	5PSQ-077	ADEQUATE NUTRITIONAL THERAPY IN CRITICAL PATIENTS WITH CORONAVIRUS DISEASE (COVID-19)
	5PSQ-078	HYPOPHOSPHATEMIA AFTER FERRIC CARBOXYMALTOSE ADMINISTRATION IN A COHORT OF ELDERLY PATIENTS WITH HIP FRACTURE
	5PSQ-079	PHARMACEUTICAL INTERVENTIONS IN A HEALTH MANAGEMENT AREA
	5PSQ-080	CLINICAL INTERVENTIONS IN PATIENTS UNDERGOING ANTIPARKINSONIAN TREATMENT: THE IMPORTANCE OF CORRECT RECONCILIATION
	5PSQ-081	SATISFACTION OF PHYSICIANS AND HOSPITAL PHARMACISTS OF A HYPERSENSITIVITY DOCUMENTATION TOOL WITH DE-LABELING FEATURE IN CLINICAL PRACTICE
	5PSQ-082	THIRD-GENERATION HOSPITAL-EXCLUSIVE CEPHALOSPORINS: DIFFERENT SAFETY PROFILES?
	5PSQ-083	MARIBAVIR-INDUCED TOXIC EPIDERMAL NECROLYSIS IN A LIVER TRANSPLANT PATIENT: A CASE REPORT.
	5PSQ-084	EROSIVE BALANITIS AS A POSSIBLE ADVERSE EFFECT TO TREATMENT WITH TOFACITINIB. A CASE REPORT.
	5PSQ-085	SAFETY ASSESSMENT OF JANUS KINASE INHIBITORS IN CLINICAL PRACTICE
	5PSQ-086	ADMINISTRATION OF TYROSINE KINASE INHIBITOR DRUGS IN PATIENTS WITH ENTERAL FEEDING TUBES
	5PSQ-087	ANALYSIS OF EFFECTIVENESS AND SAFETY OF TRALOKINUMAB IN MODERATE-SEVERE ATOPIC DERMATITIS
	5PSQ-088	ADHERENCE TO ANTIRETROVIRAL THERAPY IN VIH PATIENTS
	5PSQ-089	OUTCOME OF MOLNUPIRAVIR TREATMENT IN RENAL TRANSPLANT PATIENTS WITH COVID-19
	5PSQ-090	CAPSAICIN 8% PATCH IN TREATMENT OF PERIPHERAL NEUROPATHIC PAIN
	5PSQ-091	SUITABILITY OF TERIPARATIDE AND LEVEL OF ACCEPTANCE OF PHARMACOTHERAPEUTIC RECOMMENDATIONS IN AN AREA OF HEALTH MANAGEMENT
	5PSQ-092	ALTERED PHARMACOKINETICS PARAMETERS OF VANCOMYCIN IN PATIENTS WITH HEMATOLOGICAL MALIGNANCY WITH FEBRILE NEUTROPENIA, A BAYESIAN SOFTWARE ESTIMATION
	5PSQ-093	DOES EXPOSURE TO ANTIBIOTICS PRIOR TO TREATMENT WITH IMMUNE CHECKPOINT INHIBITORS AFFECT THEIR EFFECTIVENESS?
	5PSQ-094	INCIDENCE OF HYPERSENSITIVITY REACTIONS IN PACLITAXEL INFUSIONS FOLLOWING THE DISCONTINUATION OF RANITIDINE.
	5PSQ-095	HOSPITAL PHARMACISTS ENGAGEMENT IN PHARMACOVIGILANCE PRACTICES DURING COVID-19 IN THE NORTH MACEDONIA
	5PSQ-096	DESCRIPTION OF INMMUNOGLOBULIN REPLACEMENT THERAPY IN MULTIPLE MYELOMA PATIENTS WITH ANTI-BCMA CART
	5PSQ-097	AN APPROACH TO THE USE OF MACHINE LEARNING TOOLS FOR THE PREDICTION OF ADVERSE EVENTS IN CANCER PATIENTS ON IMMUNOTHERAPY
	5PSQ-098	PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION: OPTIMIZATION OF ACCESS TO THERAPY IN ACCORDANCE WITH EUROPEAN GUIDELINES
	5PSQ-099	DRUG-RELATED PROBLEMS ASSOCIATED WITH THE TREATMENT OF POLYCYSTIC OVARY SYNDROME
	5PSQ-100	SURVEY OF PATIENT INVOLVEMENT IN ADVERSE DRUG REACTION MONITORING: THEIR INFORMATION SOURCES AND NEEDS
	5PSQ-101	MEDICAL DEVICES INCIDENT REPORTS: AN ITALIAN EXPERIENCE
	5PSQ-102	ANALYSIS OF REPEATED EMERGENCY DEPARTMENT VISITS AND THEIR RELATIONSHIP TO MEDICATION
	5PSQ-103	VANCOMYCIN-INDUCED RENAL TOXICITY THROUGH THERAPEUTIC DRUG MONITORING IN DAILY PRACTICE
	5PSQ-104	REAL WORLD EVIDENCE: IS IBRUTINIB AS SAFE AS EVIDENCE TELLS?
	5PSQ-105	PATTERNS OF USE AND APPROPRIATENESS OF ANTICOAGULATION IN ATRIAL FIBRILLATION: AN OBSERVATIONAL STUDY AMONG GERIATRIC INPATIENTS
	5PSQ-106	FALL-INCREASING RISK DRUGS (FRIDS) AND FALL-RELATED FRACTURES
	5PSQ-107	COMPLIANCE OF FLUOROQUINOLONES PRESCRIPTIONS : A HOSPITAL ACQUIRED RESISTANCE ?
	5PSQ-108	EFFICACY AND SAFETY OF INFLIXIMAB IN NF-KB ESSENTIAL MODULATOR DELETED EXON 5 AUTO-INFLAMMATORY SYNDROME: A CASE REPORT
	5PSQ-109	HAEMOASSIST: A DIGITAL BRIDGE BETWEEN HAEMOPHILIA PATIENTS AND PHARMACISTS
	5PSQ-110	DESENSITIZATION TO MONOCLONAL ANTIBODIES IN ONCOHEMATOLOGICAL PATIENTS
	5PSQ-111	SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS AFTER HEART TRANSPLANTATION
	5PSQ-112	A SURVEY OF HOME STORAGE TEMPERATURE OF IN-USE INSULINS AND ANALYSIS OF THEIR STABILITIES UNDER THE SIMULATED HIGHEST HOME TEMPERATURE
	5PSQ-113	ROOT CAUSE ANALYSIS: STATEGY FOR A SUSTAINABLE ANTIBLASTIC THERAPY MANAGEMENT SYSTEM
	5PSQ-114	HEAD AND NECK ERYTHEMA ASSOCIATED WITH THE USE OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS
	5PSQ-115	EVALUATION OF HYPOTHYROIDISM ASSOCIATED WITH APALUTAMIDE AND ENZALUTAMIDE TREATMENT IN METASTATIC PROSTATE CANCER USING THE EUROPEAN ADVERSE EFFECT DATABASE (EUDRAVIGILANCE)
	5PSQ-116	REAL-WORLD PERSISTENCE WITH GUSELKUMAB AMONG ADULTS WITH PSORIATIC ARTHRITIS
	5PSQ-117	TRACEABILITY OF IMPLANTABLE MEDICAL DEVICES / PATIENT INFORMATION: WHERE DO WE STAND?
	5PSQ-118	NON-ACTIVE PRESCRIPTIONS IN AMBULATORY PATIENTS: ANALYSIS AND EFFECT IN CONSULTATION WAITING TIME
	5PSQ-119	REVIEW OF REAL-WORLD MANAGEMENT OF NATALIZUMAB TREATMENT IN MULTIPLE SCLEROSIS: A DOUBLE-EDGED WEAPON
	5PSQ-120	PEMBROLIZUMAB IMMUNE-MEDIATED TOXICITY
	5PSQ-121	A REVIEW OF THE EXPOSURE TO POTENTIALLY HARMFUL EXCIPIENTS THROUGH ORAL LIQUID FORMS IN PEDIATRIC INPATIENTS IN FRANCE
	5PSQ-122	SEQUENTIAL CHANGE OF DOSING INTERVAL OF PALIPERIDONE PALMITATE BASED ON PLASMA CONCENTRATION MONITORING
	5PSQ-123	SIMUALTION OF A DISCHARGE CONTROL: AN EFFECTIVE TOOL FOR QUALIFYING STAFF
	5PSQ-124	THE TREATMENT OF PRESSURE ULCERS WITH BACTERIA BINDING MEDICATION AS A VALID THERAPEUTIC OPPORTUNITY
	5PSQ-125	ANALYSIS OF INTRODUCING PROBIOTICS FOR THE PREVENTION OF NECROTIZING ENTEROCOLITIS IN PREMATURE NEONATES IN A NEONATAL UNIT
	5PSQ-126	THE ANALYSIS OF INTERACTIONS AND POTENTIALLY INAPPROPRIATE MEDICATIONS IN HOSPITALIZED SENIORS
	5PSQ-127	MEDICATION-RELATED FALLS IN A NURSING HOME: IDENTIFICATION AND HOSPITAL PHARMACY INTERVENTIONS
	5PSQ-128	COST-EFFECTIVENESS OF PHARMACEUTICAL PREOPERATIVE CONSULTATIONS: A FIVE-YEAR ANALYSIS

Section 6: Education and Research
PDF document	Poster number	Poster Title
	6ER-001	HEALTHCARE RESOURCE UTILIZATION AND COSTS OF INTRAVITREAL RANIBIZUMAB OR AFLIBERCEPT VS. DEXAMETHASONE FOR DIABETIC MACULAR EDEMA IN TAIWAN
	6ER-002	POSITIVE PREDICTIVE VALUES OF ANAPHYLAXIS DIAGNOSIS IN CLAIMS DATA: A MULTI-INSTITUTIONAL STUDY IN TAIWAN
	6ER-003	ASSESSMENT OF OVERALL SURVIVAL AND SAFETY IN NEWLY APPROVED ONCOHEMATOLOGIC DRUGS
	6ER-004	VISION RELATED QUALITY OF LIFE IN PATIENTS WITH DIABETIC MACULAR OEDEMA AND AGE-RELATED MACULAR DEGENERATION TREATED WITH ANTIVASCULAR GROWTH FACTOR THERAPY OR DEXAMETHASONE
	6ER-005	DRUG WASTAGE: A HIDDEN COST OF CANCER CARE
	6ER-006	LABOUR PRODUCTIVITY GROWTH IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES UNDERGOING BIOLOGICAL OR JANUS KINASE INHIBITORS TREATMENT
	6ER-008	QUALITY, GAPS AND OPPORTUNITIES IN SMARTPHONE APPLICATIONS FOR PULMONARY HYPERTENSION: AN EVALUATION FROM HOSPITAL PHARMACISTS AND PATIENTS PERSPECTIVE
	6ER-009	PRESCRIBING PATTERNS AND EFFECTIVENESS OF RANIBIZUMAB AND AFLIBERCEPT IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION: A RETROSPECTIVE COHORT STUDY IN TAIWAN
	6ER-010	INVESTIGATING NEED AND APPROPRIATENESS FOR PHARMACIST-LED VACCINATION SERVICES WITHIN A HEALTHCARE SYSTEM
	6ER-011	AN ASSESSMENT OF PHARMACISTS’ CONFIDENCE AND BEHAVIORS IN DISPENSING OPIOID MEDICATIONS
	6ER-012	EVALUATION OF THE EFFECT OF CLOSED SYSTEM TRANSFER DEVICE SYRINGE ADAPTOR CONNECTION IN THE ISOLATOR ON CYTOTOXIC RESIDUE CONTAMINATION DURING INTRAVENOUS ADMINISTRATION
	6ER-013	ENHANCING PATIENT-CENTERED CARE THROUGH PREDICTIVE MODELING OF PATIENT-REPORTED OUTCOMES IN HOSPITAL PHARMACY SETTING
	6ER-014	ASSESSING ADHERENCE TO ESC/ERS GUIDELINES FOR VASOREACTIVITY TESTING AND PRESCRIPTION OF CALCIUM CHANNEL BLOCKERS IN PULMONARY HYPERTENSION PATIENTS
	6ER-015	RETRACTED PHARMACOLOGY ARTICLES: A CROSS-SECTIONAL STUDY USING THE RETRACTION WATCH DATABASE
	6ER-016	REAL-WORLD EFFECTIVENESS OF ALECTINIB AS FIRST-LINE TREATMENT IN NON-SMALL CELL LUNG CANCER PATIENTS : AN EVIDENCE FROM TAIWAN
	6ER-017	FACTORS PREDICTIVE OF CLINICAL OUTCOME IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING OSIMERTINIB TREATMENT: A REAL-WORLD EXPERIENCE
	6ER-018	THE EFFECTIVENESS OF ADRENERGIC ALPHA ANTAGONISTS ON REDUCING RE-CATHETERIZATION RATES IN ADULTS WITH URINARY CATHETERS: A SYSTEMATIC REVIEW AND META-ANALYSIS.
	6ER-019	TREATMENT BEYOND PROGRESSION WITH PEMBROLIZUMAB IN ADVANCED NON-SMALL CELL LUNG CANCER
	6ER-020	WOULD CHATGPT PASS THE RESIDENT INTERNAL PHARMACIST EXAM?
	6ER-021	OPIOID-SPARING STRATEGIES FOR DISCHARGE ANALGESIA PRESCRIBING IN NON-COMPLEX SURGERIES – A MISSED OPPORTUNITY.
	6ER-022	KNOWLEDGE, ATTITUDE AND PRACTICE ABOUT PHARMACEUTICALS IN THE ENVIRONMENT AMONG HOSPITAL PHARMACISTS IN SPAIN
	6ER-023	A MULTI-SECTOR SIMULATED EXPERIENTIAL PRACTICE EVENT FOR YEAR ONE PHARMACY STUDENTS
	6ER-024	LYELL'S SYNDROME IN CAR-T TREATED PATIENTS: A CASE STUDY
	6ER-025	ANTIMICROBIAL ACTIVITY OF SUBCRITICAL CO2 EXTRACT OBTAINED FROM UNDERGROUND FERULA ASAFOETIDA L.
	6ER-026	THE IMPORTANCE OF PHARMACY DEPARTMENT CLINICAL TRIALS UNIT INTERVENTION IN A CENTRE OF REFERENCE FOR THE TREATMENT OF PARAMYLOIDOSIS
	6ER-027	ECONOMIC BENEFIT AND CLINICAL ADVANTAGES WITH THE INCLUSION OF PATIENTS IN CLINICAL TRIALS RELATED TO PARAMYLOIDOSIS
	6ER-028	REAL-WORLD TREATMENT PATTERN AND EFFECTIVENESS OF PIRFENIDONE AND NINTEDANIB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS: A MULTI-INSTITUTIONAL STUDY IN TAIWAN
	6ER-029	A SYSTEMATIC REVIEW OF COMBINED POLY (ADP-RIBOSE) POLYMERASE INHIBITOR AND ANDROGEN RECEPTOR ANTAGONISTS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER.
	6ER-030	EVALUATION OF A GROUP-BASED ONLINE INFORMED CONSENT CONVERSATION (ECONSENT) IN PARTICIPANTS FROM A VACCINATION CLINICAL TRIAL: A MIXED METHOD STUDY
	6ER-031	EXCLUSION OF PEOPLE LIVING WITH HIV FROM ONCOHAEMATOLOGICAL CLINICAL TRIALS WITH IMMUNE CHECKPOINT INHIBITORS
	6ER-032	ADJUSTED INDIRECT COMPARISON OF CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VS. IMMUNOTHERAPY ALONE IN THE FIRST-LINE TREATMENT OF METASTATIC NON-SMALL-CELL LUNG CANCER IN PATIENTS WITH PD-L1≥50%
	6ER-033	ADJUSTED INDIRECT COMPARISON OF CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VS. IMMUNOTHERAPY ALONE IN THE FIRST-LINE TREATMENT OF METASTATIC NON-SMALL-CELL LUNG CANCER IN PATIENTS WITH PD-L1≥1%
	6ER-034	EFFICACY OF NEOADJUVANT TREATMENT WITH IMMUNE CHECKPOINT INHIBITORS IN NON-SMALL CELL LUNG CANCER IN EARLY STAGES: A SYSTEMATIC REVIEW
	6ER-035	EXAMINING THE PERCEPTIONS OF PHARMACISTS OF JOB SATISFACTION, ACHIEVMENTS, AND PREPRDNESS
	6ER-036	EVALUATION OF THE EFFICACY OF NEOADJUVANCE TREATMENT WITH IMMUNOTHERAPY IN EARLY STAGE BREAST CANCER: A SYSTEMATIC REVIEW
	6ER-037	PHARMACO-UTILISATION OF IBRUTINIB IN CLL: A SINGLE CENTRE STUDY
	6ER-038	ELABORATION OF A COMPETENCY FRAMEWORK FOR PATIENTS UNDERGOING PERCUTANEOUS CLOSURE OF PATENT FORAMEN OVALE OR ATRIAL SEPTAL DEFECT
	6ER-039	PAIN MANAGEMENT: OPIOID USE IN HOSPITALS
	6ER-040	A TOOL PROPOSAL FOR IDENTIFYING THE RISK OF POLYPHARMACY IN NURSING HOMES FOR ELDERLY PEOPLE
	6ER-041	ROLE OF CHECKPOINT INHIBITORS POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA
	6ER-042	THE DISASTER PREPAREDNESS AND MANAGEMENT OF HEALTHCARE PRACTITIONERS: A SYSTEMATIC REVIEW OF THE ASSESSMENT INSTRUMENTS
	6ER-043	DEVELOPING AND VALIDATING A DISASTER MANAGEMENT ASSESSMENT TOOL FOR HEALTHCARE PRACTITIONERS

27th Congress of the EAHP

National Poster Prize Winners
PDF document	Poster number	Poster Title
	NP-001	DEVELOPING THE ROLE OF PRIMARY CARE CLINICAL PHARMACIST
	NP-002	“CAPSULE PHARMA”, AN INNOVATIVE DIGITAL TRAINING TOOL TO LEARN ABOUT IMPORTANT STERILE MEDICAL DEVICE (SMD) CONCEPTS
	NP-003	PHARMACEUTICAL INFUSION SCHEDULES AS A TOOL TO IMPROVE FLUID RESTRICTION IN PICU PATIENTS
	NP-004	RETROSPECTIVE STUDY ON INDIVIDUALISED MEDICATION OF DEMENTIA PATIENTS RECEIVING CHRONIC HOSPITAL CARES
	NP-005	SELF-ASSESSMENT ON THE IMPLEMENTATION OF RECOMMENDATIONS OF THE PERIOPERATIVE PROCESS: INFECTIOUS RISK MANAGEMENT IN SURGERY SETTING
	NP-006	IMMUNOTHERAPY IN SECOND-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER
	NP-007	RECOMMENDATIONS FOR ADMINISTRATION OF IMMUNOSUPPRESSANTS VIA ENTERAL FEEDING TUBE ACCORDING TO THEIR IN-VITRO ADMINISTRATION
	NP-008	EMERGENCY DEPARTMENT REVISIT SOCORE BASED ON PHARMACOTHERPAY
	NP-009	ASSESSMENT OF MEDICATION DISCREPANCIES BY PHARMACIST-LED MEDICATION RECONCILIATION AT ADMISSION : A PROSPECTIVE STUDY IN TRAUMATOLOGY
	NP-010	DEVELOPMENT OF A 2% LIDOCAINE GEL FOR LOCAL ANAESTHESIA OF THE EYE PRIOR TO INTRAVITREAL INJECTION
	Student Science Award	Around one-third of people with diabetes will develop foot ulcers in their lifetime

Section 1: Introductory Statements and Governance
PDF document	Poster number	Poster Title
	1ISG-001	ECONOMIC IMPACT GENERATED BY NATALIZUMAB OPTIMIZATION
	1ISG-002	MEDICATION WASTE IN AN ORTHOPAEDIC DEPARTMENT: EFFECT OF PATIENT'S OWN MEDICATION USE AND SELF-ADMINISTRATION DURING HOSPITALISATION AND THE VIEWS OF PATIENTS AND HOSPITAL STAFF
	1ISG-003	PROTOCOL FOR THE OPTIMISATION OF PHARMACEUTICAL VALIDATION IN HOSPITALIZED PATIENTS
	1ISG-004	HOME DELIVERY - EFFICIENCY, ECONOMY AND CUSTOMER SATISFACTION OUTCOMES - COMPARISON OF ASSISTANCE MODELS
	1ISG-005	DEPARTMENT COMPUTERISED PHARMACEUTICAL CABINET: RESULTS OF DEMATERIALIZATION AND TRACEABILITY OF DRUGS IN OBSTETRICS AND GYNECOLOGY
	1ISG-006	OPPORTUNITY TO STUDY ADHERENCE AND PERSISTENCE WITH HOME DELIVERY (HD) - REAL WORLD DATA (RWD) AND REAL WORLD EVIDENCE (RWE) ANALYSIS
	1ISG-007	OPPORTUNITIES FOR LOGISTIC REORGANISATION OF THE HOSPITAL PHARMACY WITH NEW CARE MODES: STOCK MANAGEMENT (SM) AND HOME DELIVERY (HD)
	1ISG-008	THE MULTIDISCIPLINARY ASSESSMENT OF RAPID ANTIGEN TESTS FOR THE DETECTION OF THE OMICRON VARIANT: THE ROLE OF THE HOSPITAL PHARMACIST IN A UNIVERSITY HOSPITAL
	1ISG-009	A FRAMEWORK FACILITATING ACCESS TO MEDICINES IN THE EUROPEAN UNION
	1ISG-010	PHARMACY STAFF SATISFACTION AND OPINION OF NEW WEBSITE APPLICATION FOR OUTPATIENT CARE
	1ISG-011	MANAGEMENT OF UNADMINISTERED THERAPIES: IMPACT OF PHARMACIST-DOCTOR COLLABORATION TO OPTIMIZE THE PROCESS OF PREPARING CANCER THERAPIES
	1ISG-012	COST-MINIMISATION ANALYSIS: PROPHYLACTIC TREATMENT OF HAEMOPHILIA TYPE A, WHAT TO CHOOSE BETWEEN FACTOR VIII, RECOMBINANT FACTORS VIII (MOROCTOCOG-ALFA AND OCTOCOG) AND EMICIZUMAB?

Section 2: Selection, Procurement and Distribution
PDF document	Poster number	Poster Title
	2SPD-001	USE AND COST EVOLUTION OF INFLIXIMAB AND ADALIMUMAB OVER 8 YEARS IN A TERTIARY HOSPITAL
	2SPD-002	COST SAVINGS IMPACT OF GENERICS: A LOCAL EXPERIENCE ON LENALIDOMIDE
	2SPD-003	ERRORS DETECTED IN THE TELEPHARMACY PROCEDURE
	2SPD-004	ECONOMIC EVALUATION AND BUDGET IMPACT FOR A REGIONAL HEALTH SERVICE ASSOCIATED WITH THE INCLUSION OF THE FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT IN A REGIONAL PHARMACOTHERAPEUTIC GUIDELINE
	2SPD-005	NEW CLOSED SYSTEM TRANSFER DEVICE CONTAINS REAL DRUG VAPOURS FOR UP TO 28 DAYS
	2SPD-006	ARE ALL BIOLOGIC AGENTS IN THE TREATMENT OF ANKYLOSING SPONDYLITIS EQUIVALENT ALTERNATIVES?
	2SPD-007	USE OF DRUGS IN SPECIAL SITUATIONS
	2SPD-008	BUDGETARY IMPACT DUE TO THE REPLACEMENT OF ORIGINAL LENALIDOMIDE INTO GENERIC LENALIDOMIDE
	2SPD-009	AVOIDED COSTS FROM THE INCLUSION OF BREAST CANCER PATIENTS IN CLINICAL TRIALS
	2SPD-010	REVIEW OF THE ENVIRONMENTAL CRITERIA INTRODUCED IN THE TENDERING OF DRUGS, MEDICAL DEVICES AND NON-MEDICAL EQUIPMENT IN A HEALTH GROUP PROCUREMENT ORGANIZATION
	2SPD-011	COMPARATIVE EFFICACY OF EPTINEZUMAB, GALCANEZUMAB, FREMANEZUMAB AND ERENUMAB IN THE PREVENTIVE TREATMENT OF CHRONIC MIGRAINE
	2SPD-012	COMPARATIVE EFFICACY OF ABROCITINIB, BARICITINIB AND UPADACITINIB IN MONOTHERAPY FOR THE TREATMENT OF ATOPIC DERMATITIS
	2SPD-013	INTERVENTIONAL CARDIOLOGY: ANALYSIS OF STERILE MEDICAL DEVICE’S CONSUMPTION AND ASSESSMENT OF DIFFERING PRACTICES
	2SPD-014	COST STUDY: REUSABLE FLEXIBLE URETEROSCOPES VERSUS SINGLE-USE IN A HEALTHCARE FACILITY
	2SPD-015	INDIRECT COMPARISON OF ANIFROLUMAB VS BELIMUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS
	2SPD-016	COMPARATIVE EFFICACY OF BIMEKIZUMAB, IXEKIZUMAB AND BRODALUMAB FOR MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
	2SPD-017	TELEPHARMACY AND HOME DELIVERY PROGRAMME FOR OUTPATIENTS THROUGH THE COMMUNITY PHARMACY
	2SPD-018	BEZLOTOXUMAB: STRATEGIES TO REDUCE ECONOMIC IMPACT
	2SPD-019	EXPLORING ECONOMIC AND QUALITATIVE ASPECTS OF DRUG USE IN A PENITENTIARY INSTITUTE
	2SPD-020	IMPACT OF COVID-19 TREATMENT OPTIONS ON HOSPITAL PHARMACY'S WORKLOAD: LESSONS LEARNED

Section 3: Production and Compounding
PDF document	Poster number	Poster Title
	3PC-001	PREPACKED BOXES FOR OUTPATIENT PARENTERAL ANTIBIOTIC THERAPY (OPAT) - A QUESTIONNAIRE SURVEY ON KNOWLEDGE, OPINION AND WISHES
	3PC-002	HAZARDOUS DRUG AND ANTIBIOTIC RESIDUE SURFACE CONTAMINATION - IS THERE A NEED TO REDUCE EXPOSURE?
	3PC-003	99m-Tc- HMPAO LABELED LEUKOCITES: STUDYING ACUTE INFECTION OUTBREAKS – NUCLEAR PHARMACIST IN NUCLEAR MEDICINE
	3PC-004	ECONOMIC SAVINGS OF ERENUMAB REDOSING IN A THIRD LEVEL HOSPITAL
	3PC-005	CLOSED SYSTEM TRANSFER DEVICE (CSTD) EXTENDS PRACTICAL IN-USE SHELF LIFE TO 28 DAYS AFTER FIRST PUNCTURE OF NON-PRESERVED SINGLE-USE-VIALS IN BOTH CONTROLLED AND UNCONTROLLED ENVIRONMENTS
	3PC-006	CONTAINER CLOSURE INTEGRITY TESTING AND PROCES VALIDATION OF CLOSED SYSTEM TRANSFER DEVICES FOR ASEPTIC RECONSTITUTION OF DRUG VIALS CONNECTED TO FLUID BAGS
	3PC-007	IMPACT OF A SUSTAINABILITY STRATEGY IN THE DEVELOPMENT OF STANDARDIZED NEONATAL PARENTERAL NUTRITION ON DEMAND
	3PC-008	SLOW ANAKINRA DESENSITIZATION PROTOCOL DESIGN FOR DELAYED HYPERSENSIBILITY REACTION
	3PC-009	CYCLOPHOSPHAMIDE SURFACE CONTAMINATION IN A ROBOTIC CHEMOTHERAPY COMPOUNDING PROCESS
	3PC-010	FORMULATION OF TACROLIMUS SOLUTION FOR SUBLINGUAL USE
	3PC-011	A VIRTUAL STERILISATION AREA : AN INTERACTIVE TRAINING TOOL
	3PC-012	IMPACT AND SATISFACTION IN DRUG ADDICTS ATTENTION CENTERS AFTER INCREASING THE STABILITY OF METHADONE ORAL SOLUTION
	3PC-013	FORMULATION AND ELABORATION OF INTRATHECAL TRASTUZUMAB FOR THE TREATMENT OF A MENINGEAL CARCINOMATOSIS
	3PC-014	METAMORPHINE INSTEAD OF POLYSUBSTANCE USE?
	3PC-015	IN-USE STABILITY OF COMIRNATY AND SPIKEVAX CLINICAL SOLUTIONS: PFIZER-BIONTECH AND MODERNA COVID-19 VACCINES. A COMPARATIVE STUDY FROM A HOSPITAL PHARMACY PERSPECTIVE
	3PC-016	DOES A HOSPITAL COMPRESSOR SYSTEM CONTINOUSLY DELIVER MEDICINAL AIR ACCORDING TO THE EUROPEAN PHARMACOPAEIA?
	3PC-017	IMPACT OF AGITATION ON PEMBROLIZUMAB (KEYTRUDA®) SAFETY AND EFFICACY: AGGREGATION AND FUNCTIONALITY.
	3PC-018	TIME TO AVAILABILITY OF INJECTABLE ANTICANCER DRUGS FOR OUTPATIENTS: REASSESSMENT IN A FRENCH COMPREHENSIVE CANCER CENTER
	3PC-019	INDIGO CARMINE SOLUTION AND ADRENALINE IN SUBMUCOSAL CHROMOENDOSCOPY
	3PC-020	CLOBETASOL PETROLATUM OINTMENT 0.015% FOR THE TREATMENT OF CUTANEOUS GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC PATIENTS: A CASE REPORT.
	3PC-021	AMPHOTERICIN AND COLISTIN GELS FOR NECROTIZING WOUNDS: GALENIC AND MICROBIOLOGICAL VALIDATION.
	3PC-022	FORMULATION AND QUALITY CONTROL OF A BISOPROLOL 0.5 MG/ML ORAL SOLUTION FOR PAEDIATRIC USE
	3PC-023	PATCH TESTS WITH ETHAMBUTOL 10%, ISONIAZID 15% AND PYRAZINAMIDE 25%: A CASE REPORT.
	3PC-024	THE PREPARATION PERSONALIZED OF IMMUNOGLOBULIN BAGS TO IMPROVE THE TREATMENT PATH OF NEUROLOGICAL PATIENTS
	3PC-025	OUTPATIENT PARENTERAL ANTIBIOTIC THERAPY (OPAT): AN EXAMPLE DURING THE COVID-19 HEALTH EMERGENCY.
	3PC-026	EFFECTIVENESS AND SAFETY OF INSULIN 1UI/ml EYE DROPS
	3PC-027	STABILITY OF TACROLIMUS ORAL SUSPENSION IN DISPOSABLE POLYPROPYLENE SYRINGE
	3PC-028	FORMULATION OF AN ORAL PLATELET LYSATE GEL TO TREAT CHRONIC GRAFT VERSUS HOST DISEASE ASSOCIATED ORAL MUCOSITIS. EFFECTIVENESS IN A SERIES OF CASES
	3PC-029	MANAGEMENT OF A CHEMOTHERAPY PRODUCTION AFTER A CYBER-ATTACK IN A PUBLIC HOSPITAL
	3PC-030	EVALUATION OF EXCIPIENTS USED IN PAEDIATRIC COMPOUNDED FORMULATIONS PRESCRIBED IN A NEONATAL INTENSIVE CARE UNIT
	3PC-031	A DELPHI METHOD TO STANDARDIZE THE PREPARATION OF AUTOLOGOUS SERUM EYE DROPS ?
	3PC-032	USE OF ORAL KETAMINE FORMULATION IN PATIENTS WITH CHRONIC REFRACTORY PAIN
	3PC-033	ECONOMIC IMPACT OF CENTRALIZING PEDIATRIC INTRAVENOUS ADMIXTURES
	3PC-034	USE OF A MIXTURE OF BLEOMYCIN, LIDOCAINE AND EPINEPHRINE IN THE TREATMENT OF KELOID SCARS.ON THE SUBJECT OF A CASE.
	3PC-035	GALENIC DEVELOPMENT OF A GENERIC SPECIALTY WITH CONVENTIONAL RELEASE BASED ON ACARBOSE
	3PC-036	CENTRALIZED AND PERSONALIZED PREPARATION OF INTRAVENOUS KETAMINE FOR PATIENTS WITH RESISTANT DEPRESSION
	3PC-037	LIQUID CHROMATOGRAPY MASS SPECTROMETRY ANALYSIS OF DOXORUBICIN AND EPIRUBICIN AFTER FREEZING

Section 4: Clinical Pharmacy Services
PDF document	Poster number	Poster Title
	4CPS-001	EMICIZUMAB IN ACQUIRED HAEMOPHILIA TYPE A: A CASE REPORT.
	4CPS-002	SAFETY AND EFFECTIVENESS OF MONOCLONAL ANTIBODIES FOR MIGRAINE PREVENTION AFTER TWO AND A HALF YEARS OF CLINICAL EXPERIENCE
	4CPS-003	EXPERIENCES WITH A BEST POSSIBLE MEDICATION HISTORY (BPMH) CONDUCTED BY PHARMACY STUDENTS IN THE HOSPITAL SETTING: A SCOPING REVIEW
	4CPS-004	TRENDS IN TREATMENTS DURING COVID-19 PANDEMIA IN A UNIVERSITY TERTIARY HOSPITAL
	4CPS-005	SUCCESSFUL TREATMENT OF OSTEOMYELITIS CAUSED BY DIFFICULT-TO-TREAT RESISTANT PSEUDOMONAS AERUGINOSA WITH CEFIDEROCOL AS MONOTHERAPY: A CASE REPORT
	4CPS-006	COMPLETE CLINICAL RESPONSE IN METASTATIC BREAST CANCER AFTER FRONT-LINE TREATMENT WITH RIBOCICLIB/TAMOXIFEN
	4CPS-007	TARGETING PATIENTS WITH PNEUMONIA BY COVID-19 THAT COULD BE BENEFICIATED BY COLCHICINE.
	4CPS-008	DOES COMORBIDITY AFFECT ADHERENCE TO INHALERS IN SEVERE ASTHMA PATIENTS TREATED WITH BIOLOGICS?
	4CPS-009	Δ-9-TETRAHYDROCANNABINOL(SATIVEX) FOR THE TREATMENT OF MULTIPLE SCLEROSIS SPASTICITY : EVALUATION OF EFFECTIVENESS AND SAFETY
	4CPS-010	DUPILUMAB FOR THE TREATMENT OF ATOPIC DERMATITIS: EVALUATION OF EFFECTIVENESS AND SAFETY
	4CPS-011	CLINICAL AND ECONOMIC IMPACT OF PHARMACIST ANTIMICROBIAL INTERVENTIONS IN A SMALL HOSPITAL
	4CPS-012	PLATELET TO LYMPHOCYTE RATIO (PLR) AS BIOLOGICAL MARKER OF INTEREST IN INMUNOTHERAPY
	4CPS-013	TREOSULFAN-BASED CONDITIONING REGIMEN FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH SICKLE CELL DISEASE. EFFICACY AND SAFETY.
	4CPS-014	COMPARISON OF TWO PROTOCOLS FOR THE ADMINISTRATION OF LEUCOVORIN RESCUES AFTER HIGH DOSE METHOTREXATE INFUSION OF 24 HOURS
	4CPS-015	ROLE OF CLINICAL PHARMACIST IN THE OPTIMISATION OF NIRMATRELVIR/RITONAVIR PRESCRIPTION IN THE EMERGENCY DEPARTMENT
	4CPS-016	PREDICTIVE PERFORMANCE OF GLOMERULAR FILTRATION RATE EQUATIONS BASED ON CYSTATIN C, CREATININE AND THEIR COMBINATION IN CRITICALLY ILL PATIENTS
	4CPS-017	REAL-WORLD EVIDENCE ON RHEUMATOID ARTHRITIS TREATMENT PERSISTENCE: JANUS KINASE INHIBITORS VERSUS BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS.
	4CPS-018	EVOLUTION OF ANTIMICROBIAL USE IN COVID-19 PATIENTS
	4CPS-019	QUALITY ASSESSMENT OF THE EVIDENCE UNDERPINNING PHARMACIST-LED ANTIMICROBIAL STEWARDSHIPS INTERVENTIONS
	4CPS-020	TREATMENT PERSISTENCE AND DISCONTINUATION REASONS OF JANUS KINASE INHIBITORS IN A REAL-WORLD SETTING OF RHEUMATOID ARTHRITIS PATIENTS.
	4CPS-021	EFFECTIVENESS, PERSISTENCE, AND ADHERENCE OF BARICITINIB IN RHEUMATOID ARTHRITIS: LONG-TERM REAL-WORLD EVIDENCE STUDY
	4CPS-022	ADHERENCE TO EVOLOCUMAB AND ITS IMPACT ON LDL CHOLESTEROL REDUCTION
	4CPS-023	TOPICAL RAPAMYCIN IN RARE TUBEROUS SCLEROSIS DISEASE: LIPOSOMAL FORMULATION STABILITY
	4CPS-024	COMPARISON OF CHANGES IN CLINICAL VALUES OF INTENSIVE CARE PATIENTS AT VETERANS HOSPITAL ACCORDING TO VARIOUS FAT EMULSIONS FOR PARENTERAL NUTRITION
	4CPS-025	FREMANEZUMAB UTILISATION STUDY AND EFFECTIVENESS IN THE ‘REAL WORLD’
	4CPS-026	EFFECTIVENESS OF SODIUM ZIRCONIUM CYCLOSILICATE IN REDUCING POTASSIUM CONCENTRATIONS IN HOSPITALISED PATIENTS
	4CPS-027	COST SAVINGS IMPACT AND EFFECTIVENESS OF OMALIZUMAB OPTIMISATION IN REFRACTORY CHRONIC URTICARIA.
	4CPS-028	DRUG BURDEN INDEX EVALUATION IN INSTITUTIONALIZED GERIATRIC PATIENTS AS A DEPRESCRIPTION STRATEGY
	4CPS-029	ECONOMIC IMPACT OF BIOLOGICAL TREATMENT OPTIMISATIONS IN RHEUMATOLOGICAL AND DERMATOLOGICAL DISEASES
	4CPS-030	IMPACT OF PHARMACEUTICAL PROPOSALS IN MULTIDISCIPLINARY PROGRAMME FOR CLINICAL DECISION-MAKING IN IMMUNE-MEDIATED INFLAMMATORY DISEASES
	4CPS-031	THERAPEUTIC DRUG MONITORING OF CEFTAZIDIME/AVIBACTAM ADMINISTERED BY CONTINUOUS INFUSION: PK/PD TARGET ACHIEVEMENT AND CLINICAL OUTCOMES
	4CPS-032	THE USE OF LEAN METHODOLOGY IN CLINICAL PHARMACOKINETICS - A RETROSPECTIVE ANALYSIS
	4CPS-033	EVALUATION OF THE EFFECTIVENESS OF REINDUCTION OR INTENSIFICATION WITH USTEKINUMAB IN INFLAMMATORY BOWEL DISEASE
	4CPS-034	ANALYSIS OF THE EFFECTIVENESS OF SOTROVIMAB IN PATIENTS DIAGNOSED WITH COVID-19
	4CPS-035	ASSOCIATON OF DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY WITH CAPECITABINE TOLERANCE
	4CPS-036	SUCCESSFUL TREATMENT OF POSTSURGICAL MENINGITIS CAUSED BY BACILLUS CEREUS: A CASE REPORT
	4CPS-037	INDIRECT COMPARISONS OF BIOLOGICAL TREATMENTS IN PSORIATIC ARTHRITIS
	4CPS-038	CHALLENGES RELATED TO TRANSITIONING FROM HOSPITAL TO TEMPORARY CARE AT A SKILLED NURSING FACILITY
	4CPS-039	CLINICAL AND ECONOMIC IMPACT OF MULTISWITCHING FROM ORIGINAL ADALIMUMAB TO BIOSIMILARS.
	4CPS-040	ELECTRONIC CLINICAL DECISION SUPPORT FOR PHARMACOTHERAPEUTIC INTERVENTIONS TO REDUCE ANTICHOLINERGIC BURDEN IN OLDER HOSPITALISED PATIENTS
	4CPS-041	ASSESSMENT OF QUALITY OF LIFE IN PATIENTS UNDERGOING ANTIMIGRAINE TREATMENT
	4CPS-042	OFF-LABEL USE OF USTEKINUMAB IN NONBULLOUS CONGENITAL ICHTHYOSIFORM ERYTHRODERMA: A CASE REPORT
	4CPS-043	DRUG-DRUG INTERACTIONS WITH NIRMATRELVIR/RITONAVIR FOR COVID-19 AND THE ROLE OF HOSPITAL PHARMACISTS
	4CPS-044	EFFECTIVENESS AND SAFETY OF DIFFERENT INITIAL DOSES OF ARIPIPRAZOLE INTRAMUSCULAR DEPOT
	4CPS-045	ECOLOGICAL AND CLINICAL IMPACT OF AN ANTIMICROBIAL STEWARDSHIP PROGRAMME ON THE INCIDENCE OF CARBAPENEM RESISTANT KLEBSIELLA PNEUMONIAE
	4CPS-046	A QUALITATIVE STUDY OF FEASABILITY AND ACCEPTABILITY OF A PHARMACY PRIORITISATION TOOLKIT BY A FRAILTY FOCUSED MULTIDICIPLINARY TEAM IN AN ACUTE HOSPITAL EMERGECY DEPARTMENT
	4CPS-047	IMPACT OF CORTICOSTEROID ON THE EFFECTIVENESS OF IMMUNOTHERAPY
	4CPS-048	ANALYSIS OF PAXLOVID® FOR THE TREATMENT OF COVID-19 IN ARAGÓN, SPAIN
	4CPS-049	TELEPHARMACY AND NEW HEALTHCARE MODELS: CLOSER TO PATIENTS
	4CPS-050	ANALYSIS OF REAL-LIFE USE OF IBRUTINIB AFTER RELAPSE TO CONVENTIONAL CHEMOTHERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA
	4CPS-051	IMPACT OF THE NEW ANTIEPILEPTIC DRUG MONITORING PROGRAMME ON THE ACTIVITY OF THE PHARMACY AND NEUROLOGY DEPARTMENTS
	4CPS-052	LONG-TERM MONITORING OF UREA AS TREATMENT FOR HYPONATREMIA ASSOCIATED TO INADEQUATE SECRETION OF ANTIDIURETIC HORMONE (ISADH)
	4CPS-053	KOUNIS SYNDROME SECONDARY TO METAMIZOLE: A CASE REPORT
	4CPS-054	USE OF INTRATHECAL LIPOSOMAL-AMPHOTERICIN B FOR CANDIDA MENINGITIS: A CASE REPORT.
	4CPS-055	EFFECTIVENESS AND SAFETY OF RIBOCICLIB IN THE FIRST LINE OF LUMINAL METASTATIC BREAST CANCER.
	4CPS-056	A CLINICAL AND COST ANALYSIS OF MEDICINES RECONCILIATION BY CLINICAL PHARMACISTS ON HOSPITAL DISCHARGE
	4CPS-057	SEARCHING FOR A TREATMENT FOR PERIPHERAL TISSUE ISCHEMIA IN NEWBORNS. A CASE REPORT.
	4CPS-058	SYMBALOO AS DIGITAL TOOL FOR HEMOPHILIA
	4CPS-059	EFFICACY AND SAFETY OF EARLY SWITCH TO ORAL ANTIBIOTHERAPY IN PNEUMOLOGY: PROPENSITY SCORE-MATCHED ANALYSIS
	4CPS-060	EFFECTIVENESS AND ECONOMIC ANALYSIS OF WEIGHT-BASED VERSUS FIXED DOSING OF PEMBROLIZUMAB IN NON SMALL CELL LUNG CANCER
	4CPS-061	APPLICATION OF PROPORTION OF DAY COVERED (PDC) TO EVALUATE ADHERENCE AND PERSISTENCE TO TREATMENT WITH FINGOLIMOD IN PATIENTS WITH MULTIPLE SCLEROSIS
	4CPS-062	EVALUATION AND FOLOW-UP OF PEDIATRIC PATIENT WITH SHORT BOWEL SYNDROME ON TREATMENT WITH TEDUGLUTIDE: CASE REPORT
	4CPS-063	USING MACHINE LEARNING TO PREDICT PHARMACEUTICAL INTERVENTIONS IN A HOSPITAL SETTING
	4CPS-064	EFFECTIVENESS OF RIBOCICLIB AND ABEMACICLIB AS FIRST LINE TREATMENT FOR METASTATIC BREAST CANCER IN POST-MENOPAUSAL WOMEN.
	4CPS-065	SIMULATION OF THE IMPACT OF PHARMACOGENETIC MONITORING OF CYTOCHROME P450 2C19 IN PATIENTS ON CLOPIDOGREL TREATMENT
	4CPS-066	BIOLOGICAL TREATMENTS USED TO TREAT HIDRADENITIS SUPPURATIVA IN A TERTIARY HOSPITAL
	4CPS-067	A CROSS-SECTORAL PHARMACIST INTERVENTION FOR PATIENTS IN TRANSITION BETWEEN HOSPITAL AND GENERAL PRACTICE: A PILOT STUDY
	4CPS-068	CONDUCTION OF AN AUDIT TO REDUCE THE ECONOMIC LOSS DUE TO UNUTILIZED ONCOLOGICAL DRUG PREPARATIONS
	4CPS-069	EXPERIENCE OF ONCOHEMATOLOGY PATIENTS IN OUTPATIENT THERAPY WITH COMPREHENSIVE MEDICATION MANAGEMENT IN THE CONTEXT OF A COVID 19 PANDEMIC
	4CPS-070	THE CLINICAL PHARMACIST : AN ESSENTIAL ACTOR IN TIMES OF CRISIS
	4CPS-071	IMPACT OF INADEQUATE EMPIRICAL THERAPY ON THE MORTALITY RATE IN PSEUDOMONAS AERUGINOSA INFECTIONS
	4CPS-072	REAL-WORLD EXPERIENCE IN HEMOPHILLIA B PATIENTS AFTER SWITCHING TO FIX EXTENDED HALF LIFE USING PHARMACOKINETIC POBLACIONAL SOFTWARE AND MONOCOMPARTIMENTAL MODEL
	4CPS-073	ANALYSIS OF EFFECTIVENESS AND POSITIVE PREDICTIVE VALUE OF ANTIMICROBIAL STEWARDSHIP ALERTS USING A CLINICAL-DECISSION SUPPORT SYSTEM
	4CPS-074	EFFICACY AND SAFETY OF SOTROVIMAB: RESULTS OF A RETROSPECTIVE OBSERVATIONAL STUDY IN A FRENCH HOSPITAL
	4CPS-075	PERSISTENCE AND COST ANALYSIS OF SECUKINUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIASIS
	4CPS-076	EFFECTIVENESS AND TOLERABILITY OF CYCLIN-DEPENDENT KINASE INHIBITOR TREATMENT IN METASTATIC BREAST CANCER: REAL-LIFE DATA.
	4CPS-077	CLINICAL-EPIDEMIOLOGICAL CHARACTERISTICS OF A COHORT OF PATIENTS TREATED WITH DORAVIRINE
	4CPS-078	ASSESSMENT OF THE QUALITY OF A HOSPITAL'S CLINICAL TRIAL INITIATION VISIT
	4CPS-079	COMPARATIVE ANALYSIS OF THE EFFECTIVENESS OF CEFTAZIDIME-AVIBACTAM ADMINISTERED BY INTERMITTENT INFUSION VERSUS CONTINUOUS INFUSION
	4CPS-080	OPTIMIZATION OF ANTIRETROVIRAL THERAPY: RESULTS AFTER SIMPLIFICATION TO BITHERAPY WITH DOLUTEGRAVIR/LAMIVUDINE OR DOLUTEGRAVIR/RILPIVIRINE.
	4CPS-081	EVALUATION OF EFFECTIVENESS, SAFETY AND ADHERENCE OF PRE-EXPOSURE PROPHYLAXIS AGAISNT HIV
	4CPS-082	MOST FREQUENT ERRORS IN THE INHALATION TECHNIQUE OF ASTHMATIC CHILDREN
	4CPS-083	CREATININE AND CYSTATIN-BASED ESTIMATED RENAL FUNCTION IN VANCOMYCIN MONITORING
	4CPS-084	EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER WITH VERY HIGH VS HIGH PD-L1 EXPRESSION
	4CPS-085	PHARMACEUTICAL INTERVENTIONS IN A NEONATOLOGY UNIT
	4CPS-086	COMPARISON OF A TRADITIONAL ELISA TECHNIQUE VERSUS A POINT-OF-CARE TECHNIQUE IN THE DETERMINATION OF ADALIMUMAB LEVELS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE.
	4CPS-087	PERSISTENCE IN THE METHADONE MAINTENANCE PROGRAMME AND ITS RELATIONSHIP WITH THE MEDICATION REGIMEN COMPLEXITY INDEX IN OPIOID DEPENDENT PATIENTS
	4CPS-088	CORRELATION BETWEEN IMMUNE-RELATED ADVERSE EVENTS AND EFFICACY IN NON-SMALL CELL LUNG CANCER TREATED WITH NIVOLUMAB
	4CPS-089	CURRENT STATUS OF HEPATITIS C VIRUS INFECTION
	4CPS-090	A REVIEW OF PHARMACY HOMECARE SERVICES WITHIN A GROUP OF UK HOSPITAL PHARMACIES
	4CPS-091	WHAT YOU NEED TO KNOW ABOUT BRUGADA SYNDROME IF YOU ARE A HOSPITAL PHARMACIST
	4CPS-092	STATISTICAL RELATIONSHIP BETWEEN BIOMARKERS WITH PROGNOSTIC VALUE IN ANTI-PDL1 TREATMENTS IN CANCER PATIENTS
	4CPS-093	POLYPHARMACY AND INAPPROPRIATE DRUGS IN PATIENTS WITH OROPHARYNGEAL DYSPHAGIA
	4CPS-094	ANALYSIS OF INTERVENTIONS ON ANTIBIOTIC PRESCRIPTIONS BY THE ANTIMICROBIAL STEWARDSHIP PROGRAMS AT THE EMERGENCY DEPARTMENT
	4CPS-095	INFUSION AUDIT IN HEMATOLOGY: IMPORTANCE OF EVALUATION AND OPTIMIZATION OF PROFESSIONAL PRACTICES
	4CPS-096	EVOLUTION OF SELECTIVE IMMUNOMODULATE THERAPY IN SPECIAL SITUATIONS
	4CPS-097	COMPARATIVE EFFECTIVENESS OF RISANKIZUMAB AND SECUKINUMAB IN MODERATE TO SERIOUS PSORIASIS.
	4CPS-098	NIRMATRELVIR-RITONAVIR EFFECTIVENESS ANALYSIS AND INTERACTION PROFILE ANALYSIS
	4CPS-099	NINTEDANIB AND PIRFENIDONE IN IDIOPATHIC PULMONARY FIBROSIS: COMPARATIVE EFFECTIVENESS AND SAFETY IN A THIRD-LEVEL HOSPITAL
	4CPS-100	VALIDITY, RELIABILITY AND USER-PRACTICABILITY OF A CLASSIFICATION TOOL FOR DRUG-RELATED PROBLEMS AND PHARMACIST INTERVENTIONS WITHIN AN UPPER AUSTRIAN HOSPITAL TRUST
	4CPS-101	CAUSALITY OF ADVERSE DRUG REACTIONS IN HIV-PATIENTS TREATED WITH BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE
	4CPS-102	DRUG RELATED PROBLEMS SECONDARY TO HEPARIN TREATMENT IN PATIENTS DISCHARGED FROM THE EMERGENCY DEPARTMENT
	4CPS-103	PHARMACOKINETIC INTERACTION STUDY OF OSIMERTINIB AND DIGOXIN: A CASE REPORT
	4CPS-104	ANALYSIS OF PHARMACEUTICAL INTERVENTIONS IN A UNIT DOSE AREA
	4CPS-105	CEFIDEROCOL TREATMENT IN COVID-19 POSITIVE PATIENTS CO-INFECTED WITH PAN-RESISTANT PSEUDOMONAS AERUGINOSA
	4CPS-106	BEDSIDE CHECK OF MEDICATION APPROPRIATENESS (BED-CMA) AS A RISK-BASED TOOL FOR BEDSIDE CLINICAL PHARMACY SERVICES: A PROOF-OF-CONCEPT STUDY AT THE TRAUMA SURGERY WARD
	4CPS-107	EFFECT OF PATIENT BODY WEIGHT ON THE PHARMACOKINETIC BEHAVIOR OF AMIKACIN
	4CPS-108	PATIENT AND PHYSICIANS'S SATISFACTION WITH CLINICAL PHARMACY SERVICES ON A HEMATOLOGY WARD IN A LARGE TERTIARY CARE HOSPITAL
	4CPS-109	THERAPEUTIC DRUG MONITORING OF VANCOMYCIN IN ONCOLOGIC AND HEMATOLOGIC PATIENTS: REAL-WORLD DATA
	4CPS-110	ASSOCIATION BETWEEN BASELINE CHARACTERISTICSTS AND FIRST LINE CHEMOTHERAPY IN ADVANCED GASTRIC CANCER PATIENTS
	4CPS-111	IMPORTANCE OF IMPLEMENTING A CLINICAL PHARMACOKINETIC UNIT IN HOSPITAL PHARMACY SERVICE
	4CPS-112	SURVEY OF DIETARY SUPPLEMENT USE AND VACCINATION STATUS AMONG RHEUMATOID ARTHRITIS PATIENTS DURING THE COVID-19 PANDEMIC
	4CPS-113	ANALYSIS OF PHARMACEUTICAL INTERVENTIONS AND ACTIVITY IN THE ARTHROPATHY PHARMACEUTICAL CARE PRACTICE IN A REGIONAL HOSPITAL
	4CPS-114	DEVELOPMENT AND PROSPECTIVE VALIDATION OF A PREDICTION MODEL TO IDENTIFY CLINICALLY RELEVANT MEDICATION DISCREPANCIES AT THE EMERGENCY DEPARTMENT
	4CPS-115	DEVELOPMENT AND IMPLEMENTATION OF A REVIEW PROGRAMME ASSISTED BY THE PHARMACIST TO IMPROVE THE ADEQUACY OF TREATMENT IN POLYMEDICATED PATIENTS IN HOSPITAL OUTPATIENT SETTING
	4CPS-116	THE EFFICIENCY AND COST-EFFECTIVENESS OF HEALTHCARE AND NUTRITIONAL INTERVENTIONS IN THE MANAGEMENT OF POST-STROKE OROPHARYNGEAL DYSPHAGIA, RESULTS OF A SYSTEMATIC REVIEW
	4CPS-117	USE OF ERYTHROMYCIN AS PROKINETIC IN CRITICALLY HOSPITALIZED PATIENTS
	4CPS-118	HEALTH OUTCOMES IN A COHORT OF HIV+ PATIENTS STRATIFIED USING THE KAISER PERMANENTE PYRAMID POPULATION-BASED RISK STRATIFICATION MODEL
	4CPS-119	PNEUMONOLOGY-PHARMACY COLLABORATION IN THE PHARMACOTHERAPEUTIC OPTIMIZATION OF MONOCLONAL ANTIBODIES IN PATIENTS WITH SEVERE UNCONTROLLED ASTHMA
	4CPS-120	ADVERSE EFFECTS OF ANTIRETROVIRALS: EXPERIENCE OF PATIENTS. «TALK ABOUT IT TO BETTER MANAGE IT»
	4CPS-121	ANALYSIS OF THE USE OF INTRAVENOUS IRON IN OUTPATIENTS
	4CPS-122	CLINICAL FOLLOW-UP IN PATIENTS WITH MIGRAINE AFTER DISCONTINUATION OF PROPHYLACTIC BIOLOGICAL TREATMENT: A REAL-WORLD EXPERIENCE
	4CPS-123	CASE-CONTROL STUDY ON THE ASSOCIATION BETWEEN NOSOCOMIAL BLOODSTREAM INFECTIONS AND GLUCOCORTICOIDS, TOCILIZUMAB, SYSTEMIC ANTIBIOTICS, MECHANICAL VENTILATION AND LENGTH OF HOSPITAL STAY IN COVID-19 HOSPITALISED PATIENTS
	4CPS-124	EFFICACY AND SAFETY OF ERENUMAB IN A SECOND-LEVEL HOSPITAL
	4CPS-125	PREEXPOSURE PROPHYLAXIS IN MEN AT HIGH RISK FOR HIV-1 INFECTION
	4CPS-126	LINEZOLID STUDY USE AND ASSESSMENT THE APPROPRIATENESS OF ITS PRESCRIPTION IN A REGIONAL HOSPITAL
	4CPS-127	PHARMACOKINETIC MONITORING OF VANCOMYCIN, GENTAMICIN AND AMIKACIN IN PAEDIATRIC POPULATION
	4CPS-128	CLINICAL PRACTICE: ANTI-VEGF THERAPY FOR RESISTANT MACULAR EDEMA.
	4CPS-129	REAL-LIFE EFFECTIVENESS AND SAFETY OF NIRAPARIB AND OLAPARIB IN HIGH-GRADE OVARIAN CANCER
	4CPS-130	EVALUATION OF TIXAGEVIMAB-CILGAVIMAB IN PRE-EXPOSURE PROPHYLAXIS OF COVID-19
	4CPS-131	SOCIAL FUNCTION OF THE TELEPHARMACY: A SOCIOECONOMIC ANALYSIS
	4CPS-132	ANALYSIS OF PHARMACEUTICAL INTERVENTIONS REGARDING ADMISSION RECONCILIATION
	4CPS-133	SAFETY AND EFFECTIVENESS OF GUSELKUMAB ON MODERATE TO SEVERE PLAQUE PSORIASIS
	4CPS-134	PERSISTENCE AND SHIFT IN THE TREATMENT OF PSORIASIS IN THE PERIOD 2019 - 2021
	4CPS-135	MELANOMA ADJUVANT THERAPY: from trials to clinical practice215
	4CPS-136	STANDARD FIRST DAY OF LIFE CENTRAL PARENTERAL NUTRITION, EXPERIENCE IN REAL CLINICAL PRACTICE
	4CPS-137	EVALUATING THE POTENTIAL CLINICAL AND ECONOMIC IMPACT OF CHEMOTHERAPY PRESCRIBING BY PHARMACISTS AT A UNIVERSITY TEACHING HOSPITAL
	4CPS-138	USE OF SODIUM ZIRCONIUM CYCLOSILICATE IN HYPERKALEMIC EMERGENCIES
	4CPS-139	THE PHARMACEUTICAL NEWSLETTER AS AN INFORMATION TOOL: USEFUL OR FUTILE ?
	4CPS-140	MEDICAL CANNABIS: PRESCRIPTION ANALYSIS IN TERMS OF FORMULATION AND THERAPEUTIC NEED IN AN HOSPITAL PHARMACY
	4CPS-141	PHARMACEUTICAL INTERVENTIONS IN A MEDICAL EMERGENCY DEPARTMENT: 6-MONTHS EXPERIENCE
	4CPS-142	EVALUATION OF PREMEDICATION USE IN ADVERSE DRUG REACTIONS OCCURENCE IN PATIENTS WHO RECEIVED INFLIXIMAB TO TREAT INFLAMMATORY BOWEL DISEASE
	4CPS-143	CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA FOLLOWING IMMUNE CHECKPOINT INHIBITION FOR SOLID TUMORS: TWO CASE REPORTS AND LITERATURE STATE OF THE ART.
	4CPS-144	EXPERIENCE OF USING REMDESIVIR IN THE TREATMENT OF PATIENTS WITH SARS-COV2 INFECTION
	4CPS-145	CONSENSUS VALIDATION OF A SCREENING TOOL FOR CARDIOVASCULAR PHARMACOTHERAPY IN GERIATRIC PATIENTS: THE RASP_CARDIO LIST
	4CPS-146	‘REAL WORLD’ EXPERIENCE OFELEXACAFTOR/TEZACAFTOR/IVACAFTOR IN THE TREATMENT OF CYSTIC FIBROSIS: EFFECTIVENESS AND SAFETY EVALUATION
	4CPS-147	REAL WORLD DATA (RWD) ANALYSIS ON USE OF IMMUNECHECKPOINT INHIBITORS (ICI) FOR NON-SMALL CELL LUNG CANCER (NSCLC)
	4CPS-148	USE OF ANTIVIRALS AUTHORIZED FOR THE TREATMENT OF COVID-19 IN PATIENTS NOT SUBJECT TO HOSPITAL ADMISSION
	4CPS-149	PAIN MANAGEMENT IN MENTAL HEALTH.
	4CPS-150	THE ROLE OF CLINICAL PHARMACIST IN EMERGENCY DEPARTMENT
	4CPS-151	ACETYLSALICYLIC ACID DESENSITIZATION IN PATIENTS WITH CORONARY ARTERY SYNDROME: LITERATURE REVIEW, RETROSPECTIVE ANALYSIS AND PATIENT FOLLOW-UP PROCEDURE IN AN ITALIAN CARDIOLOGICAL CENTER
	4CPS-152	PERSISTENT CYTOPENIA AFTER CAR-T CELLS: TREATMENT WITH ELTROMBOPAG. A CASE REPORT.
	4CPS-153	OFF-LABEL USE OF KETAMINE FOR RESISTANT DEPRESSION: ROLE OF THE HOSPITAL PHARMACIST
	4CPS-154	IFOSFAMIDE-INDUCED HEMORRHAGIC CYSTITS: INCIDENCE IN A PATIENT SAMPLE AND POSSIBLE CHEMIOTHERAPY PROTOCOL REVIEW
	4CPS-155	CREATION AND VALIDATION OF A MEDICATION REVIEW SUPPORT TOOL FOR POTASSIUM CHLORIDE INJECTION (KCl-inj) PRESCRIPTIONS
	4CPS-156	ANALYSIS OF EFECTIVENESS AND COSTS OF DRUG THERAPY PRESCRIBED IN SPECIAL SITUATIONS IN OUR HOSPITAL
	4CPS-157	COMPARISON OF THE EFFECTIVENESS BETWEEN INTERLEUKIN-23 INHIBITORS FOR TREATMENT OF PSORIASIS IN A THIRD LEVEL HOSPITAL
	4CPS-158	IMPROVEMENT IN PATIENT CARE BY PHARMACIST PHONE CALL AFTER STARTING TREATMENT
	4CPS-159	ESTIMATING RENAL FUNCTION FOR DRUG DOSING: CORRELATION BETWEEN CKD-EPI AND COCKCROFT-GAULT IN AN ELDERLY POPULATION
	4CPS-160	REAL-WORLD PERSISTENCE WITH DOLUTEGRAVIR/LAMIVUDINE VERSUS BICTEGRAVIR/EMTRICITABINA/TENOFOVIR ALAFENAMIDE AMONG HUMAN IMMUNODEFICIENCY VIRUS PATIENTS
	4CPS-161	NEGATIVE PRESSURE WOUND THERAPY IMPORTANCE IN WOUND CARE
	4CPS-162	TRIPLE WHAMMY DRUG-DRUG INTERACTION: CLINICAL RELEVANCE AND RESULTS OF PHARMACEUTICAL INTERVENTION.
	4CPS-163	CYTOCHROME P450 2C19 GENOTYPING FOR PERSONALISATION OF PROTON PUMP INHIBITOR THERAPY
	4CPS-164	ADEQUACY REVIEW IN THE USE OF DAPAGLIFLOZIN FOR THE TREATMENT OF HEART FAILURE.
	4CPS-165	ADAPTATION OF MARKETED PARENTERAL NUTRITION TO THE NEEDS OF A HOSPITAL.
	4CPS-166	IMPLEMENTATION OF A LINEZOLID PHARMACOKINETIC MONITORING PROGRAMME
	4CPS-167	CURRENT TRENDS IN THE USE OF CHECK-POINT INHIBITORS FOR NON-SMALL CELL LUNG CANCER
	4CPS-168	RESULTS OF THE USE OF GALCANEZUMAB IN ROUTINE CLINICAL PRACTICE
	4CPS-169	PHYSICOCHEMICAL CHARACTERIZATION OF ORAL LIQUID FORMS AND REVIEW OF THE LITERATURE FOR SAFE AND EFFECTIVE ADMINISTRATION BY ENTERAL FEEDING TUBES
	4CPS-170	THE HOSPITAL PHARMACIST ROLE IN MULTIDISCIPLINARY TEAM DURING THE VACCINATION CAMPAIGN
	4CPS-171	METHADONE DRUG-DRUG INTERACTIONS POTENTIALLY RELATED TO CARDIOVASCULAR EVENTS IN CLINICAL PRACTICE
	4CPS-172	BRODALUMAB'S EFFECTIVENESS ON MODERATE TO SEVERE PLAQUE PSORIASIS IN REAL PRACTISE
	4CPS-173	EVALUATION OF INCLUSION CRITERIA OF OUTPATIENTS INCLUDED AT HOSPITAL MEDICATION DISPENSING PROGRAMME THROUGH COMMUNITY PHARMACIES
	4CPS-174	EFFECTIVITY AND SAFETY OF CYCLIN-DEPENDENT KINASE INHIBITORS IN METASTATIC BREAST CANCER PATIENTS
	4CPS-175	SEPSIS CODE: IMPROVING OUTCOMES FOR PATIENTS WITH SEPSIS
	4CPS-176	EVALUATION OF NIRMATRELVIR/RITONAVIR USE AND EFFECTIVENESS
	4CPS-177	OPTIMIZATION OF THE THERAPEUTIC MANAGEMENT OF PATIENTS ON ECMO IN THE PEDIATRIC INTENSIVE CARE UNIT
	4CPS-178	DURABILITY OF TREATMENT AND REASONS FOR DISCONTINUATION OF DIMETHYL FUMARATE AND TERIFLUNOMIDE IN PATIENTS WITH MULTIPLE SCLEROSIS
	4CPS-179	REVERSAL OF ANTICOAGULATION IN ORTHOGERIATRIC PATIENTS WITH HIP FRACTURE REQUIRING EARLY SURGICAL INTERVENTION
	4CPS-180	VANCOMYCIN: CONCORDANCE OF DOSAGE ADJUSTMENT ACCORDING TO MINIMUM PLASMA CONCENTRATION AND AREA UNDER THE CURVE/MINIMUM INHIBITORY CONCENTRATION
	4CPS-181	FOLLOW-UP OF EXPOSED NEWBORNS TO HIV IN PREGNANCY IN A TERTIARY HOSPITAL
	4CPS-182	EXPERIENCE OF DISCONTINUATION TYROSINE KINASE INHIBITORS THERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CLINICAL PRACTICE
	4CPS-183	EFFECTIVENESS AND SAFETY OF NIRMATRELVIR/RITONAVIR IN REAL LIFE SETTING
	4CPS-184	WHAT IS THE ADDITIONNAL VALUE OF PHARMACEUTICAL INTERVENTIONS ON [123I]-METAIODOBENZYLGUANIDINE SCINTIGRAPHY?
	4CPS-185	COMPOUNDED INSULIN EYE DROPS: POPULATION CHARACTERISTICS, USE IN CLINICAL PRACTICE AND SAFETY
	4CPS-186	EFFECTIVENESS AND SAFETY OF CILGAVIMAB/TIXAGEVIMAB IN PRE-EXPOSURE PROPHYLAXIS OF COVID-19
	4CPS-187	PATIENTS WHO ARE CANDIDATES FOR TREATMENT WITH MONOCLONAL ANTIBODIES FOR PRE-EXPOSURE PROPHYLAXIS OF COVID-19
	4CPS-188	QUALITY OF LIFE IN PATIENTS ON GALCANEZUMAB LONG TERM TREATMENT
	4CPS-189	ANALYSIS OF MEDICATION PERSISTANCE IN MIGRAINE PATIENTS TREATED WITH ANTI-CGRP MONOCLONAL ANTIBODIES
	4CPS-190	ANALYSIS OF IBRUTINIB DOSE REDUCTION IN PATIENTS DIAGNOSED WITH CHRONIC LYMPHOCYTIC LEUKEMIA. ARE WE DOING IT RIGHT?
	4CPS-191	IMPACT OF THE COVID-19 PANDEMIC ON THE ADHERENCE OF HIV PATIENTS
	4CPS-192	ANALYSIS OF ADHERENCE AND ASSOCIATED RISK FACTORS IN MULTIPLE SCLEROSIS PATIENTS UNDER DISEASE-MODIFYING THERAPY
	4CPS-193	SUITABILITY OF THE DUAL ANTIPLATELET THERAPY TO THE GUIDELINES OF EUROPEAN SOCIETY OF CARDIOLOGY IN ACUTE CORONARY SYNDROME
	4CPS-194	BASELINE AUDIT OF POTENTIAL TO OPTIMISE THERAPY THROUGH USE OF SGLT2i IN A COHORT OF PATIENT ADMITTED WITH AN ACUTE MYOCARDIAL INFARCTION
	4CPS-195	E-LUNGING: EVALUATION OF AN E-LEARNING PROGRAM INTENDED FOR HEALTHCARE PROFESSIONALS REGARDING THE MEDICATION OF LUNG TRANSPLANT PATIENTS
	4CPS-196	POTENTIALLY INAPPROPIATE MEDICATIONS AND POTENTIALLY PRESCRIBING OMISSIONS IN OLDER PEOPLE LIVING WITH HIV
	4CPS-197	CONCOMITANT USE OF PROTON PUMP INHIBITORS AND PALBOCICLIB: ¿IS THERE A REAL IMPACT ON RESPONSE?
	4CPS-198	ANALYSIS OF ANTIPSYCHOTIC DRUGS USE AT A SPANISH TERTIARY HOSPITAL
	4CPS-199	PHARMACO-ECONOMIC IMPACT OF DRUG INTOXICATIONS IN CHILDREN
	4CPS-200	SUSTAINING A PHARMACEUTICAL DECISION SUPPORT SYSTEM BY DETERMINING THE CLINICAL RISK’S LEVEL OF DETECTED DRUG-RELATED PROBLEMS
	4CPS-201	PHARMACEUTICAL CARE TO OPTIMIZE TREATMENT FOR ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN A PRISON
	4CPS-202	THE USEFULNESS OF A PHARMACY RESIDENT STAGE IN THE CRITICAL CARE UNIT
	4CPS-203	ANTIBIOTIC STEWARDSHIP PROGRAMME INTERVENTIONS IN A THIRD LEVEL HOSPITAL IN SPAIN: A ONE-YEAR REVIEW
	4CPS-204	NATIONAL SURVEY ON CLONIDINE PRESCRIBING PRACTICES IN COMPLEX TRAUMA IN CHILD PSYCHIATRY
	4CPS-205	PHARMACIST’S INTERVENTION IN THE THERAPEUTIC MANAGEMENT OF PATIENTS WITH HEART FAILURE – AN OPPORTUNITY FOR IMPROVEMENT
	4CPS-206	EVALUATION OF IRON CARBOXYMALTOSE VS IRON SUCROSE ADMINISTRATION FOR THE CONTROL OF ANAEMIA IN HOSPITALISED PATIENTS
	4CPS-207	PHARMACEUTlCAL INTERVENTIONS IN AN INTENSIVE CARE UNIT OF EMERGENCY TRAUMA
	4CPS-208	TELEPHARMACY INTERVENTIONS IN PATIENTS WITH CHRONIC DISEASES
	4CPS-209	EXPERIENCE OF THE NOCEBO EFFECT IN PATIENTS WITH SWITCH TO BIOSIMILARS IN RHEUMATOID ARTHRITIS.
	4CPS-210	EFFICACY OF MONOCLONAL ANTIBODIES TO PREVENT PROGRESSION TO SEVERE COVID-19 DISEASE: REAL-LIFE DATA OF A UNIVERSITY HOSPITAL
	4CPS-211	DESIGN AND VALIDATION OF A QUESTIONNAIRE IN ARABIC LANGUAGE EVALUATING CHRONIC RENAL FAILURE PATIENTS'S KNOWLEDGE
	4CPS-212	SPECIALIST PHARMACIST-LED MULTIDISCIPLINARY CARE PATHWAY FOR OPTIMISING LIPID THERAPY – SIX MONTHS INTERIM ANALYSIS
	4CPS-213	CHARACTERISTICS OF MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN VERSUS KAWAZAKI ON CLINICAL ASPECTS, SPECIFICITIES AND TREATMENT
	4CPS-214	REAL-LIFE RESULTS ON THE USE OF TRASTUZUMAB EMTANSINE IN HER2-POSITIVE METASTATIC BREAST CANCER
	4CPS-215	DESCRIPTION OF THE PRE-EXPOSURE PROPHYLAXIS COVERAGE AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS.
	4CPS-216	OFF-LABEL USE OF RECOMBINANT HUMAN ERYTHROPOIETIN IN JEHOVAH'S WITNESS PATIENTS WITH HIP FRACTURE SUBJECTED TO MAJOR ORTHOPAEDIC SURGERY: A THREE CASES REPORT
	4CPS-217	THE USE OF CYSTIC FIBROSIS CONDUCTANCE REGULATOR MODULATORS IN PATIENTS WITH RARE MUTATION
	4CPS-218	TNF GENE POLYMORPHISMS PREDICTORS OF RESPONSE TO ANTI-TNF DRUGS IN PATIENTS DIAGNOSED WITH MODERATE-SEVERE PSORIASIS
	4CPS-219	AGAMENON-SEOM MODEL FOR THE PREDICTION OF SURVIVAL IN PATIENTS WITH HER2-POSITIVE ADVANCED ESOPHAGOGASTRIC ADENOCARCINOMA RECEIVING TRASTUZUMAB-BASED FIRST-LINE TREATMENT
	4CPS-220	COMPARATIVE ANALYSIS OF SKIN TOXICITY ON PATIENTS WITH METASTATIC COLON CANCER TREATED WITH EPIDERMAL GROWTH RECEPTOR BLOCKING DRUGS.
	4CPS-221	ASSESSMENT OF CLINICAL BENEFIT OF CANCER TREATMENTS ACCORDING TO THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY SCALE
	4CPS-222	HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS AGED > 55 YEARS WITH ACUTE MYELOID LEUKAEMIA
	4CPS-223	BOTULINUM TOXIN TYPE A: THE NON-INVASIVE SUCCESS FOR OVERACTIVE BLADDERS
	4CPS-224	IMPACT OF AUGMENTED RENAL CLEARANCE ON ANTIMICROBIAL DOSING IN SEVERELY BURNED PATIENTS
	4CPS-225	HEALTH IMPACT OF TREATMENT FOR INFLAMMATORY BOWEL DISEASE WITH BIOLOGICAL AGENTS FROM THE PATIENT’S PERSPECTIVE: A CROSS-SECTIONAL STUDY USING PATIENT REPORTED OUTCOME MEASURES (PROMs)
	4CPS-226	CONTINUOUS INFUSION OF VANCOMICYN: WHO ARE THE PATIENT CANDIDATES AND HOW SAFE IT IS?
	4CPS-227	REAL WORLD EVIDENCE OF THE USE OF DEFIBROTIDE FOR PROPHYLAXIS OF VENO-OCCLUSIVE DISEASE AFTER POST-HEMATOPOIETIC STEM-CELL TRANSPLANTATION IN CHILDREN
	4CPS-228	HIGH DOSE PHENOBARBITAL COMA IN PAEDIATRIC REFRACTORY STATUS EPILEPTICUS
	4CPS-229	THE ADDED VALUE OF A NATIONAL ELECTRONIC HEALTH RECORD FOR THE BEST POSSIBLE MEDICATION HISTORY OBTAINED BY A CLINICAL PHARMACIST
	4CPS-230	ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS AGED <60 YEARS WITH ACUTE MYELOID LEUKEMIA
	4CPS-231	EVALUATION OF CLINICAL DATA OF PATIENTS TREATED WITH ANTI-PCSK9 DRUGS IN TWO HEALTH DISTRICTS
	4CPS-232	COMPARATIVE EFFICACY OF RISANKIZUMAB AND GUSELKUMAB IN MODERATE TO SEVERE PLAQUE PSORIASIS
	4CPS-233	PD-L1 EXPRESSION AND HISTOLOGICAL TYPE AS PREDICTORS OF RESPONSE IN METASTASIC NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH PEMBROLIZUMAB IN FIRST LINE
	4CPS-234	DEVELOPMENT AND VALIDATION OF A RAPID HIGH PERFORMANCE CHROMATOGRAPHY METHOD (HPLC) FOR THE DETERMINATION OF LINEZOLID IN HUMAN PLASMA
	4CPS-235	IMPACT OF TELEPHARMACY ON BIOLOGIC THERAPIES ADHERENCE AND CLINICAL OUTCOMES IN PATIENTS WITH PSORIASIS
	4CPS-236	LOSS TO FOLLOW-UP FACTORS OF PEOPLE LIVING WITH HIV
	4CPS-237	HYPERKALEMIA AND RISK FACTORS: SCREENING AND ASSESSSMENT IN HOSPITAL PATIENTS.
	4CPS-238	PROFILE OF ELDERLY PATIENTS AT HIGH FALL RISK AND POLYPHARMACY IN THE EMERGENCY DEPARTMENT.
	4CPS-239	POPULATION PHARMACOKINETICS OF ISAVUCONAZOLE BASED ON PHAMACOGENETICS IN IMMUNOSUPPRESSED PATIENTS
	4CPS-240	FINGOLIMOD: ANALYSIS OF USE AND SAFETY IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
	4CPS-241	FINAL VALIDITY OF A TOOL FOR RATING SIGNIFICANCE OF PHARMACISTS’ CLINICAL CONTRIBUTIONS IN HOSPITAL
	4CPS-242	ISAVUCONAZOLE TREATMENT IN TWO PEDIATRIC PATIENTS DURING EXTRACORPOREAL MEMBRANE OXYGENATION SUPPORT: THE ROLE OF THERAPEUTIC DRUG MONITORING.
	4CPS-243	DELAYED HIV TREATMENT AND FACTORS ASSOCIATED
	4CPS-244	ANALYSIS AND COMPARISON OF OLANZAPINE ADMINISTRATION IN SMOKING AND NON-SMOKING PATIENTS
	4CPS-245	PREVENTION OF REFEEDING SYNDROME IN PATIENTS ON PARENTERAL NUTRITION: A REVIEW OF APPROPRIATENESS
	4CPS-246	TREATMENT AND NURSING CARE OF MUCORMYCOSIS IN PAEDIATRICS: A CASE REPORT
	4CPS-247	INITIATIVES TO IMPROVE THE MANAGEMENT OF PATIENTS WITH HEREDITARY ANGIOEDEMA BY HOSPITAL PHARMACY
	4CPS-248	THERAPEUTIC DRUG MONITORING OF LINEZOLID IN SOFT-TISSUE AND OSTEOARTICULAR INFECTIONS: A RETROSPECTIVE ANALYSIS
	4CPS-249	RELATIONSHIP BETWEEN RENAL FUNCTION AND ERTAPENEM PLASMA CONCENTRATION IN ADULT PATIENTS.
	4CPS-250	EXPERIENCE OF TECOVIRIMAT AND CIDOFOVIR USE IN A PATIENT WITH MONKEYPOX: A CASE REPORT
	4CPS-251	HEREDITARY ANGIOEDEMA: IMPACT OF THE BURDEN OF DISEASE IN SPAIN
	4CPS-252	OPTIMIZATION OF ERTAPENEM POSOLOGY IN A CRITICALLY ILL PATIENT BY THERAPEUTIC DRUG MONITORING: A CASE REPORT
	4CPS-253	DESCRIPTIVE STUDY OF THE ONCOLOGY AND HAEMATOLOGY POPULATION, DIAGNOSIS, AND IMMUNOTHERAPY IN PATIENTS OVER 65 YEARS OLD IN A THIRD LEVEL HOSPITAL
	4CPS-254	DAPAGLIFOZIN PRESCRIPTION PRACTICE IN PATIENTS WITH CHRONIC HEART FAILURE
	4CPS-255	ANTIPARKINSONIAN MEDICATION RECONCILIATION: HOW PREVENTING MEDICATION ERRORS PROMOTES THERAPEUTIC QUALITY AND SAFETY
	4CPS-256	ENHANCING THE SAFETY OF INJECTABLE CYTOTOXIC CHEMOTHERAPY AT A TERTIARY CARE HOSPITAL: A RETROSPECTIVE ANALYSIS OF PHARMACISTS’ INTERVENTIONS IN CHEMOTHERAPY PREPARATION SERVICES
	4CPS-257	PREOPERATIVE INTRAVENOUS IRON TO TREAT ANEMIA BEFORE MAJOR ORTHOPEDIC SURGERY
	4CPS-258	PHARMACOKINETICS ALTERATIONS IN FIVE CRITICALLY ILL PATIENTS ON EXTRACORPOREAL MEMBRANE OXYGENATION RECEIVING ISAVUCONAZOL
	4CPS-259	MANAGEMENT OF VORICONAZOLE-INDUCED LIVER TOXICITY IN A PEDIATRIC PATIENT
	4CPS-260	PERSISTENCE, SAFETY AND ASSOCIATED LYMPHOPENIA OF DIMETHYL FUMARATE IN RELAPSING REMITTING MULTIPLE SCLEROSIS, REAL WORLD DATA
	4CPS-261	ANALYSIS OF DRUG INTERACTIONS BETWEEN ORAL ONCOLOGICAL TREATMENT OF PROSTATE CANCER AND CHRONIC MEDICATION.
	4CPS-262	A NOVEL ARTIFICIAL INTELLIGENCE-BASED TOOL TO ASSESS ANTICHOLINERGIC BURDEN: A SURVEY
	4CPS-263	THE PHARMACIST’S ROLE IN OPTIMIZING SURGICAL ANTIBACTERIAL PROPHYLAXIS (SAP)

Section 5: Patient Safety and Quality Assurance
PDF document	Poster number	Poster Title
	5PSQ-001	EFFICACY AND SAFETY OF THE COMBINATION OF ISATUXIMAB, CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA: A CASE REPORT
	5PSQ-002	PHARMACIST IN SECURING DRUG CIRCUIT : FROM PRESCRIPTION TO ADMINISTRATION (ANALYSIS AND ACTIONS)
	5PSQ-003	PERFORMANCE OF A COLD MAINTENANCE DEVICE DURING THE IMPLEMENTATION OF A PNEUMATIC CIRCUIT
	5PSQ-004	EPCLUSA RELATED SLEEPINESS: A CASE REPORT
	5PSQ-005	ANALYSIS OF ANTI-ANGIOGENESIS-RELATED ADVERSE EVENTS ASSOCIATED WITH VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITORS (VEGFR-TKIS) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
	5PSQ-006	IMPACT OF PUIZZLE, A PLAYFUL EDUCATIONAL TOOL ON HIGH-ALERT MEDICATIONS ON HEALTHCARE PROFESSIONALS' KNOWLEDGE: A 7-MONTHS ANALYSIS
	5PSQ-007	IMPACT OF PUIZZLE, A PLAYFUL EDUCATIONAL TOOL ON HIGH-ALERT MEDICATIONS ON HEALTHCARE PROFESSIONALS' KNOWLEDGE: WHAT'S NEW AND WHAT'S LEFT?
	5PSQ-008	A DIGITAL ASSISTANT TO SUPPORT PATIENTS IN PREPARING MEDICATION RECONCILIATION: PATIENT EXPERIENCES.
	5PSQ-009	EFFECTIVENESS AND SAFETY OF MONOCLONAL ANTIBODY SWITCHING IN MIGRAINE PATIENTS
	5PSQ-010	DIGOXIN ADJUSTMENT: COMPARATIVE ANALYSIS OF THREE PHARMACOKINETIC SOFTWARE
	5PSQ-011	PHARMACOKINETIC EVALUATION OF DRUGS WITH A NARROW THERAPEUTIC RANGE AND THEIR INFLUENCE ON CLINICAL DECISION
	5PSQ-012	CASE REPORT: INHALED GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR FOR MILD-TO-MODERATE AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS - 24 MONTHS OF FOLLOW-UP
	5PSQ-013	PALBOCICLIB IN METASTATIC BREAST CANCER TREATMENT: NEUTROPENIA MANAGEMENT IN CLINICAL PRACTICE.
	5PSQ-014	IMPACT OF HISTAMINE-2 ANTAGONIST SHORTAGE ON THE INCIDENCE OF HYPERSENSITIVITY REACTIONS TO PACLITAXEL - TOWARDS CRISIS MANAGEMENT AND A PREMEDICATION RECONSIDERATION IN FRANCE (PACLIREACT STUDY)
	5PSQ-015	PERSISTENCE OF TREATMENT WITH JAK INHIBITORS IN RHEUMATOID ARTHRITIS IN PATIENTS ALREADY TREATED WITH THEM
	5PSQ-016	HUMAN FACTORS ROLE IN MEDICATION ERRORS: DILUTING INTRAVENOUS MEDICATIONS AT HOSPITAL WARDS - A STUDY BASED ON INCIDENT REPORTS
	5PSQ-017	IMMUNE-MEDIATED ADVERSE EFFECTS OF CHIMERIC ANTIGEN RECEPTOR T CELLS (CAR-T) THERAPY IN REAL LIFE POPULATION: WE CONTINUE TO LEARN.
	5PSQ-018	PRESCRIBING ERRORS IN CHILDREN: WHAT IS THE IMPACT OF A COMPUTERIZED PHYSICIAN ORDER ENTRY?
	5PSQ-019	ANALYSIS OF THE USE OF IDARUCIZUMAB IN A TERTIARY HOSPITAL
	5PSQ-020	ANALYSIS OF A PHARMACEUTICAL INTERVENTION IN POLYMEDICATED PATIENTS TO INCREASE THE SAFETY AND ADEQUACY OF THEIR TREATMENT
	5PSQ-021	AUTOMATION MEETS TRACEABILITY TO OPTIMIZE DRUGS AND MEDICAL DEVICES LOGISTICS GUARANTEEING PATIENT SAFETY AND HOSPITAL STAFF WELL-BEING
	5PSQ-022	ANALYSIS OF HEALTHCARE VISITS TO EMERGENCY SERVICES FROM PATIENTS WITH PAINFUL VASCULAR ULCERS TREATED WITH TOPICAL SEVOFLURANE
	5PSQ-023	SEVERE PHOTOTOXICITY REACTION ASSOCIATED WITH VANDETANIB: A CASE REPORT
	5PSQ-024	HAZARD VULNERABILITY ANALYSIS (HVA): EVALUATION OF RISK IN EXPERIMENTAL ONCOLOGICAL DRUGS COMPOUNDING
	5PSQ-025	IMPACT AND EVALUATION OF PHARMACOKINETIC MONITORING IN PRIMARY CARE.
	5PSQ-026	MEDICATION-RELATED OSTEONECROSIS OF THE JAWS AND CDK4/6 INHIBITORS
	5PSQ-027	APPROPRIATENESS OF PRESCRIPTION OF TRICYCLIC ANTIDEPRESSANTS ACCORDING TO STOPP CRITERIA
	5PSQ-028	CDK 4/6 INHIBITORS - ANALYSIS OF POTENTIAL DRUG INTERACTIONS
	5PSQ-029	PERCEIVED EXPERIENCE OF PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) AFTER IMPLEMENTING A TELEPHARMACY PROGRAMME
	5PSQ-030	SAFETY AND SECURITY OF CICLOSPORIN EYE DROPS IN PATIENTS WITH XEROPHTHALMIA
	5PSQ-031	ANALYSIS OF THE USE OF ISAVUCONAZOLE IN CRITICALLY ILL PATIENTS WHEN THE USE OF VORICONAZOLE IS INDICATED
	5PSQ-032	PHARMACIST INTEGRATION IN THE MULTIDISCIPLINARY EMERGENCY TEAM
	5PSQ-033	ANTIVIRAL TREATMENT DISCONTINUATION IN PATIENTS WITH HEPATITIS B
	5PSQ-034	FIXED VS WEIGHT-BASED DOSING OF PEMBROLIZUMAB FOR PATIENTS UNDER 80 KG, BASED ON OBSERVED ADRS IN ONE CANCER SETTING
	5PSQ-035	MASS UNIFORMITY OF HARD CAPSULES: ROYAL SPANISH PHARMACOPOEIA VS UNITED STATES PHARMACOPOEIA
	5PSQ-036	MEDICATION ERRORS RELATED TO HIGH-ALERT MEDICATIONS IN A TERTIARY CARE PEDIATRIC HOSPITAL – AN ANALYSIS OF REGISTER-BASED DATA
	5PSQ-037	IMPORTANCE AND IMPACT OF PHARMACEUTICAL RECONCILIATION AT DISCHARGE IN THE ELDERLY PATIENT WITH POLYMEDICATION
	5PSQ-038	DRUG RELATED VISITS TO THE EMERGENCY DEPARTMENT IN NURSING HOME PATIENTS
	5PSQ-039	RAF-KINASI PATHWAY INHIBITORS IN TREATMENT OF METASTATIC MELANOMA: WHEN COMPLIANCE DOESN’T MATCH WITH TOLERANCE.
	5PSQ-040	ANALYSIS OF THE IMPACT OF THE COVID-19 PANDEMIC ON PSYCHOTROPIC DRUG USE
	5PSQ-041	STERILE INTRAOCULAR INFLAMMATION AFTER INTRAVITREAL AFLIBERCEPT
	5PSQ-042	PREVALENCE OF MEDICATION PRESCRIPTION WITH A POTENTIAL NEGATIVE EFFECT ON SWALLOWING IN OUTPATIENTS WITH COGNITIVE IMPAIRMENT AND A DIAGNOSIS OF DYSPHAGIA.
	5PSQ-043	UNSUPPORTED PRESCRIPTION OF POLYVALENT IMMUNOGLOBULINS IN A UNIVERSITY HOSPITAL CENTER: FREQUENCY AND COST
	5PSQ-044	REAL-LIFE SAFETY AND SATISFACTION OF CFTR PROTEIN MODULATORS IN CYSTIC FIBROSIS
	5PSQ-045	IMPACT OF PHARMACEUTICAL INTERVENTIONS IN CRITICAL PATIENTS
	5PSQ-046	FMEA (FAILURE MODE AND EFFECT ANALYSIS) APPLICATION TO PARENTERAL NUTRITION BAGS MANUFACTURING PROCESS: ROLE OF HOSPITAL PHARMACIST
	5PSQ-047	PRECAUTIONARY CANCELLATION: TOOL TO IMPROVE PATIENT SAFETY
	5PSQ-048	WHAT DO ONCOLOGISTS AND PHARMACISTS THINK AND WANT FROM A CAHM-DRUG INTERACTION CHECKER? A BROADSCALE SURVEY TO ASSESS EXPECTATIONS.
	5PSQ-049	ASSESSMENT AND OPTIMISATION OF THE MANAGEMENT OF HIGH RISK MEDICINES IN A GENERAL HOSPITAL
	5PSQ-050	ANALYSIS OF THE USE OF USTEKINUMAB FOR CROHN DISEASE IN THE REAL CLINICAL PRACTICE
	5PSQ-051	PARKINSONISM INDUCED BY TAKING TRAZODONE AS A HYPNOTIC: A CASE REPORT
	5PSQ-052	CHANGES IN POLYMEDICATED PATIENTS’ PRESCRIPTIONS AFTER OUTPATIENT HOSPITAL CONSULTATIONS IN REAL LIFE SITUATIONS
	5PSQ-053	DESIGN OF A PRIORIZATION SYSTEM BY COMPLEXITY OF THE REVIEW IN POLYMEDICATED PATIENTS: POTENTIAL INADECUACY INDEX
	5PSQ-054	ASSESSEMENT OF OCCUPATIONAL PRACTICES: ANALYSIS OF THE PRESCRIPTIONS OF TRANSCATHETER AORTICVALVE IMPLANTATION (TAVI)
	5PSQ-055	SAFETY TESTING ASSESSMENT FOR THE ADHERENCE OF DOSE REDUCTION IN ONCOLOGY TREATMENT FOLLOWING CLINICAL GUIDELINES RECOMMENDATIONS IN PATIENTS PRIOR RECEIVING FLUOROPYRIMIDINES (5-FLUOROURACIL, CAPECITABINE AND TEGAFUR)
	5PSQ-056	HETEROGENEITY OF DEXMEDETOMIDINE TREATMENT EFFECT ON MORTALITY ACCORDING TO AGE
	5PSQ-057	EFFICACY AND SAFETY OF ADALIMUMAB IN THE TREATMENT OF INFLAMMATORY FACIAL GRANULOMA SECONDARY TO SILICONE
	5PSQ-058	MANAGEMENT OF SOLID ORAL PHARMACEUTICAL FORMS WITH UNIT DOSE
	5PSQ-059	REAL-WORLD CLINICAL DATA OF PALBOCICLIB AND RIBOCICLIB IN BREAST CANCER PATIENT
	5PSQ-060	GLUTEN IN MEDICINES. A PRESCRIPTION HELPING TOOL.
	5PSQ-061	NEW-ONSET MULTIPLE SCLEROSIS ASSOCIATED WITH ADALIMUMAB TREATMENT: ABOUT TWO CASE REPORTS
	5PSQ-062	REVIEW AND DEPRESCRIPTION OF MEDICATION IN POLYMEDICATED PATIENTS WITH PSYCHOACTIVE DRUGS.
	5PSQ-063	A CROSS-SECTIONAL STUDY ON THE POTENTIALLY INAPROPIATE PRESCRIBED AND CONTRAINDICATED HIGH-RISK MEDICATION IN HOSPITALIZED CHRONIC COMPLEX PATIENTS
	5PSQ-064	CONCOMITANT TREATMENT WITH ATEZOLIZUMAB AND ENZALUTAMIDE FOR METASTASTIC NON-SMALL-CELL LUNG CANCER AND METASTASTIC PROSTATE CANCER: A CASE REPORT
	5PSQ-065	BE A HUMAN, NOT A CASE REPORT! HOSPITAL PHARMACISTS MAKE THE DIFFERENCE
	5PSQ-066	ADEQUACY TO PROTOCOL OF USE OF TOCILIZUMAB FOR MANAGEMENT OF COVD-19 DISEASE
	5PSQ-067	TRACKING THE OVERAL IN USE AND STRESS STABILITY OF ROMIPLISTIM (N-PLATE®) BY THE EVALUATION OF A SELECTED SET OF CRITICAL QUALITY ATTRIBUTES
	5PSQ-068	DIARRHEA OCCURRENCE ANALYSIS IN IDIOPATHIC PULMONARY FIBROSIS PATIENTS
	5PSQ-069	ANALYSIS AND MONITORING OF ERRORS ASSOCIATED WITH ELECTRONIC PRESCRIPTION SYSTEMS: PRESCRIPTIONS WITH INCORRECT DRUG SCHEDULES.
	5PSQ-070	PHARMACEUTICAL CARE IN AN ONCO-HEMATOLOGICAL CLINICAL TRIALS UNIT
	5PSQ-071	ANALYSIS OF MEDICATION PROVIDED BY PATIENTS
	5PSQ-072	ANALYSIS OF THE DURATION AND COMPLICATIONS ASSOCIATED WITH PERIPHERAL PARENTERAL NUTRITION: A COHORT STUDY.
	5PSQ-073	IS THERE A SAFETY DIFFERENCE? JANUS KINASE INHIBITORS IN REAL CLINICAL PRACTICE
	5PSQ-074	INTERACTIONS DETECTED WITH THE USE OF NIRMATRELVIR/RITONAVIR IN A TERTIARY HOSPITAL
	5PSQ-075	PROPOSAL FOR THE ADJUSTMENT AND OPTIMISATION OF THE MEDICATION PROVIDED BY THE PATIENT
	5PSQ-076	PATIENTS’ SATISFACTION AFTER CHANGING FROM 150MG TO 300MG SECUKINUMAB PEN PRESENTATION
	5PSQ-077	CYCLIN DEPENDENT KINASES 4 AND 6 INHIBITORS - REAL-WORLD DATA ANALYSIS
	5PSQ-078	ANALYSIS OF CASIRIVIMAB AND IMDEVIMAB USE IN OUTPATIENTS WITH COVID-19
	5PSQ-079	FONDAPARINUX IN AN INFANT WITH SUSPECTED HEPARIN-INDUCED THROMBOCYTOPENIA. A CASE REPORT.
	5PSQ-080	IDENTIFICATION OF PHARMACOLOGICAL INTERACTIONS BETWEEN IVACAFTOR/TEZACAFTOR/ELEXACAFTOR AND DIETARY SUPPLEMENTS/HERBS IN PATIENTS WITH CYSTIC FIBROSIS IN AN OUTPATIENT PHARMACEUTICAL CARE UNIT
	5PSQ-081	ASSESSMENT OF THE IMPACT OF THE PHARMACEUTICAL INTERVENTION IN MEDICATION RECONCILIATION AT PATIENT ADMISSION IN A SURGICAL PRE-HOSPITALIZATION CLINIC
	5PSQ-082	GRAVIMETRIC CONTROL OF PARENTERAL NUTRITION IN NEONATOLOGY AND PEDIATRICS.
	5PSQ-083	FOUR YEARS OF A PHARMACEUTICAL CARE PROGRAMME IN PATIENTS UNDERGOING CARDIAC SURGERY
	5PSQ-084	ASSESSING QUALITY OF LIFE OF PATIENTS WITH SEVERE ASTHMA MEASURED BY PATIENT REPORTED OUTCOMES
	5PSQ-085	MEDICATION ADMINISTRATION IN PATIENTS WITH DYSPHAGIA: SEARCHING FOR THE BEST PHARMACEUTICAL FORM
	5PSQ-086	ANALYSIS OF POTENCIALLY INAPPROPRIATE PRESCRIPTION IN A NURSING HOME
	5PSQ-087	EVALUATION OF THE EFFECTIVENESS OF LAMIVUDINE IN THE PROPHYLAXIS OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS WITH HAEMATOLOGICAL DISEASES
	5PSQ-088	EXPLORING THE NEED FOR A CHECK OF COMPOUNDING APPROPRIATENESS SERVICE: EVALUATION OF SPONTANEOUS CHECKS BEFORE COMPOUNDING AT A LARGE TERTIARY CARE HOSPITAL
	5PSQ-089	CHRONIC NON-CANCER PAIN, WHAT ABOUT THIS PATIENTS?
	5PSQ-090	STUDY OF THE USE OF RESTRICTED ANTIBIOTICS DURING COVID-19 PANDEMIC: CEFTAROLINE, CEFTAZIDIME/AVIBACTAM AND CEFTOLOZANE/TAZOBACTAM.
	5PSQ-091	TRIFECTA™ BIOPROSTHESES : EVALUATION OF THE SAFETY BASED ON THE STUDY OF DEGENERATIONS ACCORDING TO THE VARC-3 CLASSIFICATION
	5PSQ-092	PHARMACOVIGILANCE OF BIOLOGICAL THERAPIES FROM THE OUTPATIENT DEPARTMENT
	5PSQ-093	PHARMACEUTICAL INTERVENTION AFTER INAPPROPRIATE PRESCRIPTION OF ZOLPIDEM
	5PSQ-094	TOXICITY IN PATIENTS TREATED WITH VENETOCLAX. A SAFETY STUDY IN REAL-WORLD PRACTICE
	5PSQ-095	CARDIAC CONDUCTION DISORDERS ASSOCIATED WITH THE USE OF TRICYCLIC ANTIDEPRESSANTS IN THE ELDERLY
	5PSQ-096	A PROSPECTIVE OBSERVATIONAL STUDY OF MEDICATION PRESCRIBING ERRORS IN AN EMERGENCY DEPARTMENT.
	5PSQ-097	HEALTH ALERT OF TOFACITINIB AND PHARMACEUTICAL INTERVENTION
	5PSQ-098	SAFETY AND PERSISTENCE OF ANTI-FIBROTIC DRUGS IN INTERSTITIAL LUNG DISEASES
	5PSQ-099	ADEQUACY OF SOTROVIMAB PRESCRIPTION IN SARS-CoV-2 INFECTION IN A UNIVERSITY HOSPITAL
	5PSQ-100	UTILITY OF SOCIAL MEDIA AS A SOURCE OF PAEDIATRIC DRUG SAFETY, A SYSTEMATIC REVIEW
	5PSQ-101	ANALYSIS OF HIP PROSTHESES OVER A YEAR
	5PSQ-102	SAFETY EVALUATION OF MIDLINE CATHETERS USED FOR ANTIBIOTIC THERAPY
	5PSQ-103	PARENTAL UNMET NEEDS ON PAEDIATRIC DRUGS EXPRESSED IN FORUMS
	5PSQ-104	ERRORS IN ACENOCOUMAROL RECONCILIATION IN PATIENTS ADMITTED FROM THE EMERGENCY DEPARTMENT
	5PSQ-105	DEVELOPMENT OF HYPOMAGNESEMIA IN CRITICAL PATIENTS TREATED WITH ISAVUCONAZOLE
	5PSQ-106	SAFETY PERCEIVED BY PROFESSIONALS AFTER THE INNOVATION OF THE MEDICATION USE CIRCUIT IN A NEONATAL INTENSIVE CARE UNIT
	5PSQ-107	SAFETY ASSESSMENT OF ERENUMAB AND GALCANEZUMAB IN CLINICAL PRACTICE
	5PSQ-108	COMPUTERIZED PHYSICIAN ORDER ENTRY WITH CLINICAL DECISION SUPPORT IN PREVENTING WRONG DOSE ERRORS IN PEDIATRIC MEDICATION ORDERS: A SYSTEMATIC REVIEW
	5PSQ-109	RANSOMWARE ATTACK ON A CYTOTOXIC PREPARATION UNIT (CPU): WHAT NOW?
	5PSQ-110	IMPACT OF THE USE OF TRANSPARENT ADHESIVE DRESSINGS ON INFECTIONS IN PERITONEAL DIALYSIS
	5PSQ-111	MEDICATION ERRORS, THEIR PERCEPTION, ANALYSIS, AND PROPOSAL OF SOLUTIONS IN A PUBLIC HOSPITAL
	5PSQ-112	RELATIONSHIP BETWEEN EFFECTIVENESS AND IMMUNE-MEDIATED TOXICITY OF IMMUNE CHECK-POINT INHIBITORS IN ADVANCED NON-SMALL CELL LUNG CANCER
	5PSQ-113	REAL-LIFE EFFECTIVENESS, SAFETY AND ADHERENCE OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS
	5PSQ-114	PERSISTENCE AND LEVEL OF CLEARANCE IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS TREATED WITH GUSELKUMAB
	5PSQ-115	DEPRESCRIBING LONG-TERM TREATMENTS WITH BIPHOSPHONATES. PHARMACEUTICAL INTERVENTION BRINGS VALUE.
	5PSQ-116	PERSISTENCE OF INHIBITORS OF INTERLEUKIN-23 (anti-IL-23) FOR THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS (msPs) IN THE ROUTINE CLINICAL PRACTICE CONDITIONS.
	5PSQ-117	EVALUATION OF CARDIOTOXICITY BY OSIMERTINIB IN CLINICAL PRACTICE
	5PSQ-118	PATIENTS´ EXPERIENCE WITH SUBCUTANEOUS INJECTION SELF-ADMINISTRATION AND THE ROLE OF VIRTUAL REALITY
	5PSQ-119	A NEW PHARMACEUTICAL CARE PROGRAMME FOR COVID-19 PATIENTS TREATED WITH PAXLOVID® : IMPLEMENTATION AND SAFETY OUTCOMES REPORTED
	5PSQ-120	ANALYSIS OF THE PHARMACEUTICAL INTERVENTIONS PERFORMED ON ONCOHEMATOLOGICAL PATIENTS THROUGH AN ONCOHEMATOLOGY PHARMACY CONSULTATION
	5PSQ-121	CYTOKINE RELEASE SYNDROME RELATED TO THE TREATMENT WITH TECLISTAMAB: A CASE REPORT
	5PSQ-122	COVID-19 VACCINE VIGILANCE: COMPARATIVE STUDY BETWEEN HOSPITAL, REGIONAL AND NATIONAL DATA
	5PSQ-123	IMPACT OF PHARMACOTHERAPEUTIC COMPLEXITY ON ADHERENCE TO ANTIRETROVIRAL TREATMENT IN OLDER ADULTS WITH HIV
	5PSQ-124	EFFECTIVENESS AND SAFETY OF ANTIRETROVIRAL TREATMENT SIMPLIFICATION TO DOLUTEGRAVIR+LAMIVUDINE OR DOLUTEGRAVIR+RILPIVIRINE IN OLDER ADULTS WITH HUMAN IMMUNODEFICIENCY VIRUS
	5PSQ-125	BRIDGING ANTICOAGULATION IN PATIENTS WITH ATRIAL FIBRILLATION AFTER A TRANSURETHRAL RESECTION: PATIENT MANAGEMENT IS DONE APPROPRIATELY?
	5PSQ-126	EFFICACY AND SAFETY OF OMALIZUMAB, MEPOLIZUMAB AND BENRALIZUMAB IN PATIENTS WITH SEVERE UNCONTROLLED ASTHMA
	5PSQ-127	PHARMACOLOGICAL RISK FACTORS FOR DRUG-DRUG INTERACTIONS IN PEOPLE LIVING WITH HIV: A SYSTEMATIC REVIEW
	5PSQ-128	THROMBOPROPHYLAXIS IN THE EMERGENCY DEPARTMENT. ADEQUACY OF THE PRESCRIPTION.
	5PSQ-129	SWITCHING BETWEEN ANTI-CALCITONIN GENE RELATED PEPTIDE MONOCLONAL ANTIBODIES IN MIGRAINE
	5PSQ-130	OFF-LABEL USE OF CIDOFOVIR INTRALESIONAL INJECTIONS IN EXTENSIVE ANOGENITAL CONDYLOMATOSIS: A CASE REPORT
	5PSQ-131	LETERMOVIR, GANCICLOVIR AND IMMUNOGLOBULINS COMBINATION TREATMENT IN AN IMMUNOCOMPROMISED PATIENT WITH CYTOMEGALOVIRUS INFECTION: A CASE REPORT
	5PSQ-132	PHARMACOGENETIC-GUIDED TREATMENT IN PATIENTS WITH DYHYDROPIRYMIDINE DEHYDROGENASE DEFICIENCY
	5PSQ-133	PHARMACISTS - GENERAL PRACTIONERS (GPs) COLLABORATION TO IDENTIFY DRUG-RELATED PROBLEMS (DRPs) IN PATIENTS IN POLYTHERAPY
	5PSQ-134	UNIT DOSE IN A CYBERATTACK SCENARIO
	5PSQ-135	HAS AN ANTIMICROBIAL STEWARDSHIP PROGRAMME HAD AN IMPACT ON THE ANTIBIOTIC CONSUMPTION?
	5PSQ-136	ANALYSIS OF ANTIRETROVIRAL THERAPY POTENCY IN HIV- NAÏVE PATIENTS
	5PSQ-137	ANALYSIS OF THE DPYD GENE MUTATIONS IN CANCER PATIENTS WHO ARE CANDIDATES FOR TREATMENT WITH FLUOROPYRIMIDINES
	5PSQ-138	CHEMOTHERAPY ERRORS DETECTED DURING PHARMACEUTICAL VALIDATION
	5PSQ-139	USING A TEXT-MINING APPROACH TO IDENTIFY THE CONTEXT VARIABLES LANGUAGE BARRIER, LIVING ALONE, COGNITIVE FRAILTY AND NON-ADHERENCE FROM ELECTRONIC HEALTH RECORDS (EHRs)
	5PSQ-140	FREQUENCY OF BLEEDING EVENTS REQUIRING HOSPITALIZATION IN PATIENTS UNDERGOING HOME TREATMENT WITH DIRECT-ACTING ORAL ANTICOAGULANTS (DOACs)
	5PSQ-141	FALLS IN ELDERLY PATIENTS AND CHRONIC CONSUMPTION OF ANXIOLYTIC BENZODIAZEPINES.
	5PSQ-142	EVALUATION OF ADEQUACY, ADHERENCE AND SAFETY OF HUMAN IMMUNODEFICIENCY VIRUS POST-EXPOSURE TREATMENT
	5PSQ-143	THE ROLE OF THE PHARMACIST IN INCREASING HEALTH VIGILANCE AMONG HEALTH PROFESSIONALS: QUINCKE'S EDEMA FOLLOWING THE ADMINISTRATION OF RITUXIMAB
	5PSQ-144	ELECTRONIC PATIENT-REPORTED OUTCOME (PROM) MEASUREMENT USING PRO-CTCAE®QUESTIONNAIRE TO IMPROVE QUALITY OF LIFE ASSESSMENT AND HEALTHCARE RESOURCES MANAGEMENT IN PATIENTS WITH LYMPHOMA RECEIVING INTRAVENOUS CHEMOTHERAPY
	5PSQ-145	A PATIENT SATISFACTION SURVEY ON UNIT DOSE DRUG DISTRIBUTION IN HOSPITAL

Section 6: Education and Research
PDF document	Poster number	Poster Title
	6ER-001	THE USE OF GAMIFICATION TO EVALUATE PUBLIC UNDERSTANDING OF ADVERSE DRUG REACTIONS
	6ER-002	WHAT's ANOTHER PEER? EXPLORING THE USE OF NEAR PEER TEACHING OF MEDICATION HISTORY TAKING IN PHARMACY UNDERGRADUATES IN THE UK
	6ER-003	THE CLIMATE EMERGENCY, HOW CAN PHARMACY MAKE A DIFFERENCE?
	6ER-004	EFFECTIVENESS AND SAFETY OF COVID-19 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED DISEASES ON BIOLOGICAL THERAPY
	6ER-005	EFFECTS OF ADHERENCE TO THE MEDITERRANEAN DIET IN PATIENTS WITH AUTOIMMUNE DISEASES
	6ER-006	CURRENT PERFORMANCE OF HOSPITAL PHARMACY SPECIALISTS TRAINED AT A TERTIARY HOSPITAL IN SPAIN
	6ER-007	PHYSICO-CHEMICAL PARAMETERS OF TOBACCO OIL AND PREPARATION OF A DOSAGE FORM BASED ON IT
	6ER-008	CORRELATES OF ONE-YEAR MORTALITY AMONG PATIENTS LIVING WITH HIV ACCORDING TO THE STRATIFICATION LEVEL OF THE PHARMACEUTICAL CARE MODEL
	6ER-009	COMPARATIVE EFFICACY OF ABEMACICLIB AND PALBOCICLIB AS ADJUVANT TREATMENT IN PATIENTS WITH EARLY BREAST CANCER
	6ER-010	EVOLUTION OF ONCOHAEMATOLOGICAL CLINICAL TRIALS FROM 2016 TO 2021: EXPERIENCE FROM A TERTIARY HOSPITAL
	6ER-011	EFFICACY OF THERAPIES IN NON-SMALL CELL LUNG CANCER WITH EGFR EXON 20 INSERTION MUTATIONS: A SYSTEMATIC REVIEW
	6ER-012	TREATMENT DECISIONS ACCORDING TO 1-YEAR RISK MORTALITY IN PULMONARY ARTERIAL HYPERTENSION PATIENTS. A MULTICENTRE RETROSPECTIVE STUDY.
	6ER-013	1 YEAR-MORTALITY RISK ASSESSMENT IN PULMONARY ARTERIAL HYPERTENSION PATIENTS. A MULTICENTRE RETROSPECTIVE STUDY.
	6ER-014	EFFECTIVENESS AND SAFETY OF THE ADMINISTRATION OF MURPHY’S ENEMA FOR THE TREATMENT OF REFRACTORY CONSTIPATION IN A TERTIARY HOSPITAL
	6ER-015	AZACITIDINE IN THE TREATMENT OF JUVENILE MYELOMONOCYTIC LEUKAEMIA: AN UP-TO-DATE PHARMACY PROTOCOL
	6ER-016	IDENTIFICATION OF NEW GENES OF EARLY RESPONSE TO ANTI-TNFS BY RNASEQ IN PAEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE.
	6ER-017	STRUCTURED OBJECTIVE CLINICAL EVALUATION FOR PHARMACY STUDENTS ON INTERNSHIPS AT THE HOSPITAL
	6ER-018	OFF-LABEL USE OF USTEKINUMAB IN REFRACTORY EPIDERMOLYTIC ICHTHYOSIS: A CASE REPORT
	6ER-019	THE STUDENT PHARMACIST EXPERIENCE OF ENHANCED CLINICAL PLACEMENTS
	6ER-020	PRESCRIPTION AND USE OF LIPOSOMAL AMPHOTERICIN B DURING THE COVID-19 PANDEMIC
	6ER-021	RETROSPECTIVE OF DRUG INNOVATION DURING THE SARS-Cov2 PANDEMIC : DEVELOPMENT OF A GAME-BASED TRAINING
	6ER-022	CLINICAL IMPACT OF THE USE OF GLUCOCORTICOIDS FOR THE TREATMENT OF COVID-19 IN INTERMEDIATE RESPIRATORY CARE UNITS
	6ER-023	THE ASSOCIATION BETWEEN NADROPARIN DOSE AND ANTI-XA LEVELS IN RENAL INSUFFICIENCY: A MULTICENTER STUDY
	6ER-024	COMPARISON OF REDUCTIONS IN MONTHLY MIGRAINE DAYS BETWEEN NEW SMALL MOLECULE CGRP RECEPTOR ANTAGONISTS (GEPANTS) AND MONOCLONAL ANTIBODIES TARGETING CGRP/CGRP RECEPTOR
	6ER-025	EFECTIVENESS AND SAFETY OF 20% AUTOLOGOUS SERUM EYE DROPS IN PATIENTS WITH CORNEAL SURFACE PATHOLOGIES
	6ER-026	SPECTRUM OF HEART FAILURE IN 16 SUB-SAHARAN AFRICAN COUNTRIES: TREATMENTS AND IN-HOSPITAL OUTCOME
	6ER-027	ASSESSMENT OF ATTITUDES AND PERCEIVED SKILLFULNESS OF PHARMACY STUDENTS IN CARING FOR UNDERSERVED POPULATIONS
	6ER-028	ASSESSMENT OF SYMPTOMS AND SIGNS SEVERITY IN PSORIASIS PATIENTS
	6ER-029	EYE DROPS OF INTERFERON ALPHA-2B TO TREAT OCULAR PATHOLOGIES
	6ER-030	USING A PHARMACIST-LED ASTHMA SERVICE TO ASSESS THE CONCORDANCE BETWEEN PATIENT-REPORTED ICS ADHERENCE AND OBJECTIVE E-MONITORING OF ICS THERAPY
	6ER-031	KWOLEDGE ABOUT HUMAN IMMUNODEFICIENCY VIRUS (HIV) TRANSMISSION IN PEOPLE LIVING WITH HIV IN ANTIRETROVIRAL THERAPY
	6ER-032	HOW CAN DUTCH UNIVERSITY HOSPITALS CONTRIBUTE TO AFFORDABLE MEDICINES AND COST CONTAINMENT OF TOTAL HOSPITAL DRUG EXPENDITURE: A DELPHI STUDY
	6ER-033	PEMBROLIZUMAB AND ATEZOLIZUMAB AS POSSIBLE EQUIVALENT FIRST-LINE THERAPEUTIC ALTERNATIVES IN PDL1-EXPRESSING TRIPLE-NEGATIVE BREAST CANCER
	6ER-034	USE OF CLOSED SYSTEM TRANSFER DEVICES WITH INVESTIGATIONAL DRUG PRODUCTS

26th Congress of the EAHP

National Poster Prize Winners
PDF document	Poster number	Poster Title
	NP-01	The appropriateness review FOR HOSPITAL MEDICATION ORDERS IN FINLAND
	NP-02	Usage of falls-risk-increasing drugs among patients with high risk of falls in the nursing ward of Tartu University Hospital
	NP-03	From basic to advanced computerized IV to oral switch for paracetamol and antibiotics: an interrupted time series analysis
	NP-04	MONITORING OF GRAM-NEGATIVE (G-) MULTIDRUG RESISTANT (MDR) PATIENS AT POLICLINICO UMBERTO I OF ROME WITH THE AIM OF CONTROLLING HEALTHCARE ASSOCIATED INFECTIONS, COUNTERACTING THE PHENOMENON OF ANTIMICROBIAL RESISTANCE AND...
	NP-05	INTRAVESICAL EPIRUBICIN ADMINISTRATION IN A UROLOGY DEPARTMENT
	NP-06	RELATIONSHIP BETWEEN SERUM VEDOLIZUMAB CONCENTRATIONS IN INDUCTION PHASE AND EARLY AND SUSTAINED RESPONSE ON PATIENTS WITH ULCERATIVE COLITIS
	NP-08	Integrating pharmacogenetic information into medication reviews – an interprofessional challenge

Section 1: Introductory Statements and Governance
PDF document	Poster number	Poster Title
	1ISG-003	IMPACT OF TELEPHARMACY AND COMMUNITY PHARMACY REMOTE-DISPENSING ON PATIENTS ON ORAL ANTINEOPLASTIC AGENTS
	1ISG-004	ASSESSMENT OF CUSTOMER SATISFACTION WITH HOSPITAL PHARMACY SERVICES IN ESTONIA
	1ISG-006	ESTIMATION OF DRUG COST AVOIDANCE IN CLINICAL TRIALS OF NON-SMALL CELL LUNG CANCER
	1ISG-007	ECONOMIC SAVINGS FROM WEIGHT-BASED DOSING OF PEMBROLIZUMAB: WHAT IS THE IMPACT IN A TERTIARY HOSPITAL?
	1ISG-008	OPTIMISATION PROGRAMME OF OMALIZUMAB TREATMENT FOR CHRONIC IDIOPATHIC URTICARIA
	1ISG-009	IMPLEMENTATION AND EVALUATION OF TELEPHARMACY DURING COVID-19 PANDEMIC IN AN ACADEMIC MEDICAL CITY : PAVING THE WAY FOR TELEPHARMACY
	1ISG-012	ECONOMIC EVALUATION OF DOSE BANDING IN INMUNOTHERAPY: NIVOLUMAB AND PEMBROLIZUMAB
	1ISG-013	Users’ expectations and opinions on a computerised physician order entry (CPOE) system before and after its implementation

Section 2: Selection, Procurement and Distribution
PDF document	Poster number	Poster Title
	2SPD-001	HOW CAN WE BEST MANAGE SUPPLY SHORTAGES OF EXCLUSIVELY HUMAN MOLECULES FOR SUBSTITUTION ? THE EXAMPLE OF IMMUNOGLOBULINS
	2SPD-003	TELEPHARMACY IN ONCO-HEMATOLOGIC PATIENTS: A SEVEN MONTH EXPERIENCE
	2SPD-005	SIGNIFICANT DISCONTINUATION RATES IN PATIENTS INITIATING OR SWITCHING FROM CT-P13: A RETROSPECTIVE COHORT STUDY IN A UNIVERSITY HOSPITAL
	2SPD-006	DEVELOPMENT OF A PRIORITATION PROTOCOL FOR THE USE OF IMMUNOGLBULINS IN VIEW OF THE GLOBAL SUPPLY PROBLEM
	2SPD-008	NETWORK META-ANALYSIS OF IMMUNOTHERAPIES IN UNTREATED ADVANCED OR METASTARIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA
	2SPD-011	RIVAROXABAN VERSUS ENOXAPARIN IN TRAUMATOLOGY: A PHARMACO-ECONOMIC STUDY
	2SPD-012	IMMUNOTHERAPY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER: EFFECTIVENESS AND SAFETY IN REAL LIFE
	2SPD-013	INCREASE IN HEALTHCARE COSTS WITH FIDAXOMICIN INSTEAD OF VANCOMYCINFOR CLOSTRIDIUM DIFFICLIE TREATMENT
	2SPD-014	APPROPRIATENESS OF USTEKINUMAB THERAPY PRESCRIPTION AND REAL-LIFE CONDITION USE IN CROHN’S DISEASE
	2SPD-015	LOGISTICS AUTOMATION AND PROCESS REENGINEERING: IMPACT ON INTER-HOSPITAL LOAN MANAGEMENT
	2SPD-016	APPLICATION OF FAILURE MODE AND EFFECT ANALYSIS TO IMPROVE CYTOSTATIC DRUG STOCK MANAGEMENT
	2SPD-017	ANALYSIS AND MONITORING OF THE WORKLOAD AND FINANCIAL BURDEN OF DISPENSING HIGHCOST MEDICINES WITH ITEM-BASED REIMBURSEMENT IN HUNGARIAN HOSPITAL PHARMACIES
	2SPD-019	INVENTORY MANAGEMENT DURING THE COVID-19 PANDEMIC: OUR CASE FOR THE THIRD WAVE
	2SPD-020	INTRODUCTION OF A NEW PRESENTATION OF HYALURONIC ACID FOR INTRAARTICULAR INFILTRATION
	2SPD-021	ASSESSMENT OF FORECAST ACCURACY FOR CONTRACTUAL PURCHASES
	2SPD-022	RELEVANCE OF UNIVERSAL KIT COMPOSITION AND ECONOMIC VALUE OF NON-USED MEDICAL DEVICES
	2SPD-023	CHOOSING THE RIGHT FORECASTING METHOD: WHICH PRACTICE IS BEST FOR OUR CASE?
	2SPD-024	RETROSPECTIVE EVALUATION OF THE SAFETY STOCK LEVEL DETERMINED FOR THE PANDEMIC IN TERMS OF SERVICE LEVEL
	2SPD-025	ACALABRUTINIB + OBINUTUZUMAB VERSUS IBRUTINIB + OBINUTUZUMAB AS FIRST LINEIN CHRONIC LYMPHOCYTIC LEUKEMIA
	2SPD-027	Medication storage temperatures inside emergency vehicles A pilot study in a temperate climate country
	2SPD-029	STABILITY OF NIVOLUMAB SOLUTIONS AFTER TRANSPORT THROUGH PNEUMATIC TUBE SYSTEMS
	2SPD-030	How to assess the impact of medicines shortages in the European Union?
	2SPD-031	THE ECONOMIC IMPACT OF ANTIMICROBIAL SHORTAGES IN ANTIMICROBIAL STEWARDSHIP PROGRAMMES
	2SPD-032	DRUG EXCHANGE NETWORK
	2SPD-033	Making the case for Prefilled Syringes (PFS): Development and utilisation of an economic model
	2SPD-034	METHODOLOGICAL ANALYSIS OF PHARMACOECONOMIC STUDIES IN CAR-T: A SYSTEMATIC REVIEW
	2SPD-035	COST MINIMISATION ANALYSIS IN CLINICAL PRACTICE OF RIBOCICLIB VERSUS PALBOCICLIB IN THE TREATMENT OF METASTASTIC BREAST CANCER

Section 3: Production and Compounding
PDF document	Poster number	Poster Title
	3PC-001	CHOLESTEROL 2%/SIMVASTATIN 1% OINTMENT FOR THE TREATMENT OF POROKERATOSIS PTYCHOTROPICA: A CASE REPORT
	3PC-002	GLASS AMPOULES AND DRUG FILTRATION: ¿HOW MUCH DO WE KNOW ABOUT IT?
	3PC-003	SODIUM THIOSULPHATE GEL 25% FOR THE TREATMENT OF CALCIPHYLAXIS
	3PC-004	INSULIN EYE DROP FORMULATION: EFFECTIVENESS, SAFETY AND PATIENT SATISFACTION
	3PC-005	SELECTION OF AN OSMOLARITY VALIDATION MODEL FOR NOMINATIVE PARENTERAL NUTRITION
	3PC-006	EVALUATION OF PARENTERAL NUTRITION COMPOUNDING THROUGH A CHECKLIST
	3PC-008	TIMES AND ERRORS FOR DISPENSING NARCOTICS DRUGS IN AUTOMATED SYSTEM VERSUS MANUAL SYSTEM
	3PC-009	STANOZOLOL RAPID HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) QUANTIFICATION METHOD FOR QUALITY CONTROL
	3PC-010	Assessment of Chemfort (OnGuard, US) Syringe Adaptor Lock Fitted With Luer Lock Syringes to Container Integrity Standards (NHS, UK) Supporting Dose Banding of Cytotoxic Drugs
	3PC-011	STUDY OF THE CONTAINERCONTENT INTERACTION BETWEEN ETOPOPHOS POLYVINYL CHLORIDE (PVC) PERFUSION
	3PC-012	IMPACT OF PRELIMINARY WIPING OF EQUIPMENT INTRODUCED INTO A CLEANROOM ON THE CONTROL OF THE ENVIRONMENT
	3PC-013	PHARMACEUTICAL COMPOUNDING IN PAEDIATRIC PATCH TESTING: ARE WE SURE ABOUT THE ACTUAL ACTIVE INGREDIENT CONCENTRATION?
	3PC-014	EVALUATION OF THE MICROBIOLOGICAL QUALITY OF NONSTERILE DRUGS PREPARED IN A HOSPITAL PHARMACY
	3PC-016	VANCOMYCIN EYE DROPS AT 50 MG/ML : PHYSICOCHEMICAL STABILITY, IMPACT OF PACKAGING AND STORAGE CONDITIONS
	3PC-017	Assessing the stability of Sandoz rituximab biosimilar after exposure to out-of-fridge conditions for 21 days
	3PC-018	COMPATIBILITY AND 30-DAY STABILITY OF FOUR INTRAVENOUS MIXTURES FOR MULTIMODAL ANALGESIA
	3PC-019	EVALUATION OF THE IMPACT OF MACHINE-AIDED DEBLISTERING IN UNIT DOSE BLISTER PRODUCTION ON THE FUNCTIONALITY OF TABLET COATING
	3PC-020	CHEMICAL STABILITY AND PHYSICAL COMPATIBILITY OF INSULIN EYE DROPS USED IN CLINICAL PRACTICE
	3PC-021	DESIGN AND ELABORATION OF METRONIDAZOLE 1% TOPICAL SOLUTION FOR TREATMENT OF ULCERS INFECTED BY ANAEROBIC BACTERIA
	3PC-022	PH STABILITY OF TETRACAINE SOLUTIONS FOR SURFACE ANAESTHESIA
	3PC-023	Investigation of Leachable Compounds In water for injection used in hospital pharmacy
	3PC-024	IMPACT OF PH MODIFICATION ON THE AGGREGATION OF NIVOLUMAB (OPDIVO) IN CLINICAL SOLUTIONS AT 1 AND 5 MG/ML MEASURED BY DYNAMIC LIGHT SCATTERING (DLS) AND SIZEEXCLUSION HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY-DIODE ARRAY DETECTION (SE/HPLC-DAD)
	3PC-026	Rainer Trittler, Brigitte Altmann, Manuel Garcia-Käufer, Richard Gminski, Martin J. Hug
	3PC-027	DIGITALIZATION SUPPORT SYSTEM FOR INTRAVENOUS MIXTURES ELABORATION IN A BIOLOGICAL SAFETY CABINET